| Rx0000077 |
AbbVie |
03/31/2020 |
00074634702 |
HUMIRA (adalimumab) 10mg/0.2mL, 2 Syringe |
01/01/2020 |
382.88 |
5556.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074937402 |
HUMIRA (adalimumab) 20mg/0.4mL, 2 Syringe |
01/01/2020 |
382.88 |
5556.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074379906 |
HUMIRA (adalimumab) 40MG/0.8ML , 6 Syringe |
01/01/2020 |
1148.65 |
16670.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074433902 |
HUMIRA (adalimumab) 40mg/0.8mL, 2 Pen |
01/01/2020 |
382.88 |
5556.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074379902 |
HUMIRA (adalimumab) 40mg/0.8mL, 2 Syringe |
01/01/2020 |
382.88 |
5556.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074379903 |
HUMIRA (adalimumab) 40MG/0.8ML, 3 Syringe |
01/01/2020 |
574.32 |
8335.48 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074433907 |
HUMIRA (adalimumab) 40mg/0.8mL, 4 Pen |
01/01/2020 |
765.76 |
11113.96 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074433906 |
HUMIRA (adalimumab) 40mg/0.8mL, 6 Pen |
01/01/2020 |
1148.65 |
16670.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074105305 |
LUPANETA (leuprolide acetate for depot suspension and norethindrone acetate) 11.25mg, 1 Kit |
01/01/2020 |
288.69 |
4189.84 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074105205 |
LUPANETA (leuprolide acetate for depot suspension and norethindrone acetate) 3.75mg, 1 Kit |
01/01/2020 |
96.23 |
1396.60 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074366303 |
LUPRON DEPOT (leuprolide acetate) 11.25mg, 1 Kit |
01/01/2020 |
288.69 |
4189.84 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074334603 |
LUPRON DEPOT (leuprolide acetate) 22.5mg, 1 Kit |
01/01/2020 |
344.01 |
4992.79 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074364103 |
LUPRON DEPOT (leuprolide acetate) 3.75mg, 1 Kit |
01/01/2020 |
96.23 |
1396.60 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074368303 |
LUPRON DEPOT (leuprolide acetate) 30mg, 1 Kit |
01/01/2020 |
458.68 |
6657.06 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074347303 |
LUPRON DEPOT (leuprolide acetate) 45mg, 1 Kit |
01/01/2020 |
688.03 |
9985.73 |
02/05/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074364203 |
LUPRON DEPOT (leuprolide acetate) 7.5mg, 1 Kit |
01/01/2020 |
114.67 |
1664.27 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074377903 |
LUPRON DEPOT PED (leuprolide acetate) 11.25mg, 1 Kit (3 mo) |
01/01/2020 |
630.49 |
9150.69 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074228203 |
LUPRON DEPOT PED (leuprolide acetate) 11.25mg, PDS Kit |
01/01/2020 |
210.16 |
3050.22 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074244003 |
LUPRON DEPOT PED (leuprolide acetate) 15mg, 1 Kit |
01/01/2020 |
231.47 |
3359.51 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074969403 |
LUPRON DEPOT PED (leuprolide acetate) 30mg, 1 Kit |
01/01/2020 |
694.43 |
10078.56 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074210803 |
LUPRON DEPOT PED (leuprolide acetate) 7.5mg, 1 Kit |
01/01/2020 |
115.76 |
1680.11 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074057611 |
VENCLEXTA (venetoclax) 100mg, 1 Tablet |
01/01/2020 |
4.88 |
102.44 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074057622 |
VENCLEXTA (venetoclax) 100mg, 120 Tablet |
01/01/2020 |
585.40 |
12293.47 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074056114 |
VENCLEXTA (venetoclax) 10mg, 14 2 TABLETS X 7 |
01/01/2020 |
6.83 |
143.42 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074056111 |
VENCLEXTA (venetoclax) 10mg, 2 Tablet |
01/01/2020 |
0.98 |
20.49 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074057928 |
VENCLEXTA (venetoclax) 10MG, 50MG, 100MG , 1 4X7 DAY WALLET |
01/01/2020 |
126.35 |
2653.34 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074056611 |
VENCLEXTA (venetoclax) 50mg, 1 Tablet |
01/01/2020 |
2.44 |
51.22 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074056607 |
VENCLEXTA (venetoclax) 50mg, 7 1 TABLET X 7 |
01/01/2020 |
17.07 |
358.56 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000018 |
ACADIA Pharmaceuticals Inc. |
06/30/2020 |
63090034030 |
NUPLAZID Oral Capsule 34 MG 30 |
06/29/2020 |
297.00 |
3638.00 |
08/27/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions:. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000018 |
ACADIA Pharmaceuticals Inc. |
06/30/2020 |
63090010030 |
NUPLAZID Oral Tablet 10 MG 30 |
06/29/2020 |
297.00 |
3638.00 |
08/27/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
03/31/2020 |
42192071401 |
Ciclopirox Treatment External Kit,8%, 34.6 ML, Cream |
01/03/2020 |
46.03 |
316.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=455, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=457 |
Columns 14 through 22 were left blank because this product was not acquired from another manufacturer within the last five years. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
09/30/2020 |
42192071401 |
Ciclopirox Treatment External Kit, 8%, 34.6 ML, Cream |
08/03/2020 |
14.22 |
330.22 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=456 |
Columns 14 thru 22 were not completed as the product was not acquired within the last 5 years. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
12/31/2020 |
42192011270 |
Salicylic Acid External Foam, 6 %, Size 70GM, Unit-of-Use, Can, |
10/05/2020 |
6.97 |
161.76 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=458 |
Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
12/31/2020 |
42192014301 |
Sulfacetamide Sodium-Sulfur (SSS) 10-5 External Foam 10-5 %, Size 100GM, Unit-of-Use, Can |
10/05/2020 |
16.90 |
392.54 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=459 |
Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
12/31/2020 |
42192014360 |
Sulfacetamide Sodium-Sulfur (SSS) 10-5 External Foam 10-5 %, Size 60GM, Unit-of-Use, Can |
10/05/2020 |
12.68 |
294.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=460 |
Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years. |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
72893000201 |
BELEODAQ (belinostat) Injection 500 mg |
04/01/2020 |
30.01 |
2031.00 |
10/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
1885.30 |
None |
2014 |
1500.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
72893000201 |
BELEODAQ (belinostat) Injection 500 mg, Single dose vial |
01/01/2020 |
29.57 |
2000.99 |
10/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
1885.30 |
None |
2014 |
1500.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=416 |
Acrotech Biopharma is updating the NDC number for Beleodaq to replace Spectrum Pharmaceutical’s labeler code (68152) with Acrotech Biopharma’s (72893) labeler code.
Please see the below:
• New NDC (Acrotech): 72893-0002-01
• Old NDC (Spectrum): 68152-0109-00 |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
48818000101 |
FOLOTYN (pralatrexate) Injection 20 mg, 20mg/mL, 1mL vial |
01/01/2020 |
57.14 |
5770.87 |
05/31/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
5442.69 |
None |
2009 |
3125.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
48818000101 |
FOLOTYN (pralatrexate) Injection 20 mg, 20mg/mL, 1mL vial |
04/01/2020 |
109.65 |
5880.52 |
05/31/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
5442.69 |
None |
2009 |
3125.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
48818000102 |
FOLOTYN (pralatrexate) Injection 40 mg,20mg/mL, 2mL vial |
01/01/2020 |
114.27 |
11541.74 |
05/31/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
10885.38 |
None |
2009 |
6250.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
48818000102 |
FOLOTYN (pralatrexate) Injection 40 mg,20mg/mL, 2mL vial |
04/01/2020 |
219.29 |
11761.04 |
05/31/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
10885.38 |
None |
2009 |
6250.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
68152011201 |
KHAPZORY (levoleucovorin) injection 175, Single dose vial mg |
01/01/2020 |
7.00 |
707.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
700.00 |
None |
2019 |
700.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
68152011401 |
KHAPZORY (levoleucovorin) injection 300 mg, Single dose vial |
01/01/2020 |
12.00 |
1212.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
1200.00 |
None |
2019 |
1200.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
72893000803 |
MARQIBO (vincristine sulfate) Injection 5 mg, 5mg/31mL, Single-Dose Vial |
04/01/2020 |
587.90 |
15662.36 |
09/25/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
14294.21 |
None |
2013 |
9750.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=440 |
There was an NDC change to move from the Sprectrum Pharmaceuticals NDC to Acrotech Biopharma's NDC. Please see attached Notification dated May 20, 2020 |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
72893000704 |
ZEVALIN (Ibritumomab Tiuxetan), Injection 3.2 mg, 3.2mg/2mL, Single-Dose 2mL Vial |
04/01/2020 |
821.32 |
55575.64 |
12/31/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
49949.21 |
None |
2002 |
40068.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=441 |
There was an NDC change to move from the Sprectrum Pharmaceuticals NDC to Acrotech Biopharma's NDC. Please see attached Notification dated May 19, 2020 |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431011001 |
JUXTAPID 10 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431012001 |
JUXTAPID 20 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431013001 |
JUXTAPID 30 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431014001 |
JUXTAPID 40 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431010501 |
JUXTAPID 5 MG CAPS - bottle of 28 |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431016001 |
JUXTAPID 60 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431021001 |
MYALEPT 11.3MG VIAL |
01/01/2020 |
460.50 |
5093.32 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/12/2015 |
Astra Zeneca |
325000000 |
None |
None |
3493.00 |
3493.00 |
2014 |
3493.00 |
None |
The product was introduced to the market before it was acquired by Aegerion Pharmaceuticals which was later acquired by Amryt in 2019. The information provided in this report is the only information available to Amryt. Amryt has no knowledge of the WAC at introduction. Therefore the WAC Aegerion set after acquisition was used - 3493.00 as shown in MediSpan. |
| Rx0000085 |
Akorn Inc |
03/31/2020 |
17478050305 |
Dehydrated Alcohol 0.98mL/mL, 5mL, 10 |
01/24/2020 |
3172.57 |
4467.57 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14:22- Acquisition information not applicable as this is an Akorn developed product. Column 6- No known patents. This NDC is an unapproved product and does not have an FDA approved application. |
| Rx0000085 |
Akorn Inc |
09/30/2020 |
17478071130 |
Lidocaine Hydrochloride Jelly 2%, 30mL |
08/17/2020 |
30.56 |
106.96 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14:22- Acquisition information not applicable as this is an Akorn developed product. |
| Rx0000039 |
Alkermes, Inc |
06/30/2020 |
65757040403 |
ARISTADA 1064 mg/3.9mL extended-release injectable suspension, 1 pre-filled syringe |
04/03/2020 |
187.42 |
3311.21 |
03/19/2035 |
Single Source Drug |
None |
1 |
This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need. We strive to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Aristada was developed in-house |
| Rx0000039 |
Alkermes, Inc |
06/30/2020 |
65757040103 |
ARISTADA 441 mg/ 1.6mL extended-release injectable suspension, 1 pre-filled syringe |
04/03/2020 |
77.68 |
1372.41 |
03/19/2035 |
Single Source Drug |
None |
1 |
This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need. We strive to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Aristada was developed in-house |
| Rx0000039 |
Alkermes, Inc |
06/30/2020 |
65757040203 |
ARISTADA 662 mg/2.4mL extended-release injectable suspension, 1 pre-filled syringe |
04/03/2020 |
116.61 |
2060.17 |
03/19/2035 |
Single Source Drug |
None |
1 |
This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need. We strive to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Aristada was developed in-house |
| Rx0000039 |
Alkermes, Inc |
06/30/2020 |
65757040303 |
ARISTADA 882 mg/3.2mL extended-release injectable suspension, 1 pre-filled syringe |
04/03/2020 |
155.36 |
2744.82 |
03/19/2035 |
Single Source Drug |
None |
1 |
This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need. We strive to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Aristada was developed in-house |
| Rx0000020 |
Allergan |
03/31/2020 |
00023932110 |
ALPHAGAN P-0.1 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
15.99 |
335.77 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023932115 |
ALPHAGAN P-0.1 %-15-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.99 |
503.73 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023932105 |
ALPHAGAN P-0.1 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.00 |
167.96 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023917710 |
ALPHAGAN P-0.15 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
17.05 |
358.04 |
01/28/2022 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023917715 |
ALPHAGAN P-0.15 %-15-CAPSULE,DELAYED RELEASE |
01/03/2020 |
25.58 |
537.11 |
01/28/2022 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023917705 |
ALPHAGAN P-0.15 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.53 |
179.07 |
01/28/2022 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456046101 |
ARMOUR THYROID-120 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.68 |
161.30 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456045701 |
ARMOUR THYROID-15 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
3.21 |
67.45 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456045801 |
ARMOUR THYROID-30 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
3.77 |
79.19 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456045901 |
ARMOUR THYROID-60 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
4.19 |
87.98 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456046001 |
ARMOUR THYROID-90 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
6.56 |
137.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980002210 |
BLEPHAMIDE-10 %-0.2 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
14.55 |
305.53 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980002205 |
BLEPHAMIDE-10 %-0.2 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.27 |
152.76 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456141030 |
BYSTOLIC-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.16 |
150.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456141090 |
BYSTOLIC-10 mg-90-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.49 |
451.20 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140263 |
BYSTOLIC-2.5 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
24.33 |
510.86 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140230 |
BYSTOLIC-2.5 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.16 |
150.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456142030 |
BYSTOLIC-20 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.16 |
150.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456142090 |
BYSTOLIC-20 mg-90-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.49 |
451.20 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140563 |
BYSTOLIC-5 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
24.33 |
510.86 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140530 |
BYSTOLIC-5 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.16 |
150.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140590 |
BYSTOLIC-5 mg-90-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.49 |
451.20 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
58914017014 |
CARAFATE-1 gram/10 mL-420-CAPSULE,DELAYED RELEASE |
01/03/2020 |
10.46 |
219.74 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
58914017110 |
CARAFATE-1 gram-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.43 |
407.94 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023921110 |
COMBIGAN-0.2 %-0.5 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
17.63 |
370.31 |
01/19/2023 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023921115 |
COMBIGAN-0.2 %-0.5 %-15-CAPSULE,DELAYED RELEASE |
01/03/2020 |
26.45 |
555.43 |
01/19/2023 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023921105 |
COMBIGAN-0.2 %-0.5 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.82 |
185.15 |
01/19/2023 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456221230 |
FETZIMA-120 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.64 |
412.44 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456220228 |
FETZIMA-20 mg (2)-40 mg (26)-28-CAPSULE,DELAYED RELEASE |
01/03/2020 |
18.33 |
384.95 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456222030 |
FETZIMA-20 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.64 |
412.44 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456224030 |
FETZIMA-40 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.64 |
412.44 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456228030 |
FETZIMA-80 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.64 |
412.44 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980022810 |
FML FORTE-0.25 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
15.28 |
320.81 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980022805 |
FML FORTE-0.25 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.64 |
160.40 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980021110 |
FML-0.1 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
15.28 |
320.81 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980021105 |
FML-0.1 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.64 |
160.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456201001 |
LEXAPRO-10 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
57.37 |
1204.72 |
02/12/2023 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456202001 |
LEXAPRO-20 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
59.86 |
1257.13 |
02/12/2023 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456200501 |
LEXAPRO-5 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
54.87 |
1152.25 |
02/12/2023 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456120130 |
LINZESS-145 mcg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.19 |
445.02 |
08/16/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456120230 |
LINZESS-290 mcg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.19 |
445.02 |
08/16/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456120330 |
LINZESS-72 mcg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.19 |
445.02 |
08/16/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00430042014 |
LO LOESTRIN FE-1 mg-10 mcg (24)/10 mcg (2)/75 mg (2)-28-CAPSULE,DELAYED RELEASE |
01/03/2020 |
35.15 |
738.75 |
02/02/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023320503 |
LUMIGAN-0.01 %-2.5-DROPS |
01/03/2020 |
9.85 |
206.82 |
06/13/2027 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023320505 |
LUMIGAN-0.01 %-5-DROPS |
01/03/2020 |
19.69 |
413.47 |
06/13/2027 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023320508 |
LUMIGAN-0.01 %-7.5-DROPS |
01/03/2020 |
29.53 |
620.17 |
06/13/2027 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456430001 |
MONUROL-3 gram-1-CAPSULE,DELAYED RELEASE |
01/03/2020 |
4.35 |
91.27 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456121430 |
NAMZARIC-14 mg-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.13 |
485.79 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456122130 |
NAMZARIC-21 mg-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.13 |
485.79 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456122830 |
NAMZARIC-28 mg-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.13 |
485.79 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456122929 |
NAMZARIC-7 mg-10 mg (7)/14 mg-10 mg (7)/21 mg-10 mg(7)/28 mg-10 mg(7)-28-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.59 |
453.40 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456120730 |
NAMZARIC-7 mg-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.13 |
485.79 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980018010 |
PRED FORTE-1 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
14.55 |
305.53 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980018015 |
PRED FORTE-1 %-15-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.82 |
458.29 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980018005 |
PRED FORTE-1 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.27 |
152.76 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980017410 |
PRED MILD-0.12 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
14.55 |
305.53 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980017405 |
PRED MILD-0.12 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.27 |
152.76 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023006604 |
PRED-G-0.3 %-0.6 %-3.5-OINTMENT (GRAM) |
01/03/2020 |
7.27 |
152.76 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023010605 |
PRED-G-0.3 %-1 %-5-SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML) |
01/03/2020 |
7.27 |
152.76 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023530105 |
RESTASIS MULTIDOSE-0.05 %-5.5-DROPS |
01/03/2020 |
27.89 |
585.61 |
05/11/2034 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023916330 |
RESTASIS-0.05 %-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.94 |
292.79 |
08/27/2024 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023916360 |
RESTASIS-0.05 %-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
27.89 |
585.61 |
08/27/2024 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456151060 |
SAVELLA-100 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.10 |
401.03 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456150055 |
SAVELLA-12.5 mg (5)-25 mg (8)-50 mg (42)-55-CAPSULE,DELAYED RELEASE |
01/03/2020 |
17.51 |
367.61 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456151260 |
SAVELLA-12.5 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.10 |
401.03 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456152560 |
SAVELLA-25 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.10 |
401.03 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456155060 |
SAVELLA-50 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.10 |
401.03 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023586228 |
TAYTULLA-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE PACK OF 1 |
01/03/2020 |
9.35 |
196.30 |
03/29/2020 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023586230 |
TAYTULLA-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE PACK OF 5 |
01/03/2020 |
46.74 |
981.48 |
03/29/2020 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456040001 |
TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE PACK OF 1 |
01/03/2020 |
9.61 |
201.73 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456040010 |
TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE PACK OF 10 |
01/03/2020 |
96.06 |
2017.27 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456060001 |
TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE PACK OF 1 |
01/03/2020 |
9.61 |
201.73 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456060010 |
TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE PACK OF 10 |
01/03/2020 |
96.06 |
2017.27 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
61874010060 |
VIBERZI-100 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
62.73 |
1317.39 |
03/14/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
61874007560 |
VIBERZI-75 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
62.73 |
1317.39 |
03/14/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456110130 |
VIIBRYD-10 mg (7)-20 mg (23)-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.61 |
285.85 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456111030 |
VIIBRYD-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.61 |
285.85 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456112030 |
VIIBRYD-20 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.61 |
285.85 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456114030 |
VIIBRYD-40 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.61 |
285.85 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611001 |
ZENPEP-10,000 unit-32,000 unit-42,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
16.75 |
351.77 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030602 |
ZENPEP-10,000 unit-34,000 unit-55,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
16.75 |
351.77 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611101 |
ZENPEP-15,000 unit-47,000 unit-63,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
24.19 |
508.06 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611201 |
ZENPEP-20,000 unit-63,000 unit-84,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
32.86 |
690.13 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030302 |
ZENPEP-20,000 unit-68,000 unit-109,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
32.86 |
690.13 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611601 |
ZENPEP-25,000 unit-79,000 unit-105,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
40.67 |
854.01 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030502 |
ZENPEP-25,000 unit-85,000 unit-136,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
40.67 |
854.01 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611301 |
ZENPEP-3,000 unit-10,000 unit-14,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.88 |
186.51 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030402 |
ZENPEP-3,000 unit-10,000 unit-16,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.88 |
186.51 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611401 |
ZENPEP-40,000 unit-126,000 unit-168,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
64.86 |
1362.01 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030702 |
ZENPEP-40,000 unit-136,000 unit-218,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
64.86 |
1362.01 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611501 |
ZENPEP-5,000 unit-17,000 unit-24,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.47 |
177.95 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030002 |
ZENPEP-5,000 unit-17,000 unit-27,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.47 |
177.95 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110050201 |
Acticlate 150mg 60 tablet |
01/02/2020 |
102.33 |
2204.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110050101 |
Acticlate 75mg 60 tablet |
01/02/2020 |
102.33 |
2204.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023367060 |
Aczone 5% 60 g |
01/02/2020 |
52.24 |
687.42 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
593.63 |
542.13 |
2008 |
343.48 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023367090 |
Aczone 5% 90g |
01/02/2020 |
68.52 |
901.68 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
778.65 |
711.10 |
2008 |
516.21 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023520660 |
Aczone 7.5% 60g |
01/02/2020 |
52.24 |
687.42 |
11/18/2033 |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
Indication extended to 9 years; post marketing commitment completed |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
593.63 |
542.13 |
2016 |
495.10 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023520690 |
Aczone 7.5% 90g |
01/02/2020 |
68.52 |
901.68 |
11/18/2033 |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
Indication extended to 9 years; post marketing commitment completed |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
778.65 |
711.10 |
2016 |
649.41 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110051815 |
Altabax 1% ointment 15g |
01/02/2020 |
14.73 |
315.03 |
02/14/2027 |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
11/15/2015 |
GlaxoSmithKline |
None |
1 |
None |
151.64 |
128.83 |
2007 |
217.00 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110051830 |
Altabax 1% ointment 30g |
01/02/2020 |
28.79 |
604.67 |
02/14/2027 |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
11/15/2015 |
GlaxoSmithKline |
None |
1 |
None |
288.82 |
245.38 |
2007 |
415.00 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023869450 |
Azelex 50g |
01/02/2020 |
32.52 |
682.92 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
607.85 |
555.11 |
1995 |
308.69 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110002660 |
Cordan 0.05% Ointment 60g |
01/02/2020 |
37.64 |
738.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110003512 |
Cordran 0.05% Cream 120g |
01/02/2020 |
62.37 |
1224.01 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110005212 |
Cordran 0.05% Lotion 120ml |
01/02/2020 |
62.37 |
1224.01 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023587080 |
Cordran Tape 4 ug/cm2, 1500cm2 |
01/02/2020 |
34.02 |
714.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
635.87 |
580.70 |
2016 |
580.70 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110081230 |
Fluoroplex 1% cream 30g |
01/02/2020 |
45.90 |
900.92 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023915530 |
Tazorac Cream .05% 30g |
01/02/2020 |
19.93 |
418.46 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
372.46 |
340.15 |
2000 |
221.55 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023915560 |
Tazorac Cream .05% 60g |
01/02/2020 |
39.85 |
836.76 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
744.78 |
680.16 |
2000 |
443.01 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023915630 |
Tazorac Cream 0.1% 30g |
01/02/2020 |
21.17 |
444.56 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
395.69 |
361.36 |
2000 |
235.36 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023915660 |
Tazorac Cream 0.1% 60g |
01/02/2020 |
42.33 |
888.98 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
791.26 |
722.61 |
2000 |
784.49 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023004210 |
Tazorac Gel .01% 100g |
01/02/2020 |
70.56 |
1481.75 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
1318.87 |
1204.45 |
1997 |
784.49 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023004203 |
Tazorac Gel .01% 30g |
01/02/2020 |
21.17 |
444.56 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
395.69 |
361.36 |
1997 |
235.36 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023833510 |
Tazorac Gel .05% 100g |
01/02/2020 |
66.41 |
1394.53 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
1241.23 |
1133.54 |
1997 |
738.30 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023833503 |
Tazorac Gel .05% 30g |
01/02/2020 |
19.93 |
418.46 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
372.46 |
340.15 |
1997 |
217.00 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110007130 |
Veltin 1.2%/0.025% gel 30g |
01/02/2020 |
22.04 |
462.74 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
11/15/2015 |
GlaxoSmithKline |
None |
1 |
None |
243.07 |
220.97 |
2010 |
148.00 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110007160 |
Veltin 1.2%/0.025% gel 60g |
01/02/2020 |
41.49 |
871.24 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
11/15/2015 |
GlaxoSmithKline |
None |
1 |
None |
456.61 |
415.10 |
2010 |
278.00 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110011100 |
Verdeso 0.05% foam 100g |
01/02/2020 |
50.57 |
992.41 |
08/13/2027 |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110008045 |
Xolegel 2% gel 45g |
01/02/2020 |
40.06 |
786.28 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
03/31/2020 |
59338077510 |
ferumoxytol 510MG/17 mL Feraheme (Ferumoxytol Injection) 510mg/17 mL CTN/10 |
01/01/2020 |
412.10 |
10714.20 |
06/30/2023 |
Single Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
12/31/2020 |
59338077501 |
ferumoxytol 510MG/17 mL Feraheme 510mg Each |
10/01/2020 |
42.86 |
1114.28 |
06/30/2023 |
Single Source Drug |
None |
1 |
Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_
As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_
The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_
Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_
In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_
We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_ |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
12/31/2020 |
59338077510 |
ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10 |
10/01/2020 |
428.60 |
11142.80 |
06/30/2023 |
Single Source Drug |
None |
1 |
Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_
As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_
The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_
Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_
In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_
We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_ |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
03/31/2020 |
59338077501 |
ferumoxytol 510MG/17 mL Feraheme (Ferumoxytol Injection) 510mg Each |
01/01/2020 |
41.21 |
1071.42 |
06/30/2023 |
Single Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
03/31/2020 |
64011060128 |
Intrarosa (prasterone) 6.5mg vaginal insert Package of 28 |
01/01/2020 |
10.30 |
212.30 |
03/19/2031 |
Single Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
02/14/2017 |
US commercial rights licensed from Endoceutics |
50000000 |
None |
At closing, AMAG will pay Endoceutics $50 million of total upfront consideration and issue Endoceutics 600,000 unregistered shares of AMAG common stock. In addition, AMAG will pay Endoceutics up to $10 million upon delivery of adequate launch quantities of Intrarosa and $10 million upon the first anniversary of the effective date of the agreement. Endoceutics will be entitled to certain sales milestone payments, including a first sales milestone payment of $15 million, which would be triggered when Intrarosa annual net U.S. sales exceed $150 million, and a second milestone payment of $30 million, which would be triggered when annual net U.S. sales exceed $300 million. Should annual net U.S. sales exceed $500 million, there are additional sales milestone payments of up to $850 million, which would be triggered at various sales thresholds. AMAG will also pay Endoceutics tiered royalties as a percent of Intrarosa net sales. |
1.00 |
0.00 |
2017 |
175.00 |
None |
Product acquired pre-launch |
| Rx0000050 |
Amarin Pharma, Inc. |
12/31/2020 |
52937000120 |
Vascepa(Icosapent ethyl) 120 1g |
12/29/2020 |
13.24 |
344.22 |
06/28/2033 |
Single Source Drug |
3158613 |
None |
Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study.
• The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold.
• On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA
• as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and
o Established cardiovascular disease, or
o Diabetes and two or more additional risk factors for cardiovascular disease
The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy.
Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000050 |
Amarin Pharma, Inc. |
12/31/2020 |
52937000340 |
Vascepa(Icosapent ethyl) 240 500mg |
12/29/2020 |
15.49 |
402.73 |
06/28/2033 |
Single Source Drug |
3485 |
None |
Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study.
• The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold.
• On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA
• as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and
o Established cardiovascular disease, or
o Diabetes and two or more additional risk factors for cardiovascular disease
The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy.
Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
60687012125 |
ACAMPROSATE CALCIUM DR TABLET 333MG 30UD |
11/02/2020 |
17.32 |
58.97 |
None |
Non-innovator Multiple Source Drug |
8953 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
09/30/2020 |
60687031425 |
Azithromycin Tablet 600mg 30UD |
09/22/2020 |
45.79 |
159.27 |
None |
Non-innovator Multiple Source Drug |
1818 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
68001039700 |
FAMOTIDINE TAB 20MG 100 |
12/01/2020 |
7.23 |
14.00 |
None |
Non-innovator Multiple Source Drug |
107510 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
68001039708 |
FAMOTIDINE TAB 20MG 1000 |
12/01/2020 |
78.28 |
140.00 |
None |
Non-innovator Multiple Source Drug |
20150 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
68001039800 |
FAMOTIDINE TAB 40MG 100 |
12/01/2020 |
15.77 |
28.00 |
None |
Non-innovator Multiple Source Drug |
48412 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
68001039803 |
FAMOTIDINE TAB 40MG 500 |
12/01/2020 |
40.02 |
140.00 |
None |
Non-innovator Multiple Source Drug |
7288 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
03/31/2020 |
68084082321 |
Methylphenidate HCl Tablet CII 10mg 30UD |
01/16/2020 |
10.23 |
44.41 |
None |
Non-innovator Multiple Source Drug |
5487 |
None |
Market conditions |
None |
No change/improvement in drug product description/Not applicable. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
09/30/2020 |
68084067601 |
Metoclopramide Tablet 10mg 100UD |
07/24/2020 |
20.00 |
60.00 |
None |
Non-innovator Multiple Source Drug |
19755 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
06/30/2020 |
60687037401 |
NABUMETONE TAB 500MG 100UD |
04/06/2020 |
13.19 |
118.19 |
None |
Non-innovator Multiple Source Drug |
1278 |
None |
Market Conditions |
None |
No change or improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
03/31/2020 |
60687015625 |
Phenytoin Chew Tablet 50mg 30UD |
02/26/2020 |
15.59 |
45.00 |
None |
Non-innovator Multiple Source Drug |
10773 |
None |
Market conditions |
None |
No change/improvement in the drug product description |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000128 |
American Regent |
09/30/2020 |
00517065001 |
Injectafer Intravenous Solution 750 MG/15ML |
07/01/2020 |
33.19 |
1139.67 |
02/15/2028 |
Single Source Drug |
696537 |
None |
American Regent’s US Standards of Business Conduct (available at https://www.americanregent.com/media/2747/us-sobc-112019.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Injectafer is not an acquired product. American Regent is the NDA holder of this NDC. |
| Rx0000128 |
American Regent |
03/31/2020 |
00517037405 |
PROVAYBLUE (METHYLENE BLUE) 5 MG/ML, 10 ML AMPULE, PKG. OF 5 |
03/31/2020 |
156.82 |
1189.87 |
None |
Innovator Multiple Source Drug |
67316967 |
None |
American Regent’s US Standards of Business Conduct (available at http://ari.americanregent.com/Files/Compliance/US_Standards_of_Business_Conduct_21NOV2019.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
No improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ProvayBlue is not an acquired product. The partner from whom we license the drug, (which is not affiliated with American Regent) is the NDA holder of this NDC. |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066930 |
Emverm Chewable Tablet 100 MG |
02/25/2020 |
41.92 |
465.31 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
405.53 |
None |
2018 |
405.53 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
60846030115 |
Nizatidine Oral Solution 15mg/mL 480 Bottle |
01/20/2020 |
50.63 |
557.41 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Gemini |
None |
1 |
None |
419.59 |
None |
2018 |
419.59 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069701 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 100 tablets |
07/06/2020 |
44.18 |
486.41 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
381.56 |
381.56 |
2019 |
381.56 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069713 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 60 tablets |
07/06/2020 |
26.51 |
291.85 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
228.94 |
228.94 |
2019 |
228.94 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069801 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 100 tablets |
07/06/2020 |
61.26 |
674.52 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
529.13 |
529.13 |
2019 |
529.13 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069813 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 60 tablets |
07/06/2020 |
36.76 |
404.72 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
317.48 |
317.48 |
2019 |
317.48 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069901 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 100 tablets |
07/06/2020 |
78.36 |
862.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
676.74 |
676.74 |
2019 |
676.74 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069913 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 60 tablets |
07/06/2020 |
47.01 |
517.62 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
406.05 |
406.05 |
2019 |
406.05 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896070001 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 100 tablets |
07/06/2020 |
112.78 |
1241.72 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
974.06 |
974.06 |
2019 |
974.06 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896070013 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 60 tablets |
07/06/2020 |
67.67 |
745.04 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
584.44 |
584.44 |
2019 |
584.44 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896070101 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 100 tablets |
07/06/2020 |
147.21 |
1620.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
1271.39 |
1271.39 |
2019 |
1271.39 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896070113 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 60 tablets |
07/06/2020 |
88.32 |
972.45 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
762.84 |
762.84 |
2019 |
762.84 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069501 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 100 tablets |
07/06/2020 |
23.01 |
253.31 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
198.71 |
198.71 |
2019 |
198.71 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069513 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 60 tablets |
07/06/2020 |
13.80 |
151.98 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
119.22 |
119.22 |
2019 |
119.22 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069601 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 100 tablets |
07/06/2020 |
33.59 |
369.84 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
290.12 |
290.12 |
2019 |
290.12 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069613 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 60 tablets |
07/06/2020 |
20.15 |
221.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
174.07 |
174.07 |
2019 |
174.07 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066101 |
Rytary 23.75mg/95mg ER Cap 100ct |
02/25/2020 |
14.42 |
334.98 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
291.68 |
None |
2018 |
291.68 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066201 |
Rytary 36.25mg/145mg ER Cap 100ct |
02/25/2020 |
14.42 |
334.98 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
291.68 |
None |
2018 |
291.68 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066301 |
Rytary 48.75mg/195mg ER Cap 100ct |
02/25/2020 |
14.42 |
334.98 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
291.68 |
None |
2018 |
291.68 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066401 |
Rytary 61.25mg/245mg ER Cap 100ct |
02/25/2020 |
18.13 |
420.92 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
366.51 |
None |
2018 |
366.51 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896067151 |
Zomig 2.5 mg 6 tab blister |
02/25/2020 |
69.92 |
776.18 |
None |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
584.75 |
None |
2018 |
584.75 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896068251 |
Zomig 2.5 mg Nasal Spray (2x3 packs) |
02/25/2020 |
48.08 |
533.73 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
402.09 |
None |
2018 |
402.09 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896067250 |
Zomig 5 mg 3 tab blister |
02/25/2020 |
34.96 |
388.08 |
None |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
292.37 |
None |
2018 |
292.37 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896068151 |
Zomig 5 mg Nasal Spray (2x3 packs) |
02/25/2020 |
48.08 |
533.73 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
402.09 |
None |
2018 |
402.09 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
12/31/2020 |
64896068251 |
Zomig Nasal Solution 2.5 MG, Package size of 6 tablets |
12/01/2020 |
52.84 |
586.57 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
402.09 |
402.09 |
2018 |
402.09 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
12/31/2020 |
64896068151 |
Zomig Nasal Solution 5 MG, Package size of 6 tablets |
12/01/2020 |
52.84 |
586.57 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
402.09 |
402.09 |
2018 |
402.09 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896069151 |
Zomig ZMT 2.5 mg 6 tab blister |
02/25/2020 |
69.92 |
776.18 |
None |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
584.75 |
None |
2018 |
584.75 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896069250 |
Zomig ZMT 5 mg 3 tab blister |
02/25/2020 |
34.96 |
388.08 |
None |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
292.37 |
None |
2018 |
292.37 |
None |
None |
| Rx0000176 |
ANIP |
03/31/2020 |
62559067030 |
Arimidex 1mg Tab 30 |
03/01/2020 |
129.93 |
1497.59 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559068030 |
Casodex 50mg Tab 30 |
03/01/2020 |
285.97 |
3296.13 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559011107 |
Cortenema 100mg/60mL Enema 7 |
03/01/2020 |
33.82 |
166.85 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559013807 |
HC 100mg/60mL Enema 7 |
03/01/2020 |
30.55 |
150.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559052201 |
Inderal LA 120mg Cap 100 |
03/01/2020 |
646.29 |
7449.39 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559052301 |
Inderal LA 160mg Cap 100 |
03/01/2020 |
674.68 |
7776.58 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559052001 |
Inderal LA 60mg Cap 100 |
03/01/2020 |
502.45 |
5791.35 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559052101 |
Inderal LA 80mg Cap 100 |
03/01/2020 |
586.87 |
6764.41 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559060130 |
Inderal XL 120mg Cap 30 |
03/01/2020 |
173.84 |
2003.74 |
10/04/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559060030 |
Inderal XL 80mg Cap 30 |
03/01/2020 |
173.84 |
2003.74 |
10/04/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559059130 |
InnoPran XL 120mg Cap 30 |
03/01/2020 |
173.84 |
2003.74 |
10/04/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559059030 |
InnoPran XL 80mg Cap 30 |
03/01/2020 |
173.84 |
2003.74 |
10/04/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559028001 |
Lithobid 300mg Tab 100 |
03/01/2020 |
110.57 |
1274.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559016601 |
Reglan 10mg Tab 100 |
03/01/2020 |
29.54 |
340.48 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559016501 |
Reglan 5mg Tab 100 |
03/01/2020 |
29.54 |
340.48 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559031020 |
Vancocin 125mg Cap 20 |
03/01/2020 |
149.44 |
1722.44 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559031120 |
Vancocin 250mg Cap 20 |
03/01/2020 |
275.52 |
3175.78 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000274 |
Artesa Labs, LLC |
06/30/2020 |
57893020360 |
Nicaprin, Dietary Supplement, Tablet, 60 ct. |
05/30/2020 |
54.00 |
590.00 |
None |
Single Source Drug |
17838 |
None |
Raw materials, regulations |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000075 |
Assertio Therapeutics, Inc. |
03/31/2020 |
13913001201 |
Cambia (diclofenac potassium) 50MG Oral 1 Packet |
01/03/2020 |
7.49 |
83.11 |
06/16/2026 |
Single Source Drug |
959886 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years |
| Rx0000075 |
Assertio Therapeutics, Inc. |
03/31/2020 |
13913000812 |
Zipsor (diclofenac potassium) 25MG Oral Capsule 120 Ct Bottle |
01/03/2020 |
141.48 |
1570.55 |
02/24/2029 |
Single Source Drug |
2806920 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186077660 |
Brilinta 60mg Tablets 60 count bottle |
07/01/2020 |
7.71 |
393.03 |
01/27/2036 |
Single Source Drug |
181368340 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186077739 |
Brilinta 90mg Tablets 100 count box |
07/01/2020 |
12.85 |
655.04 |
01/27/2036 |
Single Source Drug |
28772299 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186077760 |
Brilinta 90mg Tablets 60 count bottle |
07/01/2020 |
7.71 |
393.03 |
01/27/2036 |
Single Source Drug |
1182543013 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310654004 |
Bydureon 2mg Autoinjector 4 Syringes |
07/01/2020 |
14.42 |
735.18 |
10/04/2030 |
Single Source Drug |
668761831 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
407.45 |
None |
2012 |
323.44 |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310653004 |
Bydureon 2mg Pen 4 Syringes |
07/01/2020 |
14.42 |
735.18 |
03/21/2028 |
Single Source Drug |
815082319 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
407.45 |
None |
2012 |
323.44 |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310009530 |
Daliresp 500mcg Tablets 30 count bottle |
07/01/2020 |
21.67 |
382.85 |
03/08/2024 |
Single Source Drug |
214201592 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/04/2015 |
Forest Laboratories, LLC |
280000000 |
None |
The Daliresp acquisition was part of a larger acquisition that included other assets, the estimated portion for Daliresp was approximately $280 million. The acquisition was made from Forest Laboratories, LLC which was owned by Actavis PLC at the time of acquisition. |
257.88 |
None |
2011 |
172.50 |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310009590 |
Daliresp 500mcg Tablets 90 count bottle |
07/01/2020 |
65.01 |
1148.57 |
03/08/2024 |
Single Source Drug |
49787415 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/04/2015 |
Forest Laboratories, LLC |
280000000 |
None |
The Daliresp acquisition was part of a larger acquisition that included other assets, the estimated portion for Daliresp was approximately $280 million. The acquisition was made from Forest Laboratories, LLC which was owned by Actavis PLC at the time of acquisition. |
773.65 |
None |
2012 |
517.50 |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310621030 |
Farxiga 10mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
05/26/2030 |
Single Source Drug |
1438170485 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
289.20 |
289.20 |
2014 |
289.20 |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310621030 |
Farxiga 10mg tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
05/26/2030 |
Single Source Drug |
1438170485 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
289.20 |
None |
2014 |
289.20 |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310620530 |
Farxiga 5mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
05/26/2030 |
Single Source Drug |
590696676 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
289.20 |
289.20 |
2014 |
289.20 |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310620530 |
Farxiga 5mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
05/26/2030 |
Single Source Drug |
590696676 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
289.20 |
None |
2014 |
289.20 |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310678030 |
Qtern 5mg-10mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
12/16/2029 |
Single Source Drug |
10919684 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310678030 |
Qtern 5mg-10mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
12/16/2029 |
Single Source Drug |
10919684 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186037020 |
Symbicort 160/4.5mcg HFA Aerosol 1 Inhaler |
07/01/2020 |
7.15 |
364.38 |
10/07/2029 |
Innovator Multiple Source Drug |
None |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186037028 |
Symbicort 160/4.5mcg HFA Aerosol 1 Inhaler Inst Pack |
07/01/2020 |
4.85 |
247.60 |
10/07/2029 |
Innovator Multiple Source Drug |
159106270 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186037220 |
Symbicort 80/4.5mcg HFA Aerosol 1 Inhaler |
07/01/2020 |
6.25 |
318.78 |
10/07/2029 |
Innovator Multiple Source Drug |
1020316295 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186037228 |
Symbicort 80/4.5mcg HFA Aerosol 1 Inhaler Inst Pack |
07/01/2020 |
4.22 |
215.24 |
10/07/2029 |
Innovator Multiple Source Drug |
43272143 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310628030 |
Xigduo XR 10-1000mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
11/12/2030 |
Single Source Drug |
128234044 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310628030 |
Xigduo XR 10-1000mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
11/12/2030 |
Single Source Drug |
128234044 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310627030 |
Xigduo XR 10-500mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
11/12/2030 |
Single Source Drug |
13548819 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310627030 |
Xigduo XR 10-500mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
11/12/2030 |
Single Source Drug |
13548819 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310626060 |
Xigduo XR 5-1000mg Tablets 60 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
11/12/2030 |
Single Source Drug |
237728896 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310626060 |
Xigduo XR 5-1000mg Tablets 60 count bottle |
07/01/2020 |
10.14 |
517.32 |
11/12/2030 |
Single Source Drug |
237728896 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310625030 |
Xigduo XR 5-500mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
11/12/2030 |
Single Source Drug |
23387060 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310625030 |
Xigduo XR 5-500mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
11/12/2030 |
Single Source Drug |
23387060 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000265 |
Atland Pharmaceuticals |
06/30/2020 |
71993030030 |
Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets (325 mg/ 30 mg/ 16 mg) |
04/02/2020 |
150.00 |
600.00 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Atland acquired product ANDA 204209 from Larken the rights to market and distribute the NDC under a licensing agreement, the terms of which are not publicly available. |
| Rx0000058 |
Avanir Pharmaceuiticals |
03/31/2020 |
64597030160 |
NUEDEXTA (Dextromethorphan hydrobromide 20mg and quinidine sulfate 10mg capsules); 60 capsules per bottle |
01/01/2020 |
76.40 |
1250.40 |
08/13/2026 |
Single Source Drug |
None |
1 |
Avanir is committed to making responsible pricing determinations, and in so doing we consider a range of factors. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Avanir are made at the executive level in adherence with all federal and state laws. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The reason for the blank acquisition-related fields (14-22) is that Neudexta was not acquired. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264959410 |
0.4% LIDOCAINE HCL AND 5% DEXTROSE INJECTIONInjectable, 400mg/100mL500mL |
05/01/2020 |
38.95 |
187.27 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264959820 |
0.8% LIDOCAINE HCL AND DEXTROSE INJECTIONInjectable, 800mg/100mL250mL |
05/01/2020 |
53.61 |
170.25 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264180032 |
0.9% SODIUM CHLORIDE INJECTION USPInjectable, 900 mg/mL100mL |
05/01/2020 |
24.32 |
145.28 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264180036 |
0.9% SODIUM CHLORIDE INJECTION USPInjectable, 900 mg/mL25mL |
05/01/2020 |
56.40 |
244.39 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264180031 |
0.9% SODIUM CHLORIDE INJECTION USPInjectable, 900 mg/mL50mL |
05/01/2020 |
31.92 |
190.68 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264780020 |
0.9% SODIUM CHLORIDE INJECTION USPInjectable, 900mg/100mL250mL |
05/01/2020 |
2.58 |
57.54 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264762320 |
10% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USPInjectable, 10gm/100mL Dextrose; 200mg/100mL Sodium Chloride250mL |
05/01/2020 |
19.98 |
74.92 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264752000 |
10% DEXTROSE INJECTION USPInjectable, 10gm/100mL1000mL |
05/01/2020 |
8.55 |
37.06 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264752010 |
10% DEXTROSE INJECTION USPInjectable, 10gm/100mL500mL |
05/01/2020 |
15.38 |
66.63 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264320055 |
15% AMINO ACIDS INJECTION PHARMACY BULK PACKAGEInjectable, 15% (150gm/1000mL)1000mL |
05/01/2020 |
36.53 |
211.54 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264151031 |
5% DEXTROSE INJECTION USP;Injectable, 50 mg/mL;50mL |
05/01/2020 |
31.92 |
190.68 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264151032 |
5% DEXTROSE INJECTION USPInjectable, 50 mg/mL100mL |
05/01/2020 |
24.32 |
145.28 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264751000 |
5% DEXTROSE INJECTION USPInjectable, 5gm/100mL1000mL |
05/01/2020 |
7.47 |
44.31 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264751020 |
5% DEXTROSE INJECTION USPInjectable, 5gm/100mL250mL |
05/01/2020 |
18.39 |
68.47 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264751010 |
5% DEXTROSE INJECTION USPInjectable, 5gm/100mL500mL |
05/01/2020 |
22.10 |
74.51 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264738750 |
70% DEXTROSE INJECTION USPInjectable, 70gm/100mL2000mL |
05/01/2020 |
13.20 |
57.21 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264310311 |
CEFAZOLIN 1G 50ML ISO-OSMOTIC DEXINJ DUPLEX DRUG DEL SYSTEMEq 1gm base/vial50mL |
05/01/2020 |
52.56 |
272.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264310511 |
CEFAZOLIN FOR INJECTION USP AND DEXTROSE INJECTION USP IN THEEq 2gm base/vial50mL |
05/01/2020 |
31.89 |
306.45 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264319311 |
CEFEPIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEXInjectable, Eq 1gm base/vial50mL |
05/01/2020 |
26.28 |
408.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264317311 |
CEFOTETAN FOR INJECTION AND DEXTROSE INJECTIONInjectable, Eq 1gm base/vial50mL |
05/01/2020 |
109.44 |
544.80 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264317511 |
CEFOTETAN FOR INJECTION AND DEXTROSE INJECTIONInjectable, Eq 2gm base/vial50mL |
05/01/2020 |
143.56 |
766.12 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264312311 |
CEFOXITIN FOR INJECTION IN THE DUPLEX CONTAINERInjectable, Eq 1gm base/vial50mL |
05/01/2020 |
87.25 |
391.57 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264312511 |
CEFOXITIN FOR INJECTION IN THE DUPLEX CONTAINERInjectable, Eq 2gm base/vial50mL |
05/01/2020 |
142.71 |
701.43 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264314311 |
CEFTAZIDIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEXInjectable, Eq 1gm base/vial50mL |
05/01/2020 |
16.95 |
374.55 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264314511 |
CEFTAZIDIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEXInjectable, Eq 2gm base/vial50mL |
05/01/2020 |
110.89 |
527.77 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264315311 |
CEFTRIAXONE FOR INJECTION AND DEXTROSE INJECTION IN DUPLEXInjectable, Eq 1gm base/vial50mL |
05/01/2020 |
47.88 |
408.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264957710 |
HEPARIN IN DEXTROSE INJECTION4,000 Units/100mL500mL |
05/01/2020 |
33.48 |
354.12 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264987210 |
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTICInjectable. 200 units/100mL500mL |
05/01/2020 |
6.49 |
91.93 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264956710 |
HEPARIN SODIUM IN 5% DEXTROSE INJECTION (500 U/ML)5,000 Units/100mL500mL DEX |
05/01/2020 |
59.52 |
299.64 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264937155 |
HEPATAMINEInjectable, 8% (8gm/100mL)500mL |
05/01/2020 |
60.23 |
624.61 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264553532 |
METRO IV (METRONIDAZOLE INJECTION 0.5%)Injectable, 500mg/100mL100mL |
05/01/2020 |
20.96 |
71.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264446030 |
NUTRILIPID 20%Injectable, 20%250mL |
05/01/2020 |
57.69 |
255.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264446010 |
NUTRILIPID 20%Injectable, 20%500mL |
05/01/2020 |
58.51 |
323.47 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264738850 |
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERSoultion, 900mg/100mL2000mL |
05/01/2020 |
11.57 |
46.53 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264738860 |
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERSoultion, 900mg/100mL3000mL |
05/01/2020 |
10.06 |
62.42 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264785000 |
STERILE WATER FOR INJECTION USPLiquid, 100%1000mL |
05/01/2020 |
9.90 |
41.69 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264738660 |
STERILE WATER FOR IRRIGATION USPLiquid, 100%3000mL |
05/01/2020 |
11.58 |
65.26 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000013 |
B. Braun Medical Inc. |
06/30/2020 |
00264934155 |
TROPHAMINE 10%10% (10gm/100mL)500mL |
05/01/2020 |
48.52 |
211.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years. |
| Rx0000229 |
B. F. ASCHER AND COMPANY, INC. |
03/31/2020 |
00225029520 |
Anaspaz 0.125 mg Tablets 500ct |
02/01/2020 |
18.50 |
122.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208035310 |
ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 10mL |
01/09/2020 |
27.07 |
478.26 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208035305 |
ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 5mL |
01/09/2020 |
13.54 |
239.14 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208062901 |
BEPREVE™ Ophthalmic Solution USP, 1.5%, 10mL |
01/09/2020 |
24.91 |
440.09 |
09/05/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208062902 |
BEPREVE™ Ophthalmic Solution USP, 1.5%, 5mL |
01/09/2020 |
13.02 |
230.10 |
09/05/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208044605 |
BESIVANCE® (besifloxacin ophthalmic suspension 0.6%) |
01/09/2020 |
10.16 |
179.52 |
01/09/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208000401 |
ISTALOL™ Ophthalmic Solution USP, 0.5%, 2.5mL |
01/09/2020 |
10.35 |
182.77 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208000403 |
ISTALOL™ Ophthalmic Solution USP, 0.5%, 5mL |
01/09/2020 |
20.69 |
365.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208080060 |
LACRISERT® (hydroxypropyl cellulose ophthalmic insert), 5mg |
01/09/2020 |
30.08 |
531.44 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 2/5/2016 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208050307 |
LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%) |
01/09/2020 |
11.44 |
202.17 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208044335 |
LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%) |
01/09/2020 |
16.10 |
284.48 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208029910 |
LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 10mL |
01/09/2020 |
28.52 |
503.91 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208029915 |
LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 15mL |
01/09/2020 |
42.41 |
749.19 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208029905 |
LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 5mL |
01/09/2020 |
14.26 |
251.98 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208060203 |
PROLENSA™ (bromfenac ophthalmic solution) 0.07% 3mL |
01/09/2020 |
16.00 |
282.67 |
11/11/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208081205 |
TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.25%, 5mL |
01/09/2020 |
10.44 |
184.48 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 2/26/2018 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208081310 |
TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 10mL |
01/09/2020 |
14.48 |
255.79 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 2/26/2018 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208081305 |
TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 5mL |
01/09/2020 |
11.30 |
199.64 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 2/26/2018 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208081425 |
TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.25%, 5mL |
01/09/2020 |
12.22 |
215.84 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 11/6/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208081605 |
TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.50%, 5mL |
01/09/2020 |
13.39 |
236.52 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 8/19/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208053535 |
ZIRGAN™ (Ganciclovir Ophthalmic Gel 0.15%) |
01/09/2020 |
21.08 |
372.34 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208035810 |
ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 10mL |
01/09/2020 |
29.69 |
524.49 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2020 |
24208035805 |
ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 5mL |
01/09/2020 |
14.84 |
262.23 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2020 |
59385002260 |
Belbuca 150 mcg, film, 60ct box |
01/01/2020 |
16.61 |
348.82 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
278.60 |
255.60 |
2015 |
255.60 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2020 |
59385002360 |
Belbuca 300 mcg, film, 60ct box |
01/01/2020 |
26.09 |
547.83 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
437.53 |
401.40 |
2015 |
401.40 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2020 |
59385002460 |
Belbuca 450 mcg, film, 60ct box |
01/01/2020 |
35.45 |
744.36 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
594.49 |
545.40 |
2015 |
545.40 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2020 |
59385002560 |
Belbuca 600 mcg, film, 60ct box |
01/01/2020 |
37.82 |
794.29 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
634.38 |
582.00 |
2015 |
582.00 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2020 |
59385002160 |
Belbuca 75 mcg, film, 60ct box |
01/01/2020 |
16.61 |
348.82 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
278.60 |
255.60 |
2015 |
255.60 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2020 |
59385002660 |
Belbuca 750 mcg, film, 60ct box |
01/01/2020 |
39.77 |
835.24 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
667.08 |
612.00 |
2015 |
612.00 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2020 |
59385002760 |
Belbuca 900 mcg, film, 60ct box |
01/01/2020 |
40.94 |
859.80 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
686.70 |
630.00 |
2015 |
630.00 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2020 |
59385004130 |
Symproic .2mg mg tablet, 30 ct bottle |
01/01/2020 |
17.96 |
377.11 |
11/11/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/04/2019 |
Shionogi Inc. |
30000000 |
None |
None |
359.15 |
313.95 |
2017 |
313.95 |
None |
None |
| Rx0000099 |
Biogen |
03/31/2020 |
64406000501 |
Tecfidera (dimethyl fumarate) Half Dose (120 mg) Capsules: 7-day bottle of 14 capsules |
01/01/2020 |
109.30 |
1931.10 |
02/07/2028 |
Single Source Drug |
None |
1 |
Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability. |
None |
This increase was not necessitated by a change or improvement in the product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Tecfidera was not acquired by Biogen from another company in the last 5 years. |
| Rx0000099 |
Biogen |
03/31/2020 |
64406000602 |
Tecfidera (dimethyl fumarate) Regular Dose (240 mg) Capsules: 30-day bottle of 60 capsules |
01/01/2020 |
468.44 |
8275.89 |
02/07/2028 |
Single Source Drug |
None |
1 |
Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability. |
None |
This increase was not necessitated by a change or improvement in the product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Tecfidera was not acquired by Biogen from another company in the last 5 years. |
| Rx0000099 |
Biogen |
03/31/2020 |
64406000703 |
Tecfidera (dimethyl fumarate) Starter Pack (30 day): 7-day bottle 120 mg capsules, quantity 14 and 23-day bottle 240 mg capsules, quantity 46 |
01/01/2020 |
468.44 |
8275.89 |
02/07/2028 |
Single Source Drug |
None |
1 |
Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability. |
None |
This increase was not necessitated by a change or improvement in the product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Tecfidera was not acquired by Biogen from another company in the last 5 years. |
| Rx0000099 |
Biogen |
09/30/2020 |
64406000801 |
TYSABRI (natalizumab) Injection 300 mg/15 mL (20 mg/mL) solution in a single-dose vial |
07/03/2020 |
239.81 |
7091.68 |
03/05/2027 |
Single Source Drug |
None |
1 |
Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability. |
None |
This increase was not necessitated by a change or improvement in the product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Tysabri was not acquired by Biogen from another company in the last 5 years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597000201 |
APTIVUS 100 MG/ML SOLUTION |
01/01/2020 |
33.46 |
591.09 |
04/29/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=347 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597000302 |
APTIVUS 250 MG CAPSULE |
01/01/2020 |
100.38 |
1773.36 |
04/29/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=348 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597008717 |
ATROVENT 17 MCG HFA INHALER |
01/01/2020 |
23.29 |
411.39 |
01/17/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=357 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597003134 |
CATAPRES-TTS 1 PATCH |
01/01/2020 |
15.80 |
279.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=352 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597003234 |
CATAPRES-TTS 2 PATCH |
01/01/2020 |
26.80 |
469.91 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=353 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597003334 |
CATAPRES-TTS 3 PATCH |
01/01/2020 |
36.90 |
651.86 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=354 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597002402 |
COMBIVENT RESPIMAT 20-100 MCG |
01/01/2020 |
24.14 |
426.45 |
10/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=349 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014130 |
GILOTRIF 20 MG TABLET |
01/01/2020 |
704.57 |
9511.72 |
07/05/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=372 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597013730 |
GILOTRIF 30 MG TABLET |
01/01/2020 |
704.57 |
9511.72 |
07/05/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=367 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597013830 |
GILOTRIF 40 MG TABLET |
01/01/2020 |
704.57 |
9511.72 |
07/05/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=368 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597015237 |
JARDIANCE 10 MG 30 TABLET |
01/01/2020 |
29.57 |
522.42 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=380 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597015230 |
JARDIANCE 10 MG TABLET 30 |
01/01/2020 |
29.57 |
522.42 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=379 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597015290 |
JARDIANCE 10 MG TABLET 90 |
01/01/2020 |
88.71 |
1567.25 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=381 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597015337 |
JARDIANCE 25 MG 30 TABLET |
01/01/2020 |
29.57 |
522.42 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=383 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597015330 |
JARDIANCE 25 MG TABLET 30 |
01/01/2020 |
29.57 |
522.42 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=382 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597015390 |
JARDIANCE 25 MG TABLET 90 |
01/01/2020 |
88.71 |
1567.25 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=384 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014818 |
JENTADUETO 2.5 MG-1,000 MG 180 |
01/01/2020 |
78.51 |
1387.02 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=377 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014860 |
JENTADUETO 2.5 MG-1,000 MG 60 |
01/01/2020 |
26.17 |
462.34 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=378 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014618 |
JENTADUETO 2.5 MG-500 MG 180 |
01/01/2020 |
78.51 |
1387.02 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=373 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014660 |
JENTADUETO 2.5 MG-500 MG 60 |
01/01/2020 |
26.17 |
462.34 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=374 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014718 |
JENTADUETO 2.5 MG-850 MG 180 |
01/01/2020 |
78.51 |
1387.02 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=375 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014760 |
JENTADUETO 2.5 MG-850 MG 60 |
01/01/2020 |
26.17 |
462.34 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=376 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597027094 |
JENTADUETO XR 2.5 MG-1,000 MG 180 |
01/01/2020 |
78.51 |
1387.02 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=397 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597027073 |
JENTADUETO XR 2.5 MG-1,000 MG 60 |
01/01/2020 |
26.17 |
462.34 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=396 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597027533 |
JENTADUETO XR 5 MG-1,000 MG TB 30 |
01/01/2020 |
26.17 |
462.34 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=398 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597027581 |
JENTADUETO XR 5 MG-1,000 MG TB 90 |
01/01/2020 |
78.51 |
1387.02 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=399 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597010930 |
MIRAPEX ER 0.375 MG TABLET 30 |
01/01/2020 |
35.87 |
633.73 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=362 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597010917 |
MIRAPEX ER 0.375 MG TABLET 7 |
01/01/2020 |
8.37 |
147.85 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=361 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597028530 |
MIRAPEX ER 0.75 MG TABLET 30 |
01/01/2020 |
35.87 |
633.73 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=403 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597028517 |
MIRAPEX ER 0.75 MG TABLET 7 |
01/01/2020 |
8.37 |
147.85 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=402 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597011330 |
MIRAPEX ER 1.5 MG TABLET 30 |
01/01/2020 |
35.87 |
633.73 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=364 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597011317 |
MIRAPEX ER 1.5 MG TABLET 7 |
01/01/2020 |
8.37 |
147.85 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=363 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597028630 |
MIRAPEX ER 2.25 MG TABLET |
01/01/2020 |
35.87 |
633.73 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=404 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597011530 |
MIRAPEX ER 3 MG TABLET |
01/01/2020 |
35.87 |
633.73 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=365 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597028730 |
MIRAPEX ER 3.75 MG TABLET |
01/01/2020 |
35.87 |
633.73 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=405 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597011630 |
MIRAPEX ER 4.5 MG TABLET |
01/01/2020 |
35.87 |
633.73 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=366 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597003001 |
MOBIC 15 MG TABLET |
01/01/2020 |
77.42 |
1367.79 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=351 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597002901 |
MOBIC 7.5 MG TABLET |
01/01/2020 |
50.63 |
894.53 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=350 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014360 |
OFEV 100 MG CAPSULE 60s |
01/01/2020 |
593.46 |
10484.53 |
06/07/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014560 |
OFEV 150MG CAPSULE 60s |
01/01/2020 |
593.46 |
10484.53 |
06/07/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597010854 |
PRADAXA 110 MG CAPSULE 60 |
01/01/2020 |
25.96 |
458.58 |
01/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=359 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597010860 |
PRADAXA 110 MG CAPSULE 60 BOTTLE |
01/01/2020 |
25.96 |
458.58 |
01/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=360 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597036082 |
PRADAXA 150 MG 60 CAPSULE |
01/01/2020 |
25.96 |
458.58 |
06/14/2023 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=415 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. 00597-0360-82 replaced 00597-0135-60. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597036055 |
PRADAXA 150 MG CAPSULE 60 |
01/01/2020 |
25.96 |
458.58 |
06/14/2023 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=414 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597035556 |
PRADAXA 75 MG 60 CAPSULE |
01/01/2020 |
25.96 |
458.58 |
06/14/2023 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=413 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597035509 |
PRADAXA 75 MG CAPSULE 60 |
01/01/2020 |
25.96 |
458.58 |
01/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=412 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597007541 |
SPIRIVA 18 MCG CP-HANDIHALER 30 |
01/01/2020 |
25.77 |
455.24 |
04/19/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=355 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597007547 |
SPIRIVA 18 MCG CP-HANDIHALER 90 |
01/01/2020 |
77.31 |
1365.72 |
04/19/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=356 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597016061 |
SPIRIVA RESPIMAT 1.25 MCG INH |
01/01/2020 |
25.77 |
455.24 |
04/16/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=388 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597010061 |
SPIRIVA RESPIMAT 2.5 MCG INH |
01/01/2020 |
25.77 |
455.24 |
04/16/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=358 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597015561 |
STIOLTO RESPIMAT INHAL SPRAY 2.5 MCG-2.5 MCG |
01/01/2020 |
23.86 |
421.52 |
10/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=385 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597019261 |
STRIVERDI RESPIMAT INHAL SPRAY 2.5 MCG |
01/01/2020 |
12.71 |
224.54 |
10/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=395 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597016818 |
SYNJARDY 12.5-1,000 MG 180 |
01/01/2020 |
88.71 |
1567.25 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=389 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597016860 |
SYNJARDY 12.5-1,000 MG 60 |
01/01/2020 |
29.57 |
522.42 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=390 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597018018 |
SYNJARDY 12.5-500 MG 180 |
01/01/2020 |
88.71 |
1567.25 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=393 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597018060 |
SYNJARDY 12.5-500 MG 60 |
01/01/2020 |
29.57 |
522.42 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=394 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597017518 |
SYNJARDY 5-1,000 MG 180 |
01/01/2020 |
88.71 |
1567.25 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=391 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597017560 |
SYNJARDY 5-1,000 MG 60 |
01/01/2020 |
29.57 |
522.42 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=392 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597015918 |
SYNJARDY 5-500 MG TABLET 180 |
01/01/2020 |
88.71 |
1567.25 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=386 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597015960 |
SYNJARDY 5-500 MG TABLET 60 |
01/01/2020 |
29.57 |
522.42 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=387 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597028073 |
SYNJARDY XR 10 mg-1,000 mg 30 |
01/01/2020 |
29.57 |
522.42 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=400 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597028090 |
SYNJARDY XR 10 mg-1,000 mg 90 |
01/01/2020 |
88.71 |
1567.25 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=401 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597030093 |
SYNJARDY XR 12.5 mg-1,000 mg 180 |
01/01/2020 |
88.71 |
1567.25 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=411 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597030045 |
SYNJARDY XR 12.5 mg-1,000 mg 60 |
01/01/2020 |
29.57 |
522.42 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=410 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597029588 |
SYNJARDY XR 25 mg-1,000 mg 30 |
01/01/2020 |
29.57 |
522.42 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=409 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597029578 |
SYNJARDY XR 25 mg-1,000 mg 90 |
01/01/2020 |
88.71 |
1567.25 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=408 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597029059 |
SYNJARDY XR 5 mg-1,000 mg 180 |
01/01/2020 |
88.71 |
1567.25 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=406 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597029074 |
SYNJARDY XR 5 mg-1,000 mg 60 |
01/01/2020 |
29.57 |
522.42 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=407 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014061 |
TRADJENTA 5 MG TABLET 100 |
01/01/2020 |
87.23 |
1541.13 |
03/05/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=370 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014030 |
TRADJENTA 5 MG TABLET 30 |
01/01/2020 |
26.17 |
462.34 |
03/05/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=369 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2020 |
00597014090 |
TRADJENTA 5 MG TABLET 90 |
01/01/2020 |
78.51 |
1387.02 |
03/05/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=371 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003089321 |
ELIQUIS (Apixaban) 2.5 MG Tablet, Bottle of 60 Tablets |
01/01/2020 |
26.65 |
470.82 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003089331 |
ELIQUIS (Apixaban) 2.5 MG Tablet, Bottle x 100 Tablets |
01/01/2020 |
44.42 |
784.76 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003089470 |
ELIQUIS (Apixaban) 5 MG Tablet Bottle of 74 Tablets |
01/01/2020 |
32.87 |
580.69 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003376474 |
ELIQUIS (Apixaban) 5 MG Tablet, 74 Tablets (1 blister pack of 42 tablets and 1 blister pack of 32 tablets) |
01/01/2020 |
32.87 |
580.69 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003089421 |
ELIQUIS (Apixaban) 5 MG Tablet, Bottle of 60 Tablets |
01/01/2020 |
26.65 |
470.82 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003089431 |
ELIQUIS (Apixaban) 5 MG Tablet, Hospital Unit-Dose Blister Package of 100 |
01/01/2020 |
44.42 |
784.76 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003218851 |
ORENCIA (Abatacept) 125 MG/ML Solution, 1ML Single Dose Prefilled Auto-injector, Package of 4 Auto-Injectors |
01/01/2020 |
262.73 |
4641.62 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003218811 |
ORENCIA (Abatacept) 125 MG/ML Solution, 1ml Single Dose Prefilled Syringe Package of 4 Syringes |
01/01/2020 |
262.73 |
4641.62 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003218710 |
ORENCIA (Abatacept) 250 MG Solution Vial W/ Syringe, Package contains 1 Vial |
01/01/2020 |
66.54 |
1175.57 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003281411 |
ORENCIA (Abatacept) 50 MG/0.4ML Solution, 0.4ML Single Dose Prefilled Syringe, Package of 4 Syringes |
01/01/2020 |
262.73 |
4641.62 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003281811 |
ORENCIA (Abatacept) 87.5 MG/0.7ML Solution, 0.7ML Single Dose Prefilled Syringe, Package of 4 Syringes |
01/01/2020 |
262.73 |
4641.62 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003085222 |
SPRYCEL (Dasatinib) 100 MG Tablet, Bottle of 30 Tablets |
01/01/2020 |
821.21 |
14508.00 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003085722 |
SPRYCEL (Dasatinib) 140 MG Tablet, Bottle of 30 Tablets |
01/01/2020 |
821.21 |
14508.00 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003052711 |
SPRYCEL (Dasatinib) 20 MG Tablet, Bottle of 60 Tablets |
01/01/2020 |
455.64 |
8049.59 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003052811 |
SPRYCEL (Dasatinib) 50 MG Tablet, Bottle of 60 Tablets |
01/01/2020 |
911.27 |
16099.14 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003052411 |
SPRYCEL (Dasatinib) 70 MG Tablet, Bottle of 60 Tablets |
01/01/2020 |
911.27 |
16099.14 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2020 |
00003085522 |
SPRYCEL (Dasatinib) 80 MG Tablet, Bottle of 30 Tablets |
01/01/2020 |
821.21 |
14508.00 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000131 |
BTG International Inc. |
12/31/2020 |
50633012011 |
DigiFab Intravenous Solution Reconstituted 40 MG/vial - 1 vial per carton |
10/01/2020 |
153.00 |
3974.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000194 |
Cameron Pharmaceuticals, LLC |
06/30/2020 |
42494040901 |
Chlordiazepoxide Clidinium Bromide 5mg/2.5mg 100 Capsules |
06/11/2020 |
1246.00 |
1395.00 |
None |
Non-innovator Multiple Source Drug |
60226 |
None |
Approved Authorized Generic. |
None |
See below for the Medispan Listing for 42494-0409-01:
Price Rx
Product Information
User: Michael Venters June 22, 2020
Medi-Span Classification
Drug Group
Drug Class
Drug Subclass
Drug Name
49
49-10
49-10-99
49-10-99-02-45
ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS
Antispasmodics
Anticholinergic Combinations
Chlordiazepoxide HCl-Clidinium Bromide
Drug Range 46-52 Gastrointestinal Agents
GPI Name 49-10-99-02-45-01-10 Chlordiazepoxide HCl-Clidinium Bromide Cap 5-2.5 MG
GPPC 02685-003 Chlordiazepoxide HCl-Clidinium Bromide Cap 5-2.5 MG, 100 Each, Bottle
Other Classifications
AHFS 12080800 Antimuscarinics/Antispasmodics
USC 23130 GI ANTISPASMODIC, W/TRANQUILIZERS
Drug Base Name 49-10-99-02 Anticholinergic Combination - Two Ingredient
Drug Name And Dosage Form 49-10-99-02-45-01 Chlordiazepoxide HCl-Clidinium Bromide Capsule
42494-0409-01
NDC/UPC/HRI Product Name Package Size Package SUM
chlordiazePOXIDE-Clidinium Oral Capsule 5-2.5 MG 100 EA
Package Qty Package Description Labeler Name Labeler Code
1 Bottle CAMERON PHARMACEUTICALS 42494
Page 1 of 5 © Copyright 2020 Clinical Drug Information, LLC |
None |
09/25/2017 |
Bausch Health |
0 |
None |
No upfront payment to be acquire authorized generic |
1395.00 |
0.00 |
2016 |
1395.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=439 |
None |
| Rx0000139 |
Chiesi USA |
06/30/2020 |
52609000601 |
Ferriprox film-coated tablets 500mg 100ct |
04/03/2020 |
509.05 |
6872.12 |
06/28/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2011 |
3168.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000139 |
Chiesi USA |
06/30/2020 |
52609450207 |
Ferriprox Solution for oral use 100mg/ml 500ml bottle |
04/03/2020 |
509.05 |
6872.12 |
10/20/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2015 |
4533.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000146 |
Circassia Pharmaceuticals |
03/31/2020 |
72124000202 |
Tudorza Pressair Inhalation Powder 400mcg 30 actuations |
01/01/2020 |
25.74 |
285.74 |
03/13/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2019 |
AstraZeneca |
218840450 |
None |
The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales. |
175.88 |
170.75 |
2015 |
140.70 |
None |
Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective July 1st; however, Tudorza, under the new NDC, was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue. As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-60. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-01. |
| Rx0000146 |
Circassia Pharmaceuticals |
03/31/2020 |
72124000201 |
Tudorza Pressair Inhalation Powder 400mcg 60 actuations |
01/01/2020 |
51.48 |
571.48 |
03/13/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2019 |
AstraZeneca |
218840450 |
None |
The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales. |
351.75 |
341.51 |
2015 |
281.40 |
None |
Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective July 1st; however, Tudorza, under the new NDC, was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue. As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-60. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-01. |
| Rx0000030 |
Clovis Oncology, Inc |
03/31/2020 |
69660020191 |
Rubraca 200mg, 60 tabs/bottle |
01/19/2020 |
390.00 |
8351.00 |
08/17/2035 |
Single Source Drug |
None |
1 |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=420, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=423 |
Product licensing was not acquired within the last 5 years. |
| Rx0000030 |
Clovis Oncology, Inc |
03/31/2020 |
69660020291 |
Rubraca 250mg, 60 tabs/bottle |
01/19/2020 |
390.00 |
8351.00 |
08/17/2035 |
Single Source Drug |
None |
1 |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=421, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=424 |
Product licensing was not acquired within the last 5 years. |
| Rx0000030 |
Clovis Oncology, Inc |
03/31/2020 |
69660020391 |
Rubraca 300mg, 60 tabs/bottle |
01/19/2020 |
390.00 |
8351.00 |
08/17/2035 |
Single Source Drug |
None |
1 |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=422, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=425 |
Product licensing was not acquired within the last 5 years. |
| Rx0000320 |
CMP Pharma |
12/31/2020 |
46287002004 |
CaroSpir spironolactone oral suspension 25mg/5ml 18ml |
10/01/2020 |
28.90 |
349.70 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2020 |
46287002001 |
CaroSpir spironolactone oral suspension 25mg/5ml 473ml |
10/01/2020 |
98.20 |
1253.00 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865024502 |
NUCYNTA ER-100MG-100 TABLET |
01/01/2020 |
75.26 |
835.46 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510011660 |
NUCYNTA ER-100MG-100 TABLETS |
01/01/2020 |
75.26 |
835.46 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865025002 |
NUCYNTA ER-150MG-100 TABLET |
01/01/2020 |
97.10 |
1077.89 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510017460 |
NUCYNTA ER-150MG-100 TABLETS |
01/01/2020 |
97.10 |
1077.89 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865026002 |
NUCYNTA ER-200MG-100 TABLET |
01/01/2020 |
123.26 |
1368.32 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510023260 |
NUCYNTA ER-200MG-100 TABLETS |
01/01/2020 |
123.26 |
1368.32 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865026501 |
NUCYNTA ER-250MG-100 TABLET |
01/01/2020 |
154.21 |
1711.91 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510029160 |
NUCYNTA ER-250MG-100 TABLETS |
01/01/2020 |
154.21 |
1711.91 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865024002 |
NUCYNTA ER-50MG-100 TABLET |
01/01/2020 |
40.69 |
451.74 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510005860 |
NUCYNTA ER-50MG-100 TABLETS |
01/01/2020 |
40.69 |
451.74 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865023002 |
NUCYNTA IR-100MG-100 TABLET |
01/01/2020 |
98.07 |
1088.71 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510010010 |
NUCYNTA IR-100MG-100 TABLETS |
01/01/2020 |
98.07 |
1088.71 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865021002 |
NUCYNTA IR-50MG-100 TABLET |
01/01/2020 |
62.98 |
699.13 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510005010 |
NUCYNTA IR-50MG-100 TABLETS |
01/01/2020 |
62.98 |
699.13 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865022002 |
NUCYNTA IR-75MG-100 TABLET |
01/01/2020 |
73.58 |
816.86 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510007510 |
NUCYNTA IR-75MG-100 TABLETS |
01/01/2020 |
73.58 |
816.86 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510011510 |
XTAMPZA ER-13.5MG-100 CAPSULES |
01/01/2020 |
64.94 |
720.92 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510012010 |
XTAMPZA ER-18MG-100 CAPSULES |
01/01/2020 |
82.36 |
914.25 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510013010 |
XTAMPZA ER-27MG-100 CAPSULES |
01/01/2020 |
114.57 |
1271.80 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510014010 |
XTAMPZA ER-36MG-100 CAPSULES |
01/01/2020 |
141.01 |
1565.39 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510011010 |
XTAMPZA ER-9MG-100 CAPSULES |
01/01/2020 |
44.12 |
489.82 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2020 |
66220028708 |
Caldolor (ibuprofen) injection 800 mg/8ml for intravenous use; sold by the tray (25 vials/ tray) |
01/02/2020 |
32.13 |
433.78 |
09/14/2030 |
Innovator Multiple Source Drug |
373635 |
None |
Our cost of goods and manufacturing is based on forecasted demand.If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increases, the price of product will subsequently increase. |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last five years. |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2020 |
66220016010 |
Vaprisol (conivaptan hydrochloride) for intravenous use: 20 mg, injection, one 5% dextrose 100 mL Plastic Container sold in multiples of 10 cartons/case |
01/02/2020 |
52.41 |
707.56 |
None |
Single Source Drug |
1804 |
None |
Our cost of goods and manufacturing is based on forecasted demand.If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increases, the price of product will subsequently increase. |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last five years |
| Rx0000230 |
Cumberland Pharmaceuticals |
12/31/2020 |
66220016010 |
Vaprisol (conivaptan hydrochloride) for intravenous use: sold in multiples of 10 cartons/case |
10/01/2020 |
61.13 |
825.30 |
12/15/2019 |
Single Source Drug |
710 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase. |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last five years |
| Rx0000230 |
Cumberland Pharmaceuticals |
12/31/2020 |
62847000101 |
Vibativ (telavancin) for injection, for intravenous use: sold in multiples of 10 individually packaged 750 mg single-dose vials/carton. |
10/01/2020 |
11.98 |
491.16 |
01/01/2027 |
Single Source Drug |
33707 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase. |
None |
not applicable |
None |
11/12/2018 |
Theravance Biopharma, Inc |
25000000 |
None |
None |
431.91 |
412.28 |
2009 |
374.94 |
None |
None |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2020 |
64597031108 |
Onzetra Xsail Nasal Exhaler Powder 4 Dose Box (sumatriptan succinate exhale powder) 11mg |
01/01/2020 |
78.40 |
870.40 |
10/24/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/25/2019 |
Avanir Pharmaceuticals |
4480000 |
None |
None |
792.00 |
792.00 |
2016 |
488.00 |
None |
For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC, as manufacturer, are filling orders only for the Currax NDC-42847031108, the former (Avanir) NDC-64597031108 is still in the market place and may be ordered by pharmacies from their wholesalers. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2020 |
42847031108 |
Onzetra Xsail Nasal Exhaler Powder 4 Dose Kit (sumatriptan succinate exhale powder) 11mg |
02/03/2020 |
78.40 |
870.40 |
10/20/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/25/2019 |
Avanir Pharmaceuticals |
4480000 |
None |
None |
792.00 |
792.00 |
2016 |
488.00 |
None |
For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC, as manufacturer, are filling orders only for the Currax NDC-42847031108, the former (Avanir) NDC-64597031108 is still in the market place and may be ordered by pharmacies from their wholesalers. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2020 |
42847010330 |
Silenor Oral Tablet 30ct (doxepin hydrochloride) 3mg |
01/01/2020 |
44.92 |
498.90 |
09/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
453.98 |
428.28 |
2010 |
165.14 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2020 |
42847010630 |
Silenor Oral Tablet 30ct (doxepin hydrochloride) 6mg |
01/01/2020 |
44.92 |
498.90 |
09/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
453.98 |
428.28 |
2010 |
165.14 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
06/30/2020 |
42847085009 |
Treximet 9 tab/pk sumatriptan/naproxen 85 mg/500 mg |
06/26/2020 |
105.21 |
1168.11 |
04/02/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Pharmaceuticals |
None |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
967.23 |
880.09 |
2015 |
625.00 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Pharmaceuticals. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC maintains no liability for pricing and pricing history prior to April 30, 2019.
Since the acquisition was in bankruptcy, the asset purchase amount is not reported nor public. |
| Rx0000247 |
Dendreon Pharmaceuticals LLC |
12/31/2020 |
30237890006 |
Provenge Infusion, 250 ML, 1 per package |
10/01/2020 |
2247.48 |
64850.00 |
12/01/2015 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/27/2017 |
Valeant |
819900000 |
None |
NA |
44382.94 |
None |
2010 |
31000.00 |
None |
NA |
| Rx0000247 |
Dendreon Pharmaceuticals LLC |
06/30/2020 |
30237890006 |
Provenge, Infusion, 250 ml, 1 per package |
04/01/2020 |
3487.77 |
62602.52 |
12/01/2015 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/27/2017 |
Valeant |
819900000 |
None |
NA |
44382.94 |
40492.98 |
2010 |
31000.00 |
None |
NA |
| Rx0000076 |
Eisai Inc. |
03/31/2020 |
62856070830 |
LENVIMA (lenvatinib mesylate) 8 mg/day (4 mg x 2) 60 count |
01/23/2020 |
647.00 |
19021.00 |
08/26/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Fields related to product acquired within the previous five year period are not applicable. |
| Rx0000076 |
Eisai Inc. |
03/31/2020 |
62856071030 |
LENVIMA (lenvatinib mesylate)10 mg/day (10 mg x 1) 30 count |
01/23/2020 |
647.00 |
19021.00 |
08/26/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Fields related to product acquired within the previous five year period are not applicable. |
| Rx0000076 |
Eisai Inc. |
03/31/2020 |
62856071430 |
LENVIMA (lenvatinib mesylate)14 mg/day (10 mg x 1 and 4 mg x 1) 60 count |
01/23/2020 |
647.00 |
19021.00 |
08/26/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Fields related to product acquired within the previous five year period are not applicable. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2020 |
00002144511 |
TALTZ™ 80 mg/mL disposable autoinjector (1 pack) |
01/31/2020 |
322.00 |
5690.00 |
12/06/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TALTZ™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TALTZ™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2020 |
00002144527 |
TALTZ™ 80 mg/mL disposable autoinjector (2 pack) |
01/31/2020 |
644.00 |
11380.00 |
12/06/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TALTZ™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TALTZ™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2020 |
00002144509 |
TALTZ™ 80 mg/mL disposable autoinjector (3 pack) |
01/31/2020 |
966.00 |
17070.00 |
12/06/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TALTZ™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TALTZ™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2020 |
00002772411 |
TALTZ™ 80 mg/mL disposable prefilled syringe (1 per carton) |
01/31/2020 |
322.00 |
5690.00 |
12/06/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TALTZ™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TALTZ™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2020 |
00002143380 |
TRULICITY™ 0.75 mg/0.5 mL carton of 4 single-dose pens |
01/31/2020 |
37.90 |
797.30 |
12/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TRULICITY™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TRULICITY™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2020 |
00002143480 |
TRULICITY™ 1.5 mg /0.5mL carton of 4 single-dose pens |
01/31/2020 |
37.90 |
797.30 |
12/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TRULICITY™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TRULICITY™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank. |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2020 |
44087907001 |
Gonal-f Multi-Dose 1050IU (1) |
01/10/2020 |
192.08 |
2753.66 |
08/23/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2020 |
44087903001 |
Gonal-f Multi-Dose 450IU (1) |
01/10/2020 |
82.32 |
1180.14 |
08/23/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2020 |
44087900501 |
Gonal-f RFF* 75IU (1) |
01/10/2020 |
13.72 |
196.69 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2020 |
44087900506 |
Gonal-f RFF* 75IU (10) |
01/10/2020 |
137.20 |
1966.90 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2020 |
44087111501 |
Gonal-f RFF* Redi-ject™ 300IU (1) |
01/10/2020 |
54.88 |
786.76 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2020 |
44087111601 |
Gonal-f RFF* Redi-ject™ 450IU (1) |
01/10/2020 |
82.32 |
1180.14 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2020 |
44087111701 |
Gonal-f RFF* Redi-ject™ 900IU (1) |
01/10/2020 |
164.64 |
2360.28 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2020 |
44087115001 |
Ovidrel Subcutaneous Injectable 250 MCG/0.5ML (1) |
01/10/2020 |
12.38 |
177.49 |
03/16/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2020 |
67979051143 |
Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial |
04/01/2020 |
59.61 |
1288.78 |
03/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/20/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
12/31/2020 |
67979051143 |
Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial |
10/01/2020 |
62.51 |
1351.29 |
05/08/2027 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration's Orange Book, as of 1/22/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244092010 |
DILATRATE®, Isosorbide Dinitrate Cap ER 40 MG, 100 |
01/06/2020 |
41.97 |
465.90 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
302.93 |
275.64 |
2012 |
192.75 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244001002 |
Edex®, Alprostadil For Inj Kit 10 MCG, 2 |
01/06/2020 |
7.65 |
135.07 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
99.06 |
90.14 |
2012 |
78.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244001006 |
Edex®, Alprostadil For Inj Kit 10 MCG, 6 |
01/06/2020 |
22.94 |
405.25 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
297.19 |
270.42 |
2012 |
234.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244002002 |
Edex®, Alprostadil For Inj Kit 20 MCG, 2 |
01/06/2020 |
9.88 |
174.49 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
127.96 |
116.43 |
2012 |
100.75 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244002006 |
Edex®, Alprostadil For Inj Kit 20 MCG, 6 |
01/06/2020 |
29.63 |
523.44 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
383.87 |
349.29 |
2012 |
302.25 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244004002 |
Edex®, Alprostadil For Inj Kit 40 MCG, 2 |
01/06/2020 |
13.49 |
238.28 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
174.75 |
159.01 |
2012 |
137.60 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244004006 |
Edex®, Alprostadil For Inj Kit 40 MCG, 6 |
01/06/2020 |
40.46 |
714.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
524.21 |
476.99 |
2012 |
412.75 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
63481002509 |
FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9 |
01/06/2020 |
79.24 |
879.63 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
63481068706 |
LIDODERM®, Lidocaine Patch 5%, 30 |
01/06/2020 |
53.97 |
599.08 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
49884027082 |
NASCOBAL®, Cyanocobalamin Nasal Spray 500 MCG/0.1ML, 1 |
01/06/2020 |
28.70 |
614.48 |
08/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
09/28/2015 |
Par Pharmaceutical |
None |
None |
1) Endo acquired Par Pharmaceutical on 9/25/15. As a part of Endo’s acquisition of Par Pharmaceutical, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Par Pharmaceutical to the individual assets or products acquired from Par Pharmaceutical. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
396.88 |
361.13 |
2014 |
361.13 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
63481062970 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100 |
01/06/2020 |
231.86 |
2573.92 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
63481062770 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100 |
01/06/2020 |
117.27 |
1301.84 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
63481062370 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100 |
01/06/2020 |
164.13 |
1822.02 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
63481062385 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 500 |
01/06/2020 |
800.01 |
8880.92 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
63481062870 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100 |
01/06/2020 |
177.32 |
1968.45 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244044910 |
ROBAXIN®, Methocarbamol Tab 750 MG, 100 |
01/06/2020 |
26.64 |
295.72 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
202.71 |
202.71 |
2011 |
233.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244040410 |
SEMPREX®-D, Acrivastine & Pseudoephedrine Cap 8-60 MG, 100 |
01/06/2020 |
54.01 |
599.61 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
339.70 |
308.82 |
2012 |
212.50 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2020 |
67979000201 |
Supprelin LA, 50 mg implant, ea |
04/01/2020 |
1811.31 |
39157.87 |
06/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/20/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
12/31/2020 |
67979000201 |
Supprelin LA, 50 mg implant, ea |
10/01/2020 |
1899.16 |
41057.03 |
06/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration's Orange Book, as of 1/22/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244010010 |
THEO-24®, Theophylline Cap ER 24HR 100 MG, 100 |
01/06/2020 |
21.74 |
241.34 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
136.73 |
0.00 |
2014 |
136.73 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244020010 |
THEO-24®, Theophylline Cap ER 24HR 200 MG, 100 |
01/06/2020 |
32.31 |
358.68 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
203.21 |
0.00 |
2014 |
203.21 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244030010 |
THEO-24®, Theophylline Cap ER 24HR 300 MG, 100 |
01/06/2020 |
39.71 |
440.85 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
249.75 |
0.00 |
2014 |
249.75 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2020 |
52244040010 |
THEO-24®, Theophylline Cap ER 24HR 400 MG, 100 |
01/06/2020 |
55.88 |
620.33 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
01/29/2015 |
Auxilium Pharmaceuticals |
None |
None |
1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
351.43 |
0.00 |
2014 |
351.43 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2020 |
67979000101 |
Valstar, 40 mg/1ml solution, 4x5mL |
04/01/2020 |
294.84 |
6373.98 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/20/2020, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
12/31/2020 |
67979000101 |
Valstar, 40 mg/1ml solution, 4x5mL |
10/01/2020 |
309.14 |
6683.12 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/22/2021, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2020 |
67979050001 |
Vantas, 50 mg implant, ea |
04/01/2020 |
215.02 |
4648.41 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/20/2020, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
12/31/2020 |
67979050001 |
Vantas, 50 mg implant, ea |
10/01/2020 |
225.45 |
4873.86 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/22/2021, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2020 |
66887000301 |
Xiaflex, 0.9mg powder for solution, single use vial |
04/01/2020 |
181.99 |
4848.34 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank. (3) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
12/31/2020 |
66887000301 |
Xiaflex, 0.9mg powder for solution, single use vial |
10/01/2020 |
189.09 |
5037.43 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration's Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank. (3) For 'Year Introduced', Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
| Rx0000094 |
Epic Pharma |
06/30/2020 |
42806005030 |
Meperidine Hcl 50mg30 Tab Epic |
06/26/2020 |
234.90 |
1017.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/13/2010 |
Mikah Pharma LLC |
None |
1 |
None |
783.00 |
783.00 |
2003 |
783.00 |
None |
Epic Pharma lauched this new size-30 count sku in 12/31/2019.Prior companies didn’t have WAC data for this new sku. |
| Rx0000094 |
Epic Pharma |
06/30/2020 |
42806033701 |
Molindone 10mg 100 Tab |
06/26/2020 |
223.50 |
968.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/26/2017 |
CorePharma,LLC |
None |
1 |
None |
183.46 |
183.46 |
2015 |
183.46 |
None |
None |
| Rx0000094 |
Epic Pharma |
06/30/2020 |
42806033801 |
Molindone 25mg 100 Tab |
06/26/2020 |
249.00 |
1079.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/26/2017 |
CorePharma,LLC |
None |
1 |
None |
215.48 |
215.48 |
2015 |
215.48 |
None |
None |
| Rx0000094 |
Epic Pharma |
06/30/2020 |
42806033601 |
Molindone 5mg 100 Tab |
06/26/2020 |
186.00 |
806.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/26/2017 |
CorePharma,LLC |
None |
1 |
None |
127.60 |
127.60 |
2015 |
127.60 |
None |
None |
| Rx0000094 |
Epic Pharma |
06/30/2020 |
42806050109 |
Nicardipine Hcl 20mg90 Cap Epic |
06/26/2020 |
318.74 |
1115.59 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/24/2010 |
Amneal Pharmaceuticals |
None |
1 |
None |
9.65 |
9.65 |
2006 |
9.65 |
None |
the original manufacture Genpharm/ lipha introduced the products on market in 2006, but there is no WAC. Amneal bought this product and then they introduced to maket with WAC $9.65 in 2008. |
| Rx0000094 |
Epic Pharma |
06/30/2020 |
42806050209 |
Nicardipine Hcl 30mg90 Cap Epic |
06/26/2020 |
456.50 |
1597.76 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/24/2010 |
Amneal Pharmaceuticals |
None |
1 |
None |
14.90 |
14.90 |
2006 |
14.90 |
None |
the original manufacture Genpharm/ lipha introduced the products on market in 2006, but there is no WAC. Amneal bought this product and then they introduced to maket with WAC $14.9 in 2008. |
| Rx0000104 |
EUSA Pharma (US) LLC |
12/31/2020 |
57894042001 |
SYLVANT, 100mg, intravenous powder for solution |
10/01/2020 |
101.79 |
1173.26 |
08/01/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/22/2018 |
Janssen Biotech |
115000000 |
None |
Acquisition price is for both NDCs |
910.24 |
883.73 |
2014 |
833.00 |
None |
None |
| Rx0000104 |
EUSA Pharma (US) LLC |
12/31/2020 |
57894042101 |
SYLVANT, 400mg, intravenous powder for solution |
10/01/2020 |
407.16 |
4693.03 |
08/01/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/22/2018 |
Janssen Biotech |
115000000 |
None |
Acquisition price is for both NDCs |
3640.96 |
3534.92 |
2014 |
3332.00 |
None |
None |
| Rx0000010 |
Exelixis, Inc. |
03/31/2020 |
42388002426 |
CABOMETYX 20MG 30 TAB BTL EACH |
01/01/2020 |
959.59 |
20151.54 |
07/09/2033 |
Single Source Drug |
None |
1 |
Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions.
Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to CABOMETYX?s wholesale acquisition cost.
Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX.
CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors.
CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. |
None |
It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX? when market conditions permit such an increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date |
| Rx0000010 |
Exelixis, Inc. |
03/31/2020 |
42388002526 |
CABOMETYX 40MG 30 TAB BTL EACH |
01/01/2020 |
959.59 |
20151.54 |
07/09/2033 |
Single Source Drug |
None |
1 |
Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions.
Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to CABOMETYX?s wholesale acquisition cost.
Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX.
CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors.
CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. |
None |
It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX? when market conditions permit such an increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date |
| Rx0000010 |
Exelixis, Inc. |
03/31/2020 |
42388002326 |
CABOMETYX 60MG 30 TAB BTL EACH |
01/01/2020 |
959.59 |
20151.54 |
07/09/2033 |
Single Source Drug |
None |
1 |
Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions.
Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to CABOMETYX?s wholesale acquisition cost.
Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX.
CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors.
CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. |
None |
It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX? when market conditions permit such an increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date |
| Rx0000010 |
Exelixis, Inc. |
03/31/2020 |
42388001214 |
COMETRIQ 100 MG DAILY-DOSE PACK, 56 ct (4 X 14 ct Blister Cards Per Package) |
01/01/2020 |
857.11 |
17999.31 |
02/10/2032 |
Single Source Drug |
None |
1 |
Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing COMETRIQ consistent with its value when compared to competitive products approved for similar conditions.
Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to COMETRIQ?s wholesale acquisition cost.
Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of COMETRIQ.
COMETRIQ Value Factors: COMETRIQ has been approved by the FDA to treat patients with medullary thyroid cancer and has shown impressive efficacy relative to its competitors in treating patients with this life-threatening disease. When Exelixis contemplated a change to the wholesale acquisition cost for COMETRIQ, Exelixis considered the clinical value proposition of COMETRIQ relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors.
COMETRIQ Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of COMETRIQ for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of COMETRIQ, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. |
None |
It is Exelixis? stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer.? To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities.? In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine?s full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of COMETRIQ? when market conditions permit such an increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date |
| Rx0000010 |
Exelixis, Inc. |
03/31/2020 |
42388001114 |
COMETRIQ 140 MG DAILY-DOSE PACK, 112 ct (4 X 28 ct Blister Cards Per Package) |
01/01/2020 |
857.11 |
17999.31 |
02/10/2032 |
Single Source Drug |
None |
1 |
Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing COMETRIQ consistent with its value when compared to competitive products approved for similar conditions.
Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to COMETRIQ?s wholesale acquisition cost.
Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of COMETRIQ.
COMETRIQ Value Factors: COMETRIQ has been approved by the FDA to treat patients with medullary thyroid cancer and has shown impressive efficacy relative to its competitors in treating patients with this life-threatening disease. When Exelixis contemplated a change to the wholesale acquisition cost for COMETRIQ, Exelixis considered the clinical value proposition of COMETRIQ relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors.
COMETRIQ Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of COMETRIQ for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of COMETRIQ, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. |
None |
It is Exelixis? stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer.? To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities.? In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine?s full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of COMETRIQ? when market conditions permit such an increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date |
| Rx0000010 |
Exelixis, Inc. |
03/31/2020 |
42388001314 |
COMETRIQ 60 MG DAILY-DOSE PACK, 84 ct (4 X 21 ct Blister Cards Per Package) |
01/01/2020 |
857.11 |
17999.31 |
02/10/2032 |
Single Source Drug |
None |
1 |
Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing COMETRIQ consistent with its value when compared to competitive products approved for similar conditions.
Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to COMETRIQ?s wholesale acquisition cost.
Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of COMETRIQ.
COMETRIQ Value Factors: COMETRIQ has been approved by the FDA to treat patients with medullary thyroid cancer and has shown impressive efficacy relative to its competitors in treating patients with this life-threatening disease. When Exelixis contemplated a change to the wholesale acquisition cost for COMETRIQ, Exelixis considered the clinical value proposition of COMETRIQ relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors.
COMETRIQ Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of COMETRIQ for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of COMETRIQ, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. |
None |
It is Exelixis? stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer.? To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities.? In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine?s full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of COMETRIQ? when market conditions permit such an increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date |
| Rx0000205 |
Eyevance Pharmaceuticals LLC |
12/31/2020 |
71776010005 |
Flarex (fluorometholone acetate), ophthalmic suspension, 0.1%, 5mL |
10/24/2020 |
29.11 |
119.07 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
10/23/2018 |
Novartis AG |
None |
1 |
None |
70.01 |
70.01 |
1986 |
7.48 |
None |
(1) We do not have the actual price when the product was introduced as it was purchased. For this entry, we used the baseline Average Manufacturers Price (AMP) that was established for the product when the Medicaid Pricing Program began. This is the best estimation available for an introductory market price.
(2) The NDC# prior to the Eyevance NDC# was 00065-0096-05. In the 5 Year WAC history field we used the current Eyevance NDC# (71776-0100-05) although the WAC increases prior to 2020 were reflective of the old 00065-0096-05 NDC#. |
| Rx0000063 |
Ferring Pharmaceuticals |
06/30/2020 |
55566280001 |
Cervidil 10MG VAGINAL INSERT (dinoprostone, 10mg) |
04/28/2020 |
24.64 |
435.23 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
10/01/2015 |
Allergan plc |
None |
1 |
None |
306.27 |
None |
1995 |
140.00 |
None |
None |
| Rx0000063 |
Ferring Pharmaceuticals |
03/31/2020 |
55566750102 |
MENOPUR (menotropins for injection)/75 units/vial - 5 single-dose vials per package |
02/20/2020 |
59.30 |
1047.55 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note: The acquisition fields do not apply because Ferring did not acquire the product within the past five years.
NDC 55566750101 is the NDC for the 0.9% Sodium Chloride Injection, USP, 2 mL product included in the Menopur kit. The Sodium Chloride is used for mixing the medicine. NDC 55566750101 does not have a WAC price. " |
| Rx0000193 |
Forte Bio-Pharma, LLC |
12/31/2020 |
72245019310 |
Nalocet 2.5mg/300mg Tablet 100Ct |
10/01/2020 |
218.50 |
2403.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000193 |
Forte Bio-Pharma, LLC |
12/31/2020 |
72245019303 |
Nalocet 2.5mg/300mg Tablet 30ct |
10/01/2020 |
65.55 |
721.05 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000129 |
Fresenius Kabi USA LLC |
03/31/2020 |
63323016505 |
Dexamethasone Sodium Phosphate Liquid 20 mg 5mL |
03/21/2020 |
13.75 |
157.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=335 |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range). |
| Rx0000129 |
Fresenius Kabi USA LLC |
09/30/2020 |
63323022935 |
Protamine Sulfate Inj. 250mg 25mL SDV NOVAPLUS |
07/01/2020 |
3.05 |
29.17 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the previous 5 years |
| Rx0000129 |
Fresenius Kabi USA LLC |
09/30/2020 |
63323022915 |
Protamine Sulfate Inj. 50mg 5mL SDV NOVAPLUS |
07/01/2020 |
27.50 |
244.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the previous 5 years |
| Rx0000260 |
Galderma Laboratories |
06/30/2020 |
00299590645 |
Epiduo?Forte Gel 0.1% / 2.5% Pump 45GM (Adapalene and Benzoyl Peroxide) 3 mg/g, 25 mg/g |
06/05/2020 |
27.20 |
581.45 |
03/12/2013 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug developed by Galderma |
| Rx0000260 |
Galderma Laboratories |
06/30/2020 |
00299590660 |
Epiduo?Forte Gel 0.1% / 2.5% Pump 60GM (Adapalene and Benzoyl Peroxide) 3 mg/g, 25 mg/g |
06/05/2020 |
36.25 |
775.30 |
03/12/2023 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug developed by Galderma |
| Rx0000260 |
Galderma Laboratories |
06/30/2020 |
00299598030 |
Mirvaso? Topical Gel 0.33% 30GM (Brimonidine) 5 mg/g |
06/05/2020 |
24.60 |
525.75 |
06/13/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug developed by Galderma |
| Rx0000260 |
Galderma Laboratories |
06/30/2020 |
00299598035 |
Mirvaso? Topical Gel 0.33% 30GM PUMP (Brimonidine) 5 mg/g |
06/05/2020 |
24.60 |
525.75 |
06/13/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug developed by Galderma |
| Rx0000260 |
Galderma Laboratories |
06/30/2020 |
00299382230 |
Oracea? Capsules 40MG (Doxycycline, USP) 40 mg/1 |
06/05/2020 |
36.25 |
775.20 |
12/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug purchased by Galderma more than five years ago |
| Rx0000260 |
Galderma Laboratories |
06/30/2020 |
00299382330 |
Soolantra? Cream 1% 30GM (Ivermectin) 10 mg/g |
06/05/2020 |
36.70 |
401.65 |
03/13/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug developed by Galderma |
| Rx0000260 |
Galderma Laboratories |
06/30/2020 |
00299382345 |
Soolantra? Cream 1% 45GM (Ivermectin) 10 mg/g |
06/05/2020 |
28.15 |
602.45 |
03/13/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug developed by Galderma |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958200201 |
DESCOVY (emtricitabine 200mg/tenofovir alafenamide 25mg) tablets, 30ct bottle |
01/01/2020 |
84.38 |
1842.28 |
08/15/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958190101 |
GENVOYA (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg) tablets, 30ct bottle |
01/01/2020 |
148.32 |
3238.31 |
10/04/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958050101 |
HEPSERA (adefovir dipivoxil 10mg) tablets, 30ct bottle |
01/01/2020 |
71.25 |
1555.60 |
07/23/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958210101 |
ODEFSEY (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) tablets, 30ct bottle |
01/01/2020 |
134.98 |
2947.11 |
08/15/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958070301 |
TRUVADA (emtricitabine 100mg/tenofovir disoproxil fumarate 150mg) tablets, 30ct bottle |
01/01/2020 |
84.38 |
1842.28 |
09/09/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958070401 |
TRUVADA (emtricitabine 133mg/tenofovir disoproxil fumarate 200mg) tablets, 30ct bottle |
01/01/2020 |
84.38 |
1842.28 |
09/09/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958070501 |
TRUVADA (emtricitabine 167mg/tenofovir disoproxil fumarate 250mg) tablets, 30ct bottle |
01/01/2020 |
84.38 |
1842.28 |
09/09/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958070101 |
TRUVADA (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) tablets, 30ct bottle |
01/01/2020 |
84.38 |
1842.28 |
01/13/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958140101 |
TYBOST (cobicistat 150mg) tablets, 30ct bottle |
01/01/2020 |
11.07 |
241.73 |
09/03/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958230101 |
VEMLIDY (tenofovir alafenamide 25mg) tablets, 30ct bottle |
01/01/2020 |
53.71 |
1172.59 |
08/15/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958040401 |
VIREAD (tenofovir disoproxil fumarate 150mg) tablets, 30ct bottle |
01/01/2020 |
53.21 |
1161.71 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958040501 |
VIREAD (tenofovir disoproxil fumarate 200mg) tablets, 30ct bottle |
01/01/2020 |
53.21 |
1161.71 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958040601 |
VIREAD (tenofovir disoproxil fumarate 250mg) tablets, 30ct bottle |
01/01/2020 |
53.21 |
1161.71 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958040101 |
VIREAD (tenofovir disoproxil fumarate 300mg) tablets, 30ct bottle |
01/01/2020 |
57.41 |
1253.50 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2020 |
61958040301 |
VIREAD (tenofovir disoproxil fumarate 40mg/scoop) oral powder, 60g |
01/01/2020 |
31.30 |
683.48 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000088 |
Gilead Sciences, LLC |
03/31/2020 |
15584010101 |
ATRIPLA (efavirenz 600mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) tablets, 30ct bottle |
01/01/2020 |
137.16 |
2994.71 |
04/28/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000144 |
Helsinn Therapeutics, Inc |
12/31/2020 |
69639010201 |
AKYNZEO® (fosnetupitant 235mg/ palonosetron 0.25mg) for injection (235MG/0.25MG PER VIAL) |
12/31/2020 |
54.34 |
669.78 |
05/23/2032 |
Single Source Drug |
3500 |
None |
The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. |
None |
n/a |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This is a product that was launched in 2018. We are taking a planned price increase on 12/31/2020.
Since this product was released in 2018, a full 5 year history is not available. Only from 2018 to present.
This product was not acquired, therefore fields 14-22 are blank. |
| Rx0000144 |
Helsinn Therapeutics, Inc |
09/30/2020 |
69639012001 |
Valchlor 0.02% Gel 60gm tube |
09/01/2020 |
372.33 |
4555.79 |
07/08/2029 |
Single Source Drug |
8575 |
None |
The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. |
None |
None |
1 |
03/20/2018 |
Actelion Pharmaceuticals, Ltd. |
330000000 |
None |
None |
3654.00 |
3355.00 |
2013 |
3165.00 |
None |
None |
| Rx0000119 |
Heron Therapeutics, Inc. |
03/31/2020 |
47426020101 |
CINVANTI; 130 mg; single-dose vial |
01/01/2020 |
7.72 |
359.38 |
09/18/2035 |
Single Source Drug |
278108 |
None |
Increase due to market factors |
None |
There were no noted changes to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was developed by Heron |
| Rx0000119 |
Heron Therapeutics, Inc. |
06/30/2020 |
47426020101 |
CINVANTI; 130 mg; single-dose vial |
04/01/2020 |
8.09 |
367.47 |
09/18/2035 |
Single Source Drug |
726540 |
None |
Increase due to market factors |
None |
There were no changes to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000119 |
Heron Therapeutics, Inc. |
09/30/2020 |
47426020101 |
CINVANTI; 130 mg; single-dose vial |
07/01/2020 |
8.27 |
375.74 |
09/18/2035 |
Single Source Drug |
726540 |
None |
Increase due to market factors. |
None |
There were no changes to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000119 |
Heron Therapeutics, Inc. |
12/31/2020 |
47426020101 |
CINVANTI; 130 mg; single-dose vial; injectable emulsion |
10/01/2020 |
8.45 |
384.19 |
09/18/2035 |
Single Source Drug |
726540 |
None |
Increase due to market factors. |
None |
There were no changes to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000119 |
Heron Therapeutics, Inc. |
06/30/2020 |
47426010106 |
Sustol (granisetron) ER injection. 10 mg/.4mL. 6 kits/carton. |
05/15/2020 |
94.99 |
3894.55 |
09/28/2024 |
Single Source Drug |
100241 |
None |
Increase due to market factors |
None |
There were no changes to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000119 |
Heron Therapeutics, Inc. |
12/31/2020 |
47426010106 |
Sustol (granisetron) ER injection. 10 mg/.4mL. 6 kits/carton. |
10/01/2020 |
97.38 |
3991.92 |
09/28/2024 |
Single Source Drug |
100241 |
None |
Increase due to market factors |
None |
There were no changes to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2020 |
00143987825 |
Cefoxtin Sodium Intravenous Solution, 1GM, Vial x 25 |
03/14/2020 |
71.51 |
247.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
With respect to Column 6, Patent Expiration Date; this is a generic drug and this does not apply. With respect to Columns 14-22. this product originated with Hikma and was not acquired. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2020 |
00143987725 |
Cefoxtin Sodium Intravenous Solution, 2GM, Vial x 25 |
03/14/2020 |
182.26 |
495.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
With respect to Column 6, Patent Expiration Date; this is a generic drug and this does not apply. With respect to Columns 14-22. this product originated with Hikma and was not acquired. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2020 |
00143978710 |
Enalaprilat Intravenous Injectable, 1.25mg/1mL, Vial x10 |
03/14/2020 |
3.96 |
43.96 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
With respect to Column 6, Patent Expiration Date; this is a generic drug and this does not apply. With respect to Columns 14-22. this product originated with Hikma and was not acquired. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2020 |
00143978610 |
Enalaprilat Intravenous Injectable, 1.25mg/2 mL, Vial x10 |
03/14/2020 |
7.07 |
78.51 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
With respect to Column 6, Patent Expiration Date; this is a generic drug and this does not apply. With respect to Columns 14-22. this product originated with Hikma and was not acquired. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
06/30/2020 |
00641039112 |
Heparin Sodium (Porcine) Injection Solution 1000 UNIT/1ML, 25 Vials |
06/19/2020 |
20.46 |
71.61 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
06/30/2020 |
00641245055 |
Heparin Sodium (Porcine) Injection Solution 1000 UNIT/30ML, 25 Vials |
06/19/2020 |
68.00 |
238.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
06/30/2020 |
00641246055 |
Heparin Sodium (Porcine) Injection Solution 5000 UNIT/10ML, 25 Vials |
06/19/2020 |
84.00 |
294.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2020 |
00641605425 |
Meperidine HCl Injection Solution 100 MG/ML, 25 Vials |
03/17/2020 |
6.52 |
72.39 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2020 |
00641605225 |
Meperidine HCl Injection Solution 25 MG/ML, 25 Vials |
03/17/2020 |
5.71 |
63.41 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2020 |
00641605325 |
Meperidine HCl Injection Solution 50MG/ML, 25 Vials |
03/17/2020 |
5.95 |
66.05 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000145 |
Horizon Therapeutics USA, Inc. |
03/31/2020 |
75987008010 |
Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial |
02/01/2020 |
1107.50 |
23709.50 |
08/03/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/13/2016 |
Crealta Holdings LLC |
None |
1 |
Horizon acquired this particular product as part of the overall acquisition of Crealta Holdings LLC, and its acquisition price was incorporated into that deal’s overall purchase price of approximately $510 million with no means of individually identifying the purchase price of this asset. |
14000.00 |
14000.00 |
2010 |
2300.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Please note the Patent Expiration date for KRYSTEXXA is not publicly available. |
| Rx0000145 |
Horizon Therapeutics USA, Inc. |
03/31/2020 |
75987002001 |
Product Name: RAYOS; Product Strength: 1mg ; Dosage Form / Product Package: Delayed-release 30 tablets |
02/01/2020 |
129.00 |
2762.10 |
08/03/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Drug was not acquired within the previous 5 years. |
| Rx0000145 |
Horizon Therapeutics USA, Inc. |
03/31/2020 |
75987002101 |
Product Name: RAYOS; Product Strength: 2mg ; Dosage Form / Product Package: Delayed-release 30 tablets |
02/01/2020 |
129.00 |
2762.10 |
08/03/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Drug was not acquired within the previous 5 years. |
| Rx0000145 |
Horizon Therapeutics USA, Inc. |
03/31/2020 |
75987002201 |
Product Name: RAYOS; Product Strength: 5mg ; Dosage Form / Product Package: Delayed-release 30 tablets |
02/01/2020 |
129.00 |
2762.10 |
01/07/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Drug was not acquired within the previous 5 years. |
| Rx0000040 |
Ingenus Pharmaceuticals, LLC |
06/30/2020 |
50742051530 |
Nitro-Dur Patch 0.3mg/hr 30 ct |
05/01/2020 |
314.02 |
942.06 |
None |
Single Source Drug |
5664 |
None |
Increased overhead, expenses, and distribution costs causing need for price increase |
None |
No changes made |
None |
08/31/2017 |
USPharma |
2000000 |
None |
The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure |
316.92 |
157.50 |
2017 |
316.92 |
None |
Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year |
| Rx0000040 |
Ingenus Pharmaceuticals, LLC |
06/30/2020 |
50742051830 |
Nitro-Dur Patch 0.8mg/hr 30 ct |
05/01/2020 |
340.57 |
1021.70 |
None |
Single Source Drug |
3540 |
None |
Increased overhead, expenses, and distribution costs causing need for price increase |
None |
No changes made |
None |
08/31/2017 |
USPharma |
2000000 |
None |
The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure |
343.71 |
170.70 |
2017 |
343.71 |
None |
Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year |
| Rx0000266 |
Intercept Pharmaceuticals, Inc. |
09/30/2020 |
69516001030 |
OCALIVA (obeticholic acid), 10mg tablets, 30 count bottle |
08/20/2020 |
338.58 |
7248.41 |
04/26/2036 |
Single Source Drug |
None |
1 |
Intercept’s pricing decisions take into careful consideration a variety of interdependent factors, including R&D investments, clinical/economic value, patient affordability, and current market dynamics. |
None |
This WAC increase was not necessitated by a change or improvement in the product. Intercept’s goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. Per State requirements, the information reported is limited to that which is otherwise in the public domain or publicly available. |
| Rx0000266 |
Intercept Pharmaceuticals, Inc. |
09/30/2020 |
69516000530 |
OCALIVA (obeticholic acid), 5mg tablets, 30 count bottle |
08/20/2020 |
338.58 |
7248.41 |
04/26/2036 |
Single Source Drug |
None |
1 |
Intercept’s pricing decisions take into careful consideration a variety of interdependent factors, including R&D investments, clinical/economic value, patient affordability, and current market dynamics. |
None |
This WAC increase was not necessitated by a change or improvement in the product. Intercept’s goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. Per State requirements, the information reported is limited to that which is otherwise in the public domain or publicly available. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2020 |
15054104005 |
Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 4ml. |
01/01/2020 |
442.00 |
4906.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
The product was not acquired by Ipsen within the previous five years. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2020 |
15054004301 |
Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml. |
01/01/2020 |
214.00 |
2366.00 |
10/15/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/03/2017 |
Merrimack Pharmaceuticals |
None |
1 |
For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased the global oncology assets of Merrimack Pharmaceuticals in April 2017, including Onivyde. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of the assets from Merrimack Pharmaceuticals is available on p. 97, Note 12.1.1 of section 3.2.5, of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2018/03/15164935/IPSEN_DDR_2017_VA_complet_clean-003.pdf |
1652.40 |
None |
2015 |
1620.00 |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01 |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2020 |
15054112004 |
Drug product name: Somatuline Depot - New NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml. |
01/01/2020 |
789.00 |
8756.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
New Delivery Device |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This NDC was launched on September 1, 2019 and will replace NDC 15054112003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2020 |
15054106004 |
Drug product name: Somatuline Depot - New NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml. |
01/01/2020 |
503.00 |
5575.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
New Delivery Device |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This NDC was launched on September 1, 2019 and will replace NDC 15054106003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2020 |
15054109004 |
Drug product name: Somatuline Depot - New NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml. |
01/01/2020 |
669.00 |
7425.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
New Delivery Device |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This NDC was launched on September 1, 2019 and will replace NDC 15054109003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2020 |
15054112003 |
Drug product name: Somatuline Depot - Old NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml. |
01/01/2020 |
789.00 |
8756.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
In September 2019, Ipsen launched a new Somatuline Depot delivery device. The version of the product with the new delivery device will replace the version of the product with the prior device. The price increase for this period applied to the NDCs for the product with the old device and the new device to ensure consistent pricing for any product with the old device that may remain in the supply chain. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2020 |
15054109003 |
Drug product name: Somatuline Depot - Old NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml. |
01/01/2020 |
669.00 |
7425.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
In September 2019, Ipsen launched a new Somatuline Depot delivery device. The version of the product with the new delivery device will replace the version of the product with the prior device. The price increase for this period applied to the NDCs for the product with the old device and the new device to ensure consistent pricing for any product with the old device that may remain in the supply chain. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2020 |
15054106003 |
Drug product name: Somatuline Depot - Old NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml. |
01/01/2020 |
503.00 |
5575.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
In September 2019, Ipsen launched a new Somatuline Depot delivery device. The version of the product with the new delivery device will replace the version of the product with the prior device. The price increase for this period applied to the NDCs for the product with the old device and the new device to ensure consistent pricing for any product with the old device that may remain in the supply chain. |
| Rx0000191 |
Jaguar Health |
06/30/2020 |
70564080260 |
Mytesi |
04/09/2020 |
1537.60 |
2206.12 |
None |
Single Source Drug |
None |
1 |
None |
1 |
No changes. |
None |
09/25/2017 |
Glenmark Pharmaceuticals Ltd |
None |
1 |
https://www.businesswire.com/news/home/20170925005703/en/Jaguar-Subsidiary-Napo-Pharmaceuticals-Glenmark-Pharmaceuticals-Sign |
652.21 |
540.00 |
2012 |
540.00 |
None |
None |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058501 |
CONCERTA® Strength:18 mg. Package Size:100 Form:Tablet |
01/20/2020 |
23.17 |
1181.87 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058801 |
CONCERTA® Strength:27 mg. Package Size:100 Form:Tablet |
01/20/2020 |
23.75 |
1211.49 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058601 |
CONCERTA® Strength:36 mg. Package Size:100 Form:Tablet |
01/20/2020 |
24.50 |
1249.70 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058701 |
CONCERTA® Strength:54 mg. Package Size:100 Form:Tablet |
01/20/2020 |
26.66 |
1359.85 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676027801 |
EDURANTTM Strength:25 MG Package Size:30 Form:Tablet |
01/20/2020 |
50.18 |
1165.29 |
04/21/2025 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676057001 |
INTELENCE® Strength:100 MG Package Size:120 Form:Tablet |
01/20/2020 |
27.14 |
1383.82 |
06/13/2021 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676057101 |
INTELENCE® Strength:200 MG Package Size:60 Form:Tablet |
01/20/2020 |
27.13 |
1383.82 |
06/13/2021 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676057201 |
INTELENCE® Strength:25 MG Package Size:120 Form:Tablet |
01/20/2020 |
6.78 |
345.95 |
06/13/2021 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055401 |
INVEGA® Strength:1.5 mg Package Size:30 Form:Extended Release Tablet |
01/20/2020 |
23.57 |
1202.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055010 |
INVEGA® Strength:3 mg Package Size:100 Form:Extended Release Tablet |
01/20/2020 |
78.57 |
4007.18 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055001 |
INVEGA® Strength:3 mg Package Size:30 Form:Extended Release Tablet |
01/20/2020 |
23.57 |
1202.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055110 |
INVEGA® Strength:6 mg Package Size:100 Form:Extended Release Tablet |
01/20/2020 |
78.57 |
4007.18 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055101 |
INVEGA® Strength:6 mg Package Size:30 Form:Extended Release Tablet |
01/20/2020 |
23.57 |
1202.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055210 |
INVEGA® Strength:9 mg Package Size:100 Form:Extended Release Tablet |
01/20/2020 |
117.86 |
6010.72 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055201 |
INVEGA® Strength:9 mg Package Size:30 Form:Extended Release Tablet |
01/20/2020 |
35.36 |
1803.22 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056201 |
INVEGA® SUSTENNA® Strength:117 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
65.52 |
1402.65 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056301 |
INVEGA® SUSTENNA® Strength:156 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
87.36 |
1870.28 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056401 |
INVEGA® SUSTENNA® Strength:234 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
131.04 |
2805.35 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056001 |
INVEGA® SUSTENNA® Strength:39 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
21.84 |
467.53 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056101 |
INVEGA® SUSTENNA® Strength:78 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
43.68 |
935.09 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458060601 |
INVEGA® TRINZA® Strength:273 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
131.04 |
2805.26 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458060701 |
INVEGA® TRINZA® Strength:410 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
196.56 |
4207.94 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458060801 |
INVEGA® TRINZA® Strength:546 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
262.09 |
5610.85 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458060901 |
INVEGA® TRINZA® Strength:819 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
393.12 |
8416.04 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458054360 |
INVOKAMET® Strength:150/1000 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458054260 |
INVOKAMET® Strength:150/500 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458054160 |
INVOKAMET® Strength:50/1000 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458054060 |
INVOKAMET® Strength:50/500 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458094301 |
INVOKAMET® XR Strength:150/1000 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458094201 |
INVOKAMET® XR Strength:150/500 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458094101 |
INVOKAMET® XR Strength:50/1000 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458094001 |
INVOKAMET® XR Strength:50/500 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458014030 |
INVOKANA® Strength:100mg Package Size:30 Form:Tablet |
01/20/2020 |
24.22 |
518.53 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458014090 |
INVOKANA® Strength:100mg Package Size:90 Form:Tablet |
01/20/2020 |
72.67 |
1555.61 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458014130 |
INVOKANA® Strength:300mg Package Size:30 Form:Tablet |
01/20/2020 |
24.22 |
518.53 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458014190 |
INVOKANA® Strength:300mg Package Size:90 Form:Tablet |
01/20/2020 |
72.67 |
1555.61 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676057530 |
PREZCOBIX™ (darunavir 800mg, cobicistat 150mg) Strength:800 MG/150 MG Package Size:30 Form:Tablet |
01/20/2020 |
86.91 |
2018.20 |
10/04/2032 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056401 |
PREZISTA® Strength:150 MG Package Size:240 Form:Tablet |
01/20/2020 |
76.03 |
1765.73 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056201 |
PREZISTA® Strength:600 MG Package Size:60 Form:Tablet |
01/20/2020 |
76.03 |
1765.73 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056301 |
PREZISTA® Strength:75 MG Package Size:480 Form:Tablet |
01/20/2020 |
76.03 |
1765.73 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056630 |
PREZISTA® Strength:800 MG Package Size:30 Form:Tablet |
01/20/2020 |
76.02 |
1765.73 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056501 |
PREZISTA® ORAL SUSPENSION Strength:100MG/mL Package Size:200mL Form:Oral Suspension |
01/20/2020 |
42.24 |
980.90 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458030911 |
RISPERDAL® CONSTA® Strength:12.5 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
11.87 |
254.27 |
None |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458030611 |
RISPERDAL® CONSTA® Strength:25 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
23.75 |
508.50 |
11/25/2020 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458030711 |
RISPERDAL® CONSTA® Strength:37.5 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
35.63 |
762.79 |
11/25/2020 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458030811 |
RISPERDAL® CONSTA® Strength:50 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
47.51 |
1017.07 |
11/25/2020 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894007101 |
SIMPONI® (golimumab) Prefilled Syringe Strength:100mg/1mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
248.86 |
5779.26 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894007001 |
SIMPONI® (golimumab) Prefilled Syringe Strength:50mg/0.5mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
216.41 |
5025.43 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894007102 |
SIMPONI® (golimumab) SmartJect® xAutoinjector Strength:100mg/1mL Package Size:1 Form:1 Single Autoinjector |
01/20/2020 |
248.86 |
5779.26 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894007002 |
SIMPONI® (golimumab) SmartJect® xAutoinjector Strength:50mg/0.5mL Package Size:1 Form:1 Single Autoinjector |
01/20/2020 |
216.41 |
5025.43 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894006003 |
STELARA® (ustekinumab) prefilled syringe Strength:45mg/0.5mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
539.11 |
11541.42 |
09/25/2023 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894006103 |
STELARA® (ustekinumab) prefilled syringe Strength:90mg/1mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
1078.23 |
23082.84 |
09/25/2023 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894006002 |
STELARA® (ustekinumab) vial Strength:45mg Package Size:1 Form:1 Single vial |
01/20/2020 |
539.11 |
11541.42 |
09/25/2023 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064165 |
TOPAMAX® Strength:100 mg Package Size:60 Form:Tablet |
01/20/2020 |
19.80 |
1009.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064765 |
TOPAMAX® Strength:15 mg Package Size:60 Form:Sprinkle |
01/20/2020 |
6.87 |
350.45 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064265 |
TOPAMAX® Strength:200 mg Package Size:60 Form:Tablet |
01/20/2020 |
23.18 |
1182.26 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064565 |
TOPAMAX® Strength:25 mg Package Size:60 Form:Sprinkle |
01/20/2020 |
8.31 |
423.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458063965 |
TOPAMAX® Strength:25 mg Package Size:60 Form:Tablet |
01/20/2020 |
7.27 |
370.52 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064065 |
TOPAMAX® Strength:50 mg Package Size:60 Form:Tablet |
01/20/2020 |
14.50 |
739.47 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894064001 |
TREMFYA™ (guselkumab) prefilled syringe Strength:100mg/1mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
532.11 |
11391.57 |
01/18/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available, and includes pending patent term extension. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215061006 |
UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215061206 |
UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215061406 |
UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215061606 |
UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060214 |
UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet |
01/20/2020 |
1286.46 |
27540.66 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
22652.00 |
None |
2015 |
21780.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060206 |
UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet |
01/20/2020 |
551.34 |
11803.14 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
9714.00 |
None |
2015 |
9340.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215062820 |
UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet |
01/20/2020 |
1286.44 |
27540.44 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
22652.00 |
None |
2015 |
21780.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060406 |
UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060606 |
UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060806 |
UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058451 |
XARELTO Starter Pack™ Strength:15mg/20mg Package Size:51 Form:Tablet |
01/20/2020 |
37.32 |
798.90 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058010 |
XARELTO® Strength:10 mg Package Size:100 Form:Tablet |
01/20/2020 |
73.17 |
1566.46 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058030 |
XARELTO® Strength:10 mg Package Size:30 Form:Tablet |
01/20/2020 |
21.95 |
469.94 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058090 |
XARELTO® Strength:10 mg Package Size:90 Form:Tablet |
01/20/2020 |
65.85 |
1409.81 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057810 |
XARELTO® Strength:15 mg Package Size:100 Form:Tablet |
01/20/2020 |
73.17 |
1566.46 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057830 |
XARELTO® Strength:15 mg Package Size:30 Form:Tablet |
01/20/2020 |
21.95 |
469.94 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057890 |
XARELTO® Strength:15 mg Package Size:90 Form:Tablet |
01/20/2020 |
65.85 |
1409.81 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057910 |
XARELTO® Strength:20 mg Package Size:100 Form:Tablet |
01/20/2020 |
73.17 |
1566.46 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057930 |
XARELTO® Strength:20 mg Package Size:30 Form:Tablet |
01/20/2020 |
21.95 |
469.94 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057990 |
XARELTO® Strength:20 mg Package Size:90 Form:Tablet |
01/20/2020 |
65.85 |
1409.81 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000008 |
Jazz Pharmaceuticals, Inc. |
03/31/2020 |
68727010001 |
Xyrem 500 MG/ML Oral Solution 180 ml |
01/08/2020 |
400.33 |
5110.12 |
09/15/2033 |
Single Source Drug |
1642525000 |
None |
None |
1 |
A change or improvement to the drug did not necessitate the price increase |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 30, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
The drug was not was acquired from another manufacturer within the last five years. |
| Rx0000150 |
Kala Pharmaceuticals, Inc. |
03/31/2020 |
71571012128 |
INVELTYS, Loteprednol Etabonate 1%, Suspension/Eye Drop, 2.8ml bottle |
01/01/2020 |
24.28 |
269.53 |
01/01/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
06/30/2020 |
76125090010 |
Gammaked 10% 100ML Vial |
04/01/2020 |
61.96 |
1438.93 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
09/30/2020 |
76125090010 |
Gammaked 10% 100ML Vial |
09/11/2020 |
79.17 |
1518.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
06/30/2020 |
76125090001 |
Gammaked 10% 10ML Vial |
04/01/2020 |
6.20 |
143.90 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
09/30/2020 |
76125090001 |
Gammaked 10% 10ML Vial |
09/11/2020 |
7.91 |
151.81 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
06/30/2020 |
76125090020 |
Gammaked 10% 200ML Vial |
04/01/2020 |
123.93 |
2877.87 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
09/30/2020 |
76125090020 |
Gammaked 10% 200ML Vial |
09/11/2020 |
158.33 |
3036.20 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
06/30/2020 |
76125090050 |
Gammaked 10% 50ML Vial |
04/01/2020 |
30.98 |
719.47 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
09/30/2020 |
76125090050 |
Gammaked 10% 50ML Vial |
09/11/2020 |
39.58 |
759.05 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000023 |
Kowa Pharmaceuticals America, Inc. |
03/31/2020 |
66869010490 |
LIVALO 1 MG - bottle of 90 tablets |
01/06/2020 |
44.35 |
931.25 |
08/19/2024 |
Single Source Drug |
55524 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired from another manufacturer. |
| Rx0000023 |
Kowa Pharmaceuticals America, Inc. |
03/31/2020 |
66869020490 |
LIVALO 2 MG - bottle of 90 tablets |
01/06/2020 |
44.35 |
931.25 |
08/19/2024 |
Single Source Drug |
231261 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired from another manufacturer. |
| Rx0000023 |
Kowa Pharmaceuticals America, Inc. |
03/31/2020 |
66869040490 |
LIVALO 4 MG - bottle of 90 tablets |
01/06/2020 |
44.35 |
931.25 |
08/19/2024 |
Single Source Drug |
175990 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired from another manufacturer. |
| Rx0000083 |
Laboratoire HRA Pharma |
03/31/2020 |
76336008060 |
Lysodren (mitotane) 500 mg tablets 100 count bottles |
01/13/2020 |
83.10 |
922.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Column 6: Patent(s) expired. Product FDA approved 1970.
Column 21: WAC at Intro to Market unknown. Introducted to U.S. market in 1970.
WAC at market introduction unknown.
NDC change in March 2019.
5 year pricing history believed to be $479.95 until 3/2019. |
| Rx0000083 |
Laboratoire HRA Pharma |
03/31/2020 |
76336045518 |
Metopirone (metryapone) 250 mg capsules 18 count bottles |
01/13/2020 |
38.05 |
422.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
HRA Pharma acquired Metopirone from Novartis in 2011 and began US distribution in 2015 (exact date unknown).
WAC at introduction to market unknown.
5 year price history included.
Original approval 1961 |
| Rx0000083 |
Laboratoire HRA Pharma |
09/30/2020 |
76336045518 |
Metopirone 250 mg capsules 18 count bottles |
07/14/2020 |
105.50 |
527.50 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was FDA approved 1961.
Innovator company was Novartis.
Product was acquired by HRA Pharma from Novartis in 2011.
Acquisition price of the product is unknown. |
| Rx0000089 |
Lannett Company, Inc. |
12/31/2020 |
00527169801 |
CODEINE SULFATE 30 MG TABLET |
11/23/2020 |
79.50 |
119.25 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years |
| Rx0000089 |
Lannett Company, Inc. |
12/31/2020 |
00527147501 |
DIETHYLPROPION 25 MG TABLET |
11/23/2020 |
22.30 |
44.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years |
| Rx0000089 |
Lannett Company, Inc. |
12/31/2020 |
00527147701 |
DIETHYLPROPION ER 75 MG TABLET |
11/23/2020 |
42.18 |
126.54 |
None |
Single Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years |
| Rx0000089 |
Lannett Company, Inc. |
12/31/2020 |
54838051240 |
Doxepin Hydrochloride Oral Solution 10mg/mL - 120mL |
11/23/2020 |
37.92 |
56.88 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields were not filled out because this drug was not acquired within the previous 5 years. |
| Rx0000089 |
Lannett Company, Inc. |
03/31/2020 |
54838055170 |
Escitalopram Oxalate Oral Solution 5mg/5ml - 240ml |
01/31/2020 |
8.00 |
160.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
06/02/2015 |
Silarx |
None |
1 |
Lannett Company Acquired Silarx Company in 2015 |
152.00 |
None |
2013 |
152.00 |
None |
None |
| Rx0000089 |
Lannett Company, Inc. |
12/31/2020 |
62175010601 |
ISOSORBIDE MONONIT 10 MG TAB |
11/23/2020 |
7.74 |
48.47 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years |
| Rx0000089 |
Lannett Company, Inc. |
12/31/2020 |
62175010701 |
ISOSORBIDE MONONIT 20 MG TAB |
11/23/2020 |
17.75 |
50.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years |
| Rx0000089 |
Lannett Company, Inc. |
03/31/2020 |
00527194313 |
Memantine Oral Solution 2mg - 360ml |
01/31/2020 |
292.35 |
817.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years |
| Rx0000089 |
Lannett Company, Inc. |
03/31/2020 |
62175048537 |
Verapamil HCl 100 MG Capsule Extended Release 24 Hour 100 EA |
01/31/2020 |
40.27 |
487.69 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years |
| Rx0000089 |
Lannett Company, Inc. |
03/31/2020 |
62175048637 |
Verapamil HCl 200 MG Capsule Extended Release 24 Hour 100 EA |
01/31/2020 |
51.86 |
628.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years |
| Rx0000089 |
Lannett Company, Inc. |
03/31/2020 |
62175048737 |
Verapamil HCl 300 MG Capsule Extended Release 24 Hour 100 EA |
01/31/2020 |
75.40 |
913.17 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years |
| Rx0000009 |
Lantheus Medical Imaging, Inc. |
03/31/2020 |
11994001116 |
Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution, 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS |
01/01/2020 |
202.38 |
4250.05 |
03/16/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000009 |
Lantheus Medical Imaging, Inc. |
03/31/2020 |
11994001104 |
Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution, 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS |
01/01/2020 |
50.60 |
1062.52 |
03/16/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000009 |
Lantheus Medical Imaging, Inc. |
03/31/2020 |
11994001601 |
QUADRAMET® (Samarium Sm 153 Lexidronam Injection), 3 mL in 1 VIAL, SINGLE-DOSE (11994-016-01) |
01/01/2020 |
1065.23 |
16282.88 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000243 |
Larken Laboratories, Inc. |
03/31/2020 |
70569015001 |
Allzital 100ct (Butalbital-Acetaminophen Tabs 25-325 MG |
02/14/2020 |
286.31 |
1431.54 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired within the previous 5 years. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50419082806 |
DESONATE 0.05% GEL 60GM TB 60G |
01/01/2020 |
35.72 |
630.97 |
08/03/2020 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/04/2018 |
Bayer Pharmaceuticals |
None |
1 |
None |
564.22 |
513.39 |
2007 |
120.00 |
None |
Market WAC effective 01/30/2007. Bayer NDC 50419082806 was replaced by Leo NDC 50222050460. Bayer NDC 50419082806 uses the same history as Leo NDC 50222050460. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50222050460 |
DESONATE 0.05% GEL 60GM TUBE 60G |
01/01/2020 |
35.72 |
630.97 |
08/03/2020 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/04/2018 |
Bayer Pharmaceuticals |
None |
1 |
None |
564.22 |
513.39 |
2007 |
120.00 |
None |
Market WAC effective 01/30/2007. LEO NDC 50222050460 replaces Bayer NDC 50419082806. LEO NDC 50222050460 uses the same history as Bayer NDC 50419082806. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50222030260 |
ENSTILAR AEROSOL FOAM, 1 CAN 60gm 0.005-0.064 % |
01/01/2020 |
63.01 |
1113.28 |
12/10/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired and therefore the acquisition related fields are not applicable |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50222030266 |
ENSTILAR AEROSOL FOAM, 2 CANS 120 gm 0.005-0.064 % |
01/01/2020 |
126.04 |
2226.56 |
12/10/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired and therefore the acquisition related fields are not applicable |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50222030350 |
FINACEA 15% FOAM 50GM CAN |
01/01/2020 |
20.69 |
365.56 |
02/28/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/04/2018 |
Bayer Pharmaceuticals |
None |
1 |
None |
326.89 |
297.44 |
2015 |
255.01 |
None |
Market WAC effective 08/31/2015. We are reporting this NDC because it replaced the Bayer NDC 50419082901. The LEO NDC 50222030350 shares the same history as the Bayer NDC 50419082901. The market entry date for this LEO NDC 50222030350 was April 2020. WAC in Medispan for this LEO NDC reflects 1/1/2020 WAC for Bayer NDC 50419082901. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50419082901 |
FINACEA 15% FOAM 50GM CN |
01/01/2020 |
20.69 |
365.56 |
02/28/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/04/2018 |
Bayer Pharmaceuticals |
None |
1 |
None |
326.89 |
297.44 |
2015 |
255.01 |
None |
Market WAC effective 08/31/2015. Bayer NDC 50419082901 was replaced by LEO NDC 50222030350. LEO NDC 50222030350 entered market in April 2020 and uses the same history as Bayer NDC 50419082901. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50419082502 |
FINACEA 15% GEL 50GM TB |
01/01/2020 |
17.24 |
362.11 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/04/2018 |
Bayer Pharmaceuticals |
None |
1 |
None |
326.89 |
297.44 |
2003 |
75.40 |
None |
Market WAC effective 03/10/2005. No date listed for patent expiration information based on Orange book. We are reporting this NDC because the LEO NDC 50222050550 is a replacement for this NDC 50419082502. This Bayer NDC 50419082502 shares the same history as the LEO NDC 50222050550. No increase in price shown in Medispan for the Bayer NDC 50419082502. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50222050550 |
FINACEA 15% GEL 50GM TUBE |
01/01/2020 |
17.24 |
362.11 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/04/2018 |
Bayer Pharmaceuticals |
None |
1 |
None |
326.89 |
297.44 |
2003 |
75.40 |
None |
Market WAC effective 03/10/2005, No date listed for patent expiration information based on Orange book. LEO NDC 50222050550 replaces Bayer NDC 50419082502. LEO NDC 50222050550 uses the same history as Bayer NDC 50419082502. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50222050247 |
PICATO (ingenaol mebutate 0.015%) Gel 3 x .47gm |
01/07/2020 |
62.74 |
1108.37 |
05/15/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Patent Exp date different for .05%. Drug was not acquired and therefore the acquisition related fields are not applicable; |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50222050347 |
PICATO (ingenaol mebutate 0.05%) Gel 2 x .47gm |
01/07/2020 |
62.74 |
1108.37 |
07/06/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Patent Exp date different for .015%. Drug was not acquired and therefore the acquisition related fields are not applicable; |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50222050166 |
TACLONEX TOPICAL SUSPENSION (0.005%, 0.064%) Solution 120g |
01/01/2020 |
126.04 |
2226.56 |
01/27/2020 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired and therefore the acquisition related fields are not applicable |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2020 |
50222050106 |
TACLONEX TOPICAL SUSPENSION (0.005%, 0.064%) Solution 60g |
01/01/2020 |
63.01 |
1113.28 |
01/27/2020 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired and therefore the acquisition related fields are not applicable |
| Rx0000196 |
Lexicon Pharmaceuticals |
03/31/2020 |
70183012584 |
XERMELO Telotristat Ethyl 250 mg 84 tablets |
01/02/2020 |
306.00 |
6559.00 |
02/27/2031 |
Single Source Drug |
None |
1 |
Lexicon’s focus on improving the lives of all patients we serve shapes our pricing decisions. Our pricing is designed to ensure full access by balancing affordability with availability of patient assistance programs for our patients in need while factoring in market dynamics of competitor pricing and changing reimbursement rates. |
None |
no change |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product developed internally. No acquistion. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386082019 |
Northera 100mg. 90 Capsules |
01/02/2020 |
204.95 |
2799.21 |
02/18/2021 |
Single Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386082119 |
Northera 200mg. 90 Capsules |
01/02/2020 |
409.89 |
5598.40 |
02/18/2021 |
Single Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386082219 |
Northera 300mg. 90 Capsules |
01/02/2020 |
614.84 |
8397.62 |
02/18/2021 |
Single Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386031401 |
Onfi 10mg. 100 Tablets |
01/02/2020 |
191.12 |
2202.86 |
None |
Innovator Multiple Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386031501 |
Onfi 20mg. 100 Tablets |
01/02/2020 |
382.23 |
4405.67 |
None |
Innovator Multiple Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386031321 |
Onfi Oral Suspension 2.5mg/mL 120mL Bottle |
01/02/2020 |
100.41 |
1157.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386011101 |
Sabril 500mg. 100 Tablets |
01/02/2020 |
1388.11 |
15999.84 |
None |
Innovator Multiple Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386021165 |
Sabril 500mg. 50 Packets 10mg. each |
01/02/2020 |
694.06 |
7999.93 |
None |
Innovator Multiple Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386042101 |
Xenazine 12.5mg. 112 Tablets |
01/02/2020 |
1339.43 |
15438.72 |
None |
Innovator Multiple Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2020 |
67386042201 |
Xenazine 25.0mg. 112 Tablets |
01/02/2020 |
2678.87 |
30877.45 |
None |
Innovator Multiple Source Drug |
None |
1 |
Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000052 |
Mallinckrodt Hospital Products Inc. |
03/31/2020 |
43825010201 |
OFIRMEV INJECTION 1000MG/100ML (10mg/ml) (24 vials/case) |
01/02/2020 |
93.87 |
1136.87 |
03/11/2032 |
Single Source Drug |
None |
1 |
None |
1 |
Mallinckrodt has voluntarily made a public pledge on responsible drug pricing and innovation which is our social contract to those we serve and which can be found at https://www.mallinckrodt.com/corporate-responsibility/pledge-on-drug-pricing--innovation/. Our commitment is to price our innovative products responsibly while providing broad patient access. In so doing, we continue to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. The current price increase for Ofirmev is not necessitated by a change or improvement to the drug but by the larger principles set forth in our pledge. |
None |
03/19/2014 |
Cadence Pharmaceuticals, Inc. |
1400000000 |
None |
Acquisition Price field reflects the total price paid for all of Cadence inclusive of Ofirmev |
354.00 |
None |
2011 |
258.00 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862006410 |
DIAZEPAM 10MG TABLETS 1000 |
01/03/2020 |
90.80 |
181.60 |
None |
Non-innovator Multiple Source Drug |
10676 |
None |
CHANGING MARKET DYNAMICS |
None |
NONE |
None |
08/03/2016 |
ALLERGAN |
None |
None |
Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million. |
36.32 |
36.32 |
2005 |
36.32 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862094310 |
DIAZEPAM 10MG TABLETS 1000 (NEW MAYNE NDC) |
01/03/2020 |
90.80 |
181.60 |
None |
Non-innovator Multiple Source Drug |
10676 |
None |
CHANGING MARKET DYNAMICS |
None |
NONE |
None |
08/03/2016 |
ALLERGAN |
None |
None |
Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million. |
36.32 |
36.32 |
2005 |
36.32 |
None |
NEW PRODUCT NDC |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862006405 |
DIAZEPAM 10MG TABLETS 500 |
01/03/2020 |
46.33 |
92.66 |
None |
Non-innovator Multiple Source Drug |
9676 |
None |
CHANGING MARKET DYNAMICS |
None |
NONE |
None |
08/03/2016 |
ALLERGAN |
None |
None |
Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million. |
18.53 |
18.53 |
2005 |
18.53 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862094305 |
DIAZEPAM 10MG TABLETS 500 (NEW MAYNE NDC) |
01/03/2020 |
46.33 |
92.66 |
None |
Non-innovator Multiple Source Drug |
455 |
None |
CHANGING MARKET DYNAMICS |
None |
NONE |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NEW PRODUCT NDC |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862006205 |
DIAZEPAM 2MG TABLETS 500 |
01/03/2020 |
34.20 |
68.40 |
None |
Non-innovator Multiple Source Drug |
9040 |
None |
CHANGING MARKET DYNAMICS |
None |
NONE |
None |
08/03/2016 |
ALLERGAN |
None |
None |
Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million. |
13.68 |
13.68 |
2005 |
13.68 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862006310 |
DIAZEPAM 5MG TABLETS 1000 |
01/03/2020 |
69.85 |
139.70 |
None |
Non-innovator Multiple Source Drug |
4444 |
None |
CHANGING MARKET DYNAMICS |
None |
NONE |
None |
08/03/2016 |
ALLERGAN |
None |
None |
Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million. |
27.94 |
27.94 |
2001 |
42.95 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862094210 |
DIAZEPAM 5MG TABLETS 1000 (NEW MAYNE NDC) |
01/03/2020 |
69.85 |
139.70 |
None |
Non-innovator Multiple Source Drug |
1 |
None |
CHANGING MARKET DYNAMICS |
None |
NONE |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NEW PRODUCT NDC, NO SALES AS OF 04-30-2020; USED 1 AS A PLACEHOLDER TO SUBMIT INCREASE |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862006305 |
DIAZEPAM 5MG TABLETS 500 |
01/03/2020 |
35.65 |
71.30 |
None |
Non-innovator Multiple Source Drug |
35620 |
None |
CHANGING MARKET DYNAMICS |
None |
NONE |
None |
08/03/2016 |
ALLERGAN |
None |
None |
Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million. |
14.26 |
14.26 |
2005 |
14.26 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862094205 |
DIAZEPAM 5MG TABLETS 500 (NEW MAYNE NDC) |
01/03/2020 |
35.65 |
71.30 |
None |
Non-innovator Multiple Source Drug |
11479 |
None |
CHANGING MARKET DYNAMICS |
None |
NONE |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NEW PRODUCT NDC |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862029510 |
Fabior External Foam 0.1 % 100g Can |
01/13/2020 |
80.65 |
1155.94 |
02/24/2030 |
Single Source Drug |
11455 |
None |
None |
1 |
None |
None |
08/17/2016 |
GlaxoSmithKline LLC |
None |
1 |
None |
830.32 |
722.02 |
2014 |
607.76 |
None |
Product NDC at WAC Introduction in 2014 was 00145-0020-02. Product WAC Introduction for current 51862-0295-10 NDC was $830.32 on 03/17/2017. Unit Sales reported for calendar year 2019. |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862029550 |
Fabior External Foam 0.1 % 50g Can |
01/13/2020 |
40.32 |
577.96 |
02/24/2030 |
Single Source Drug |
96108 |
None |
None |
1 |
None |
None |
08/17/2016 |
GlaxoSmithKline LLC |
None |
1 |
None |
415.16 |
361.01 |
2014 |
303.88 |
None |
Product NDC at WAC Introduction in 2014 was 00145-0020-03. Product WAC Introduction for current 51862-0295-50 NDC was $415.16 on 03/03/2017. Unit Sales reported for calendar year 2019. |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862015904 |
Hydrocortisone Butyrate External Lotion 0.1 % 118ML PER BOTTLE |
01/28/2020 |
439.45 |
894.10 |
None |
Non-innovator Multiple Source Drug |
279 |
None |
Initial launch price listed on 8/23/2019 was for a different pack size. Price change is to update to correct pack size. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired; this is a licensing deal with Teligent. |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862037612 |
Sorilux External Foam 0.005 % 120g Can |
01/13/2020 |
110.51 |
1583.97 |
05/07/2028 |
Single Source Drug |
4615 |
None |
None |
1 |
None |
None |
08/17/2016 |
GlaxoSmithKline LLC |
None |
1 |
None |
1240.18 |
1078.42 |
2012 |
650.00 |
None |
Product NDC at WAC Introduction in 2012 was 00145-2130-07. Product WAC Introduction for current 51862-0376-12 NDC was $1240.18 on 05/11/2017. Unit Sales reported for calendar year 2019. |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2020 |
51862037660 |
Sorilux External Foam 0.005 % 60g Can |
01/13/2020 |
57.80 |
828.52 |
05/07/2028 |
Single Source Drug |
29204 |
None |
None |
1 |
None |
None |
08/17/2016 |
GlaxoSmithKline LLC |
None |
1 |
None |
648.70 |
564.09 |
2012 |
340.00 |
None |
Product NDC at WAC Introduction in 2012 was 00145-2130-06. Product WAC Introduction for current 51862-0376-60 NDC was $648.7 on 05/11/2017. Unit Sales reported for calendar year 2019. |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538050106 |
Ciclodan Kit, 8%, TOPSOL, 34.60 ML |
07/31/2020 |
10.85 |
444.88 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538050006 |
Ciclodan Topical Solution, 8%, TOPSOL, 6.60 ML |
07/31/2020 |
10.85 |
444.88 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538017360 |
Clindacin ETZ Kit, 1%, TOPCMB, 1 EA |
07/31/2020 |
15.20 |
623.14 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538017260 |
Clindacin ETZ, 1%, SGPDSW, 60 EA |
07/31/2020 |
15.20 |
623.14 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538017069 |
Clindacin P, 1%, SGPDSW, 69 EA |
07/31/2020 |
15.20 |
623.14 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538017169 |
Clindacin Pac, 1%, TOPCMB, 1 EA |
07/31/2020 |
15.20 |
623.14 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538095104 |
Clodan Kit, 0.05%, TOPCMB, 1 EA |
07/31/2020 |
15.22 |
623.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538095004 |
Clodan Shampoo, 0.05%, TOPSHMPO, 118 ML |
07/31/2020 |
15.22 |
623.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538051112 |
Genadur Kit, 2500MCG, COMB, 1 EA |
07/31/2020 |
12.48 |
511.67 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538051012 |
Genadur, TOPLIQ, 12 ML |
07/31/2020 |
12.48 |
511.67 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538094160 |
Neo-Synalar Cream Kit, 0.5-0.025%, EXTCRM, 315 GM |
07/31/2020 |
20.11 |
824.25 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538094060 |
Neo-Synalar Cream, 0.5-0.025%, EXTCRM, 60 GM |
07/31/2020 |
20.11 |
824.25 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538017645 |
Neuac Gel, 1.2(1)%-5%, TOPGEL, 45 GM |
07/31/2020 |
14.79 |
606.52 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538017745 |
Neuac Kit, 1.2(1)%-5%, TOPCMB, 130 GM |
07/31/2020 |
14.79 |
606.52 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538044060 |
Nicadan, 800-10-100, TAB, 60 EA |
07/31/2020 |
11.29 |
463.17 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538018145 |
Rosadan Cream Kit, 0.75%, RCTCMB, 1 EA |
07/31/2020 |
11.93 |
489.26 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538018045 |
Rosadan Cream, 0.75%, EXTCRM, 45 GM |
07/31/2020 |
11.93 |
489.26 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538018345 |
Rosadan Gel Kit, 0.75%, TOPCMB, 1 EA |
07/31/2020 |
11.93 |
489.27 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538018245 |
Rosadan Gel, 0.75%, TOPGEL, 45 GM |
07/31/2020 |
11.93 |
489.27 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538019116 |
Sumadan Kit, 9%-4.5%, TOPCMB, 1 EA |
07/31/2020 |
19.98 |
818.87 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538019016 |
Sumadan Wash, 9%-4.5%, TOPCLNSR, 454 GM |
07/31/2020 |
19.98 |
818.87 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538019216 |
Sumadan XLT, 9%-4.5%, TOPCMB, 539 GM |
07/31/2020 |
19.98 |
818.87 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538010060 |
Sumaxin Cleansing Pad, 10%-4%, SGPDSW, 60 EA |
07/31/2020 |
20.48 |
839.49 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538010160 |
Sumaxin CP Kit, 10%-4%, TOPCMB, 1 EA |
07/31/2020 |
20.48 |
839.49 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538016016 |
Sumaxin TS, 8%-4%, TOPSUSP, 473 ML |
07/31/2020 |
15.73 |
644.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538013016 |
Sumaxin Wash, 9%-4%, TOPCLNSR, 454 GM |
07/31/2020 |
17.84 |
731.32 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538090112 |
Synalar Cream Kit, 0.025%, EXTCRM, 375 GM |
07/31/2020 |
14.01 |
574.46 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538090012 |
Synalar Cream, 0.025%, EXTCRM, 120 GM |
07/31/2020 |
14.01 |
574.46 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538091112 |
Synalar Ointment Kit, 0.025%, TOPCMB, 375 GM |
07/31/2020 |
14.01 |
574.46 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
09/30/2020 |
43538091012 |
Synalar Ointment, 0.025%, EXTONT, 120 GM |
07/31/2020 |
14.01 |
574.46 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006003330 |
BELSOMRA 10 mg Tablets 30 |
01/03/2020 |
17.40 |
365.70 |
05/29/2033 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006032530 |
BELSOMRA 15 mg Tablets 30 |
01/03/2020 |
17.40 |
365.70 |
05/29/2033 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006033530 |
BELSOMRA 20 mg Tablets 30 |
01/03/2020 |
17.40 |
365.70 |
05/29/2033 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006000530 |
BELSOMRA 5 mg Tablets 30 |
01/03/2020 |
17.40 |
365.70 |
05/29/2033 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
67919002010 |
ENTEREG 12 mg Capsules 30 |
01/03/2020 |
242.70 |
5195.40 |
02/12/2030 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00052031301 |
FOLLISTIM AQ 300 unit/0.36 mL CARTRIDGE (ML) 0.42 |
01/03/2020 |
36.00 |
792.00 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00052031601 |
FOLLISTIM AQ 600 unit/0.72 mL deliverable (833 unit/mL) CARTRIDGE (ML) 0.78 |
01/03/2020 |
72.00 |
1584.00 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00052032601 |
FOLLISTIM AQ 900 unit/1.08 mL CARTRIDGE (ML) 1.17 |
01/03/2020 |
108.00 |
2376.00 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
12/31/2020 |
00006412102 |
GARDASIL 9 0.5 mL Syringes 10 |
11/12/2020 |
113.59 |
2385.40 |
12/10/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
12/31/2020 |
00006411903 |
GARDASIL 9 0.5 mL Vials 10 |
11/12/2020 |
113.59 |
2385.40 |
12/10/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006047761 |
ISENTRESS 100 mg Chewable Tablets 60 |
01/03/2020 |
19.68 |
413.28 |
09/11/2029 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) the patent expiration date for this product includes 6 month pediatric exclusivity. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006047361 |
ISENTRESS 25 mg Chewable Tablets 60 |
01/03/2020 |
4.92 |
103.32 |
09/11/2029 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) the patent expiration date for this product includes 6 month pediatric exclusivity. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006022761 |
ISENTRESS 400 mg Tablets 60 |
01/03/2020 |
78.72 |
1653.12 |
09/11/2029 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) the patent expiration date for this product includes 6 month pediatric exclusivity. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006308001 |
ISENTRESS HD 600 mg Tablets 60 |
01/03/2020 |
78.72 |
1653.12 |
04/21/2031 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) the patent expiration date for this product includes 6 month pediatric exclusivity. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006057782 |
JANUMET 50 mg-1000 mg Tablets 1000 |
01/03/2020 |
370.00 |
7890.00 |
07/21/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006057762 |
JANUMET 50 mg-1000 mg Tablets 180 |
01/03/2020 |
66.60 |
1420.20 |
07/21/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006057761 |
JANUMET 50 mg-1000 mg Tablets 60 |
01/03/2020 |
22.20 |
473.40 |
07/21/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006057582 |
JANUMET 50 mg-500 mg Tablets 1000 |
01/03/2020 |
370.00 |
7890.00 |
07/21/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006057562 |
JANUMET 50 mg-500 mg Tablets 180 |
01/03/2020 |
66.60 |
1420.20 |
07/21/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006057561 |
JANUMET 50 mg-500 mg Tablets 60 |
01/03/2020 |
22.20 |
473.40 |
07/21/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006008182 |
JANUMET XR 100 mg-1000 mg Tablets 1000 |
01/03/2020 |
740.00 |
15780.00 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006008131 |
JANUMET XR 100 mg-1000 mg Tablets 30 |
01/03/2020 |
22.20 |
473.40 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006008154 |
JANUMET XR 100 mg-1000 mg Tablets 90 |
01/03/2020 |
66.60 |
1420.20 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006008082 |
JANUMET XR 50 mg-1000 mg Tablets 1000 |
01/03/2020 |
370.00 |
7890.00 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006008062 |
JANUMET XR 50 mg-1000 mg Tablets 180 |
01/03/2020 |
66.60 |
1420.20 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006008061 |
JANUMET XR 50 mg-1000 mg Tablets 60 |
01/03/2020 |
22.20 |
473.40 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006007882 |
JANUMET XR 50 mg-500 mg Tablets 1000 |
01/03/2020 |
370.00 |
7890.00 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006007862 |
JANUMET XR 50 mg-500 mg Tablets 180 |
01/03/2020 |
66.60 |
1420.20 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2 )the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006007861 |
JANUMET XR 50 mg-500 mg Tablets 60 |
01/03/2020 |
22.20 |
473.40 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006027728 |
JANUVIA 100 mg Tablets 100 |
01/03/2020 |
74.00 |
1578.00 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006027782 |
JANUVIA 100 mg Tablets 1000 |
01/03/2020 |
740.00 |
15780.00 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006027731 |
JANUVIA 100 mg Tablets 30 |
01/03/2020 |
22.20 |
473.40 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006027754 |
JANUVIA 100 mg Tablets 90 |
01/03/2020 |
66.60 |
1420.20 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006022128 |
JANUVIA 25 mg Tablets 100 |
01/03/2020 |
74.00 |
1578.00 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006022131 |
JANUVIA 25 mg Tablets 30 |
01/03/2020 |
22.20 |
473.40 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006022154 |
JANUVIA 25 mg Tablets 90 |
01/03/2020 |
66.60 |
1420.20 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006011228 |
JANUVIA 50 mg Tablets 100 |
01/03/2020 |
74.00 |
1578.00 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006011231 |
JANUVIA 50 mg Tablets 30 |
01/03/2020 |
22.20 |
473.40 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
00006011254 |
JANUVIA 50 mg Tablets 90 |
01/03/2020 |
66.60 |
1420.20 |
11/24/2026 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000138 |
Merck & Co., Inc. |
12/31/2020 |
00006468100 |
M-M-R II 0.5 mL Vials 10 |
11/12/2020 |
38.21 |
802.49 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
12/31/2020 |
00006483703 |
PNEUMOVAX 23 0.5 mL Syringes 10 |
11/12/2020 |
52.60 |
1104.54 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
12/31/2020 |
00006494300 |
PNEUMOVAX 23 0.5 mL Vials 10 |
11/12/2020 |
52.60 |
1104.54 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
12/31/2020 |
00006417100 |
PROQUAD 0.5 mL Vials 10 |
11/12/2020 |
110.97 |
2330.34 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
12/31/2020 |
00006482700 |
VARIVAX 0.5 mL Vials 10 |
11/12/2020 |
67.49 |
1417.24 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
03/31/2020 |
67919003001 |
ZERBAXA 1.5 gram Vial 10 |
01/03/2020 |
112.80 |
1252.20 |
08/14/2035 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
•capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers.
•investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years. |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2020 |
72495020105 |
FEMRING 0.05MG/DAY (ESTRADIOL ACETATE VAGINAL RING) for 3 months usage, package size 1 |
01/01/2020 |
46.12 |
531.49 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/18/2018 |
Allergan |
None |
1 |
None |
443.67 |
None |
2003 |
76.50 |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2020 |
72495020210 |
FEMRING 0.10MG/DAY (ESTRADIOL ACETATE VAGINAL RING) for 3 months usage, package size 1 |
01/01/2020 |
49.14 |
566.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/18/2018 |
Allergan |
None |
1 |
None |
472.79 |
None |
2003 |
81.50 |
None |
None |
| Rx0000318 |
Mission Pharmacal Company |
12/31/2020 |
00178074001 |
URIBEL, methenamine 118mg, sodium phosphate monobasic 40.8mg, phenyl salicylate 10mg, methylene blue 10mg, and hyoscyamine sulfate capsule 0.12mg, 100 capsules |
10/01/2020 |
26.33 |
355.44 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Product was acquired from another labeler |
None |
No formulation changes were made, just Labeler change |
None |
01/01/2019 |
Star Pharmaceuticals, LLC |
None |
1 |
Additional Information is needed, no enough or clear information is provided in the sample form |
313.44 |
290.22 |
2010 |
170.00 |
None |
None |
| Rx0000296 |
MOLECULAR BIOLOGICALS INC |
09/30/2020 |
71474030310 |
KERAMATRIX WOUND DRESSING 10CMX10CM 10'S |
07/01/2020 |
22485.00 |
29980.00 |
None |
Single Source Drug |
100 |
None |
COMPETITIVE MARKET ANALYSIS |
None |
No change |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000296 |
MOLECULAR BIOLOGICALS INC |
09/30/2020 |
71474030350 |
KERAMATRIX WOUND DRESSING 10CMX10CM 5'S |
07/01/2020 |
11242.50 |
14990.00 |
None |
Single Source Drug |
100 |
None |
COMPETITIVE MARKET ANALYSIS |
None |
No change |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000296 |
MOLECULAR BIOLOGICALS INC |
09/30/2020 |
71474030301 |
KERAMATRIX WOUND DRESSING 10CMX10CM SINGLE |
07/01/2020 |
2248.50 |
2998.00 |
None |
Single Source Drug |
100 |
None |
COMPETITIVE MARKET ANALYSIS |
None |
No change |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000296 |
MOLECULAR BIOLOGICALS INC |
09/30/2020 |
71474030351 |
KERAMATRIX WOUND DRESSING 5CMX5CM 10'S |
07/01/2020 |
3970.10 |
7495.00 |
None |
Single Source Drug |
100 |
None |
COMPETITIVE MARKET ANALYSIS |
None |
No change |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000296 |
MOLECULAR BIOLOGICALS INC |
09/30/2020 |
71474030355 |
KERAMATRIX WOUND DRESSING 5CMX5CM 5'S |
07/01/2020 |
1985.05 |
3747.50 |
None |
Single Source Drug |
100 |
None |
COMPETITIVE MARKET ANALYSIS |
None |
No change |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000296 |
MOLECULAR BIOLOGICALS INC |
09/30/2020 |
71474030305 |
KERAMATRIX WOUND DRESSING 5CMX5CM SINGLE |
07/01/2020 |
397.01 |
749.50 |
None |
Single Source Drug |
100 |
None |
COMPETITIVE MARKET ANALYSIS |
None |
No change |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000044 |
Mylan Institutional Inc |
09/30/2020 |
67457022005 |
Isosulfan Blue 1% 50mg/5mL Liq 6s SUV |
07/21/2020 |
288.68 |
6062.23 |
12/15/2028 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1)NDC 67457-0220-00 is an innerpack of the NDC 67457-0220-05. As defined in the CA Code of Regulations Title 22, Divsion 7, Chapters 9.5 ("Regulations"), “Wholesale Acquisition Cost (“WAC”)” means a manufacturer’s published list price for a prescription drug product with a unique NDC. Because the innerpack is not commercially available for sale by Mylan, Mylan does not submit pricing to the pricing compendium and has no control on what the pricing compendium posts for these innerpack NDCs. Therefore, since there is no applicable WAC as defined in the Regulations for the innerpack NDC, Mylan is reporting only for the commercially available NDC 67457-0220-05. (2)FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. (3) Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V. |
| Rx0000044 |
Mylan Institutional Inc |
09/30/2020 |
67457025905 |
Isosulfan Blue N+ 1% 50mg/5mL Liq 6s SUV |
07/21/2020 |
288.68 |
6062.23 |
12/15/2028 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1) FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. (2) Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V. |
| Rx0000044 |
Mylan Institutional Inc |
09/30/2020 |
67457058605 |
Isosulfan Blue PRX 1% 50mg/5mL Liq 6s SUV |
07/21/2020 |
288.68 |
6062.23 |
12/15/2028 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1) NDC 67457-0586-00 is an innerpack of the NDC 67457-0586-05. As defined in the CA Code of Regulations Title 22, Divsion 7, Chapters 9.5 ("Regulations"), “Wholesale Acquisition Cost (“WAC”)” means a manufacturer’s published list price for a prescription drug product with a unique NDC. Because the innerpack is not commercially available for sale by Mylan, Mylan does not submit pricing to the pricing compendium and has no control on what the pricing compendium posts for these innerpack NDCs. Therefore, since there is no applicable WAC as defined in the Regulations for the innerpack NDC, Mylan is reporting only for the commercially available NDC 67457-0586-05. (2) FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. (3) Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V. |
| Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165002030 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 12.5 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165002530 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 15.7 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165003030 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 18.8 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165000530 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 3.1 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165001030 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 6.3 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
09/30/2020 |
70165001530 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 9.4 MG |
07/06/2020 |
36.00 |
396.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved.
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2020 |
70165020030 |
COTEMPLA XR-ODT 17.3MG 30 Tabs/Bottle |
01/01/2020 |
49.11 |
420.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
The price increase on Cotempla XR was taken to support factors impacting the business including increased manufacturing costs, increased cost from operations and increased distribution costs. |
None |
No Significant Change/Improvement to Drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug has not been acquired. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2020 |
70165030030 |
COTEMPLA XR-ODT 25.9MG 30 Tabs/Bottle |
01/01/2020 |
49.11 |
420.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
The price increase on Cotempla XR was taken to support factors impacting the business including increased manufacturing costs, increased cost from operations and increased distribution costs. |
None |
No Significant Change/Improvement to Drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug has not been acquired. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2020 |
70165010030 |
COTEMPLA XR-ODT 8.6MG, 30 Tabs/Bottle |
01/01/2020 |
49.11 |
420.00 |
06/28/2032 |
Single Source Drug |
None |
1 |
The price increase on Cotempla XR was taken to support factors impacting the business including increased manufacturing costs, increased cost from operations and increased distribution costs. |
None |
No Significant Change/Improvement to Drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug has not been acquired. |
| Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839015030 |
Tekturna 150mg aliskirin tablets 30 tablet bottle |
04/20/2020 |
16.62 |
224.42 |
02/19/2026 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other non-included milestone payments. Acquired the worldwide rights to tekturna/rasilez. |
150.19 |
133.66 |
2007 |
58.50 |
None |
None |
| Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839030030 |
Tekturna 300mg aliskirin tablets 30 tablet bottle |
04/20/2020 |
20.97 |
283.13 |
02/19/2026 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. Acquired the worldwide rights to tekturna/rasilez. |
189.48 |
172.41 |
2007 |
73.80 |
None |
None |
| Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839011230 |
Tekturna HCT oral tablet 150mg aliskirin/12.5mg hydrochlorthiazide 30 tablet bottle |
04/20/2020 |
16.62 |
224.42 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. Acquisition of worldwide rights to tekturna/rasilez. |
150.19 |
136.66 |
2008 |
62.01 |
None |
None |
| Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839012530 |
Tekturna HCT oral tablet 150mg aliskirin/25mg hydrochlorothiazide 30 tablet bottle |
04/20/2020 |
16.62 |
224.42 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. Acquisition of entire worldwide rights to tekturna/rasilez. |
150.19 |
136.66 |
2008 |
62.01 |
None |
None |
| Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839031230 |
Tekturna HCT oral tablet 300mg aliskirin/12.5mg hydrochlorothiazide 30 tablet bottle |
04/20/2020 |
20.97 |
283.13 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. acquisition of entire worldwide rights to tekturna/rasilez |
189.48 |
172.41 |
2008 |
78.23 |
None |
None |
| Rx0000204 |
Noden Pharma USA, Inc. |
06/30/2020 |
70839032530 |
Tekturna HCT oral tablet 300mg aliskirin/25mg hydrochlorothiazide 30 tablet bottle |
04/20/2020 |
20.97 |
283.13 |
07/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis AG |
199000000 |
None |
includes milestones, other milestones not included. Acquisition of entire worldwide rights to tekturna/rasilez |
189.48 |
172.41 |
2008 |
78.23 |
None |
None |
| Rx0000226 |
Nostrum Laboratories, Inc. |
06/30/2020 |
29033002602 |
Calcium Acetate Oral Capsule 667mg 200count |
06/25/2020 |
90.36 |
140.36 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The Product was not acquired. |
| Rx0000226 |
Nostrum Laboratories, Inc. |
03/31/2020 |
29033002901 |
Pindolol Oral Tablets, 10mg - 100ct |
01/06/2020 |
287.95 |
431.81 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We did not acquire this item. We developed it at Nostrum |
| Rx0000226 |
Nostrum Laboratories, Inc. |
03/31/2020 |
29033002801 |
Pindolol Oral Tablets, 5mg - 100ct |
01/06/2020 |
263.48 |
369.06 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We did not acquire this item. We developed it at Nostrum. |
| Rx0000226 |
Nostrum Laboratories, Inc. |
03/31/2020 |
70408014634 |
Promethazine HCL Oral Solution, 6.25mg/5mL - 473mL |
01/13/2020 |
159.56 |
170.55 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/11/2015 |
Sun Pharmaceuticals |
None |
1 |
None |
10.99 |
10.99 |
2009 |
10.99 |
None |
None |
| Rx0000073 |
Novartis |
03/31/2020 |
00065027510 |
Azopt 1% Drops 10mL, 10pk |
01/03/2020 |
16.96 |
325.34 |
None |
Single Source Drug |
95822 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00065027515 |
Azopt 1% Drops 15mL, 15pk |
01/03/2020 |
25.44 |
487.96 |
None |
Single Source Drug |
95822 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00065853302 |
CIPRODEX 0.3% / 0.1%, Drops, 7.5pk |
01/03/2020 |
12.99 |
249.09 |
06/04/2025 |
Single Source Drug |
2459065 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078063968 |
Cosentyx 150mg/ml (Sensoready Pen x1) |
01/03/2020 |
362.52 |
5541.43 |
05/05/2033 |
Single Source Drug |
123823 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078063941 |
Cosentyx 150mg/ml (Sensoready Pen x2) |
01/03/2020 |
362.52 |
5541.43 |
05/05/2033 |
Single Source Drug |
615929 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078063997 |
Cosentyx 150mg/ml (Syringe x1) |
01/03/2020 |
362.52 |
5541.43 |
05/05/2033 |
Single Source Drug |
25407 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078063998 |
Cosentyx 150mg/ml (Syringe x2) |
01/03/2020 |
362.52 |
5541.43 |
05/05/2033 |
Single Source Drug |
74145 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00065924007 |
DUREZOL 0.05% 5mL, Drops, 5pk |
01/03/2020 |
10.26 |
196.80 |
None |
Single Source Drug |
1019407 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078065967 |
Entresto 24/26mg - Tabs, 180 Each Bottle |
01/03/2020 |
106.92 |
1634.28 |
11/27/2027 |
Single Source Drug |
35604 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078065920 |
Entresto 24/26mg - Tabs, 60 Each Bottle |
01/03/2020 |
35.64 |
544.76 |
11/27/2027 |
Single Source Drug |
1360497 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078077767 |
Entresto 49/51mg - Tabs, 180 Each Bottle |
01/03/2020 |
106.92 |
1634.28 |
11/27/2027 |
Single Source Drug |
33446 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078077720 |
Entresto 49/51mg - Tabs, 60 Each Bottle |
01/03/2020 |
35.64 |
544.76 |
11/27/2027 |
Single Source Drug |
886774 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078069667 |
Entresto 97/103mg - Tabs, 180 Each Bottle |
01/03/2020 |
106.92 |
1634.28 |
11/27/2027 |
Single Source Drug |
30547 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078069620 |
Entresto 97/103mg - Tabs, 60 Each Bottle |
01/03/2020 |
35.64 |
544.76 |
11/27/2027 |
Single Source Drug |
627167 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078060715 |
Gilenya, Capsule 0.5mg - 30 each bottle |
01/03/2020 |
451.59 |
8662.23 |
09/30/2032 |
Single Source Drug |
318725 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00065175007 |
Ilevro 0.3%, Drops, 1.7ml per bottle |
01/03/2020 |
15.13 |
290.21 |
03/31/2032 |
Single Source Drug |
245494 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00065175014 |
Ilevro 0.3%, Drops, 3mL per bottle |
01/03/2020 |
15.13 |
290.21 |
03/31/2032 |
Single Source Drug |
169319 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078090961 |
Kisqali + Femara Co-Pack 200 mg, 49 tabs per bottle |
01/03/2020 |
276.16 |
5297.34 |
11/09/2031 |
Single Source Drug |
300 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078091661 |
Kisqali + Femara Co-Pack 400 mg, 70 tabs per bottle |
01/03/2020 |
552.33 |
10594.71 |
11/09/2031 |
Single Source Drug |
1176 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078092361 |
Kisqali + Femara Co-Pack 600 mg, 91 tabs per bottle |
01/03/2020 |
690.41 |
13243.38 |
11/09/2031 |
Single Source Drug |
4331 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078086001 |
Kisqali 200 mg, 21 Tabs per bottle |
01/03/2020 |
276.16 |
5297.34 |
11/09/2031 |
Single Source Drug |
4420 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078086742 |
Kisqali 400 mg, 42 Tabs per bottle |
01/03/2020 |
552.33 |
10594.71 |
11/09/2031 |
Single Source Drug |
4568 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078087463 |
Kisqali 600 mg, 63 Tabs per bottle |
01/03/2020 |
690.41 |
13243.38 |
11/09/2031 |
Single Source Drug |
14532 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078066615 |
Mekinist 0.5 mg 30 tabs per bottle |
01/03/2020 |
182.95 |
3509.28 |
01/28/2032 |
Single Source Drug |
20572 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00065427325 |
PAZEO 0.007 Drops, 2.5mL |
01/03/2020 |
10.71 |
205.42 |
05/19/2032 |
Single Source Drug |
1237067 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078068415 |
Promacta 12.5 mg, 30 tabs per bottle |
01/03/2020 |
344.85 |
5271.32 |
02/01/2028 |
Single Source Drug |
8885 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078068515 |
Promacta 25 mg, 30 tabs per bottle |
01/03/2020 |
344.85 |
5271.32 |
02/01/2028 |
Single Source Drug |
35420 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078068615 |
Promacta 50 mg, 30 tabs per bottle |
01/03/2020 |
624.07 |
9539.41 |
02/01/2028 |
Single Source Drug |
46343 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078068715 |
Promacta 75 mg, 30 tabs per bottle |
01/03/2020 |
936.11 |
14309.12 |
02/01/2028 |
Single Source Drug |
23048 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078069899 |
Rydapt 25 mg - 56 tabs per bottle |
01/03/2020 |
467.55 |
8968.38 |
12/02/2030 |
Single Source Drug |
7953 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078069819 |
Rydapt 25 mg, 112 tabs per bottle |
01/03/2020 |
935.09 |
17936.75 |
12/02/2030 |
Single Source Drug |
2769 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00065414727 |
SIMBRINZA 1% / 0.2%, Drops, 8mL per bottle |
01/03/2020 |
8.95 |
171.68 |
10/30/2030 |
Single Source Drug |
872007 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078068266 |
Tafinlar 50 mg, 120 tabs per bottle |
01/03/2020 |
445.01 |
8536.05 |
10/15/2030 |
Single Source Drug |
4352 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078059287 |
Tasigna 150mg, 28 capsule per bottle, 4 bottles |
01/03/2020 |
962.73 |
14716.02 |
10/15/2030 |
Single Source Drug |
21978 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078052687 |
Tasigna 200mg, 28 capsule per bottle, 4 bottles |
01/03/2020 |
962.73 |
14716.02 |
10/15/2030 |
Single Source Drug |
21978 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00065026025 |
TRAVATAN Z 0.00004, Drops, 2.5mL per bottle |
01/03/2020 |
10.11 |
193.98 |
10/13/2029 |
Innovator Multiple Source Drug |
2226281 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00065026005 |
TRAVATAN Z 0.00004, Drops, 5mL per bottle |
01/03/2020 |
20.22 |
387.94 |
10/13/2029 |
Innovator Multiple Source Drug |
456823 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078067119 |
Tykerb 250 mg, 150 tabs per bottle |
01/03/2020 |
435.48 |
8353.31 |
09/18/2029 |
Single Source Drug |
12617 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2020 |
00078067066 |
Votrient 200 mg 120 tabs per bottle |
01/03/2020 |
719.32 |
13797.84 |
10/19/2023 |
Single Source Drug |
33010 |
None |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968051408 |
Estradiol & Norethindrone Acetate 0.05-0.14 MG/DAY Patch Twice Weekly 8 EA UU |
01/01/2020 |
15.80 |
207.41 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/13/2014 |
Novartis |
None |
1 |
Not a matter of public record |
80.50 |
70.06 |
1998 |
23.75 |
None |
None |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968052508 |
Estradiol & Norethindrone Acetate 0.05-0.25 MG/DAY Patch Twice Weekly 8 EA UU |
01/01/2020 |
15.80 |
207.41 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/13/2014 |
Novartis |
None |
1 |
Not a matter of public record. |
80.40 |
69.97 |
1998 |
23.75 |
None |
None |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968662508 |
Estradiol 0.025 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968663708 |
Estradiol 0.0375 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968665008 |
Estradiol 0.05 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968667508 |
Estradiol 0.075 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968661008 |
Estradiol 0.1 MG/24HR Patch Twice Weekly 8 EA UU |
01/01/2020 |
14.96 |
196.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968555203 |
Methylphenidate 10 MG/9HR Patch 30 EA UU |
01/01/2020 |
30.20 |
396.32 |
10/07/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968555303 |
Methylphenidate 15 MG/9HR Patch 30 EA UU |
01/01/2020 |
30.20 |
396.32 |
10/07/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968555403 |
Methylphenidate 20 MG/9HR Patch 30 EA UU |
01/01/2020 |
30.20 |
396.32 |
10/07/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
| Rx0000017 |
Noven Therapeutics, LLC |
03/31/2020 |
68968555503 |
Methylphenidate 30 MG/9HR Patch 30 EA UU |
01/01/2020 |
30.20 |
396.32 |
10/07/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired |
| Rx0000033 |
Novo |
03/31/2020 |
00169413212 |
Ozempic (0.25 or 0.5 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML |
01/10/2020 |
38.62 |
811.05 |
06/21/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2020 |
00169413602 |
Ozempic (1 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML |
01/10/2020 |
38.62 |
811.05 |
06/21/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2020 |
00169406012 |
Victoza 6mg/mL 2x3mL Prefilled Pens |
01/10/2020 |
30.72 |
645.24 |
07/09/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2020 |
00169406013 |
Victoza 6mg/mL 3x3mL Prefilled Pens |
01/10/2020 |
46.08 |
967.86 |
07/09/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company. |
| Rx0000249 |
Octapharma USA, Inc. |
03/31/2020 |
68982085003 |
Octagam 10% 5Gm Vial 100Ml |
02/01/2020 |
185.00 |
1727.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
These products were not acquired. |
| Rx0000249 |
Octapharma USA, Inc. |
03/31/2020 |
68982085004 |
Octagam 10% Vial 10Gm 200Ml |
02/01/2020 |
369.98 |
3454.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
These products were not acquired. |
| Rx0000249 |
Octapharma USA, Inc. |
03/31/2020 |
68982085001 |
Octagam 10% Vial 20Ml 2Gm |
02/01/2020 |
37.00 |
345.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
These products were not acquired. |
| Rx0000249 |
Octapharma USA, Inc. |
03/31/2020 |
68982085002 |
Octagam 10% Vial 50Ml |
02/01/2020 |
92.50 |
863.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
These products were not acquired. |
| Rx0000249 |
Octapharma USA, Inc. |
03/31/2020 |
68982084003 |
Octagam 5% 5Gm Vial 100Ml |
02/01/2020 |
92.50 |
863.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
These products were not acquired. |
| Rx0000249 |
Octapharma USA, Inc. |
03/31/2020 |
68982084004 |
Octagam 5% Vial 10Gm 200Ml |
02/01/2020 |
185.00 |
1727.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
These products were not acquired. |
| Rx0000249 |
Octapharma USA, Inc. |
03/31/2020 |
68982084001 |
Octagam 5% Vial 20Ml |
02/01/2020 |
18.50 |
172.70 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
These products were not acquired. |
| Rx0000249 |
Octapharma USA, Inc. |
03/31/2020 |
68982084002 |
Octagam 5% Vial 50Ml |
02/01/2020 |
46.25 |
431.75 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
These products were not acquired. |
| Rx0000197 |
OPKO Pharmaceutucals, LLC |
12/31/2020 |
70301100101 |
Rayaldee 30mcg 30 count bottle |
12/28/2020 |
64.92 |
1146.92 |
03/14/2034 |
Single Source Drug |
None |
1 |
Increase in distribution costs, cost-of-goods, and third party costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired within the past five years. |
| Rx0000197 |
OPKO Pharmaceutucals, LLC |
12/31/2020 |
70301100102 |
Rayaldee 30mcg 60 count bottle |
12/28/2020 |
129.84 |
2293.84 |
03/14/2034 |
Single Source Drug |
None |
1 |
Increase in distribution costs, cost-of-goods, and third party costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired within the past five years. |
| Rx0000234 |
Optinose US, Inc. |
03/31/2020 |
71143037501 |
Fluticasone Propionate (Nasal) 93 MCG/ACT Exhaler Suspension, 1 Exhaler of 16 ML |
01/01/2020 |
24.04 |
514.63 |
07/07/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2020 |
59148002050 |
Samsca 15 mg tablets, blister pack of 10 |
02/10/2020 |
446.29 |
4954.26 |
09/01/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Samsca was developed by Otsuka. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2020 |
59148002150 |
Samsca 30 mg tablets, blister pack of 10 |
02/10/2020 |
462.97 |
5139.46 |
09/01/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Samsca was developed by Otsuka. |
| Rx0000101 |
Par Pharmaceutical |
09/30/2020 |
42023011925 |
Tigan®, Trimethobenzamide HCl Inj 100 MG/ML, 2 ML, Unit-Dose, Vial Qty 25 |
07/15/2020 |
95.40 |
1059.06 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 10/21/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the “Patent Expiration Date” field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
09/30/2020 |
42023011801 |
Tigan®, Trimethobenzamide HCl Inj 100 MG/ML, 20 ML, Vial |
07/15/2020 |
32.71 |
363.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 10/21/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the “Patent Expiration Date” field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2020 |
42023016425 |
Vasostrict®, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 1 mL x 25 VL |
02/14/2020 |
444.25 |
4939.00 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the “Patent Expiration Date” field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2020 |
42023019001 |
Vasostrict®, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 10 mL |
02/14/2020 |
177.70 |
1975.60 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the “Patent Expiration Date” field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224031060 |
Zohydro ER Oral Capsule 10 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
44.67 |
600.00 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
555.33 |
514.19 |
2014 |
368.40 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376031060 Effective date 03-11-2015 WAC 368.40
NDC 43376031060 Effective date 01-08-2016 WAC 404.87 |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224031560 |
Zohydro ER Oral Capsule 15 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
47.49 |
640.80 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
593.31 |
549.36 |
2014 |
393.60 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376031560 Effective Date 03-11-2015 WAC 393.60
NDC 43376031560 Effective Date 01-08-2016 WAC 432.57 |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224033060 |
Zohydro ER Oral Capsule 30 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
50.29 |
681.60 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, LLC |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
631.31 |
584.54 |
2014 |
418.40 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376033060 Effective Date 03-11-2015 WAC 418.80
NDC 43376033060 Effective Date 01-08-2016 WAC 460.26 |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224034060 |
Zohydro ER Oral Capsule 40 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
52.31 |
702.60 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, LLC |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
650.29 |
602.12 |
2014 |
431.40 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376034060 Effective Date 03-11-2015 WAC 431.40
NDC 43376034060 Effective Date 01-08-2016 WAC 474.11 |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224035060 |
Zohydro ER Oral Capsule 50 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
54.27 |
732.60 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, LLC |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
678.33 |
628.08 |
2014 |
450.00 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376035060 Effective Date 03-11-2015 WAC 450.00
NDC 43376035060 Effective Date 01-08-2016 WAC 494.55 |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121048900 |
DIPHENHYDRAMINE HCL ORAL SOLUTION USP 12.5 mg 5 mL 100 UDcups/case |
01/31/2020 |
26.90 |
298.53 |
None |
Non-innovator Multiple Source Drug |
2277 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121097800 |
DIPHENHYDRAMINE HCL ORAL SOLUTION USP 25 mg 10 mL 100 UDcups/case |
01/31/2020 |
28.23 |
313.29 |
None |
Non-innovator Multiple Source Drug |
2053 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121058105 |
HALOPERIDOL ORAL SOLUTION USP (CONCENTRATE), AF SF DF 10 mg 5 mL 100 UDcups/case |
01/31/2020 |
31.46 |
349.21 |
None |
Non-innovator Multiple Source Drug |
40332 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121481140 |
HYDROCODONE BITARTRATE & HOMATROPINE METHYLBROMIDE SYRUP CII 5 mg/1.5 mg 5 mL 40UDcups/case |
01/31/2020 |
27.49 |
305.15 |
None |
Non-innovator Multiple Source Drug |
3181 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121059500 |
SODIUM CITRATE and CITRIC ACID ORAL SOLUTION USP, AF SF DF 1500 mg/1002 mg 15 mL 100 UDcups/case |
01/31/2020 |
29.48 |
327.18 |
None |
Non-innovator Multiple Source Drug |
1591 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121119000 |
SODIUM CITRATE and CITRIC ACID ORAL SOLUTION USP, AF SF DF 3000 mg/2004 mg 30 mL 100 UDcups/case |
01/31/2020 |
31.99 |
355.04 |
None |
Non-innovator Multiple Source Drug |
2725 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2020 |
57962014012 |
IMBRUVICA (ibrutinib); 140mg capsule; 120 ct |
01/02/2020 |
1276.26 |
18522.99 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
AbbVie Inc. acquired Pharmacyclics in May 2015 for approximately $21 billion. In 2013 the 120 count bottle of 140mg IMBRUVICA capsules was introduced to market at a WAC of $10,933.33. At the time of the 2015 acquisition, the 120 capsule bottle had a WAC of $12,225.10. |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2020 |
57962014009 |
IMBRUVICA (ibrutinib); 140mg capsule; 90 ct |
01/02/2020 |
957.19 |
13892.24 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
AbbVie Inc. acquired Pharmacyclics in May 2015 for approximately $21 billion. In 2013 the 90 count bottle of 140mg IMBRUVICA capsules was introduced to market at a WAC of $8,200.00. At the time of the 2015 acquisition, the 90 capsule bottle had a WAC of $$9,168.83. |
| Rx0000225 |
PruGen, LLC |
03/31/2020 |
42546001660 |
BenzePro (benzoyl peroxide) 6% Foaming Cloths - 60 packets in 1 carton |
01/22/2020 |
32.74 |
500.47 |
None |
Single Source Drug |
13281 |
None |
Increase product, packaging and shipping costs from the contract manufacturer organization. |
None |
Increase in WAC product pricing due to increased overhead costs to supply the product to the virtual manufacturer. |
None |
08/01/2015 |
PruGen, LLC |
299 |
None |
None |
299.34 |
None |
2015 |
299.34 |
None |
No patent on this product |
| Rx0000225 |
PruGen, LLC |
03/31/2020 |
42546017516 |
SulfaCleanse 8/4 (sodium sulfacetamide & sulfur) suspension 8%-4% - 473ml |
01/20/2020 |
31.73 |
485.05 |
None |
Single Source Drug |
42751 |
None |
Increase product, packaging and shipping costs from the contract manufacturer organization. |
None |
Increase in WAC product pricing due to increased overhead costs to supply the product to the virtual manufacturer. |
None |
05/01/2011 |
PruGen, LLC |
100 |
None |
None |
99.72 |
None |
2011 |
99.72 |
None |
No Patent on this product |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
52856050203 |
Emflaza 18 mg tablet, 30 |
01/01/2020 |
414.21 |
4965.92 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
3925.00 |
None |
2017 |
3925.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
52856050303 |
Emflaza 30 mg tablet, 30 |
01/01/2020 |
690.38 |
8276.96 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
6542.00 |
None |
2017 |
6542.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
52856050403 |
Emflaza 36 mg tablet, 30 |
01/01/2020 |
769.32 |
9223.33 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
7290.00 |
None |
2017 |
7290.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
42998050101 |
Emflaza 6 mg tablet, 100 |
01/01/2020 |
460.22 |
5517.55 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
4361.00 |
None |
2017 |
4361.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
52856050522 |
Emflaza Oral suspension 22.75 mg/mL, 13ml |
01/01/2020 |
303.19 |
3634.93 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
2873.00 |
None |
2017 |
2873.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050203 |
Emflaza/ 18mg tabs/ 30 ct |
08/17/2020 |
451.90 |
5417.82 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
3925.00 |
0.00 |
2017 |
3925.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050522 |
Emflaza/ 22.75mg/mL susp/ 13ml in 30 ml bottle |
08/17/2020 |
330.78 |
3965.71 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
2873.00 |
0.00 |
2017 |
2873.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050303 |
Emflaza/ 30mg tabs/ 30 ct |
08/17/2020 |
753.20 |
9030.16 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
6542.00 |
0.00 |
2017 |
6542.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050403 |
Emflaza/ 36mg tabs/ 30 ct |
08/17/2020 |
839.32 |
10062.65 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
7290.00 |
0.00 |
2017 |
7290.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050101 |
Emflaza/ 6mg tabs/ 100 ct |
08/17/2020 |
502.10 |
6019.65 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
4361.00 |
0.00 |
2017 |
4361.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000220 |
Puma Biotechnology, Inc. |
03/31/2020 |
70437024018 |
Nerlynx 40mg 180 tablets |
03/01/2020 |
1368.00 |
15191.00 |
12/31/2025 |
Single Source Drug |
17400 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Nerlynx was developed by Puma Biotechnology. |
| Rx0000220 |
Puma Biotechnology, Inc. |
09/30/2020 |
70437024018 |
Nerlynx 40mg 180 tablets |
07/31/2020 |
1504.00 |
16695.00 |
None |
Single Source Drug |
17400 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Nerlynx was developed by Puma |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075104 |
BUTRANS 10MCG/HOUR TDS 4S |
01/01/2020 |
22.05 |
462.98 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075804 |
BUTRANS 15 MCG/HOUR TDS 4S |
01/01/2020 |
31.80 |
667.84 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075204 |
BUTRANS 20MCG/HOUR TDS 4S |
01/01/2020 |
39.03 |
819.63 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075004 |
BUTRANS 5 MCG/HOUR TDS 4S |
01/01/2020 |
14.70 |
308.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075704 |
BUTRANS 7.5 MCG/HOUR TDS 4S |
01/01/2020 |
20.58 |
432.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027660 |
HYSINGLA ER 100MG TABLETS 60S |
01/01/2020 |
132.37 |
2779.67 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027760 |
HYSINGLA ER 120MG TABLETS 60S |
01/01/2020 |
146.68 |
3080.37 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027160 |
HYSINGLA ER 20MG TABLETS 60S |
01/01/2020 |
28.34 |
595.07 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027260 |
HYSINGLA ER 30MG TABLETS 60S |
01/01/2020 |
41.36 |
868.59 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027360 |
HYSINGLA ER 40MG TABLETS 60S |
01/01/2020 |
55.72 |
1170.19 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027460 |
HYSINGLA ER 60MG TABLETS 60S |
01/01/2020 |
77.16 |
1620.34 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027560 |
HYSINGLA ER 80MG TABLETS 60S |
01/01/2020 |
104.03 |
2184.61 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011041010 |
OXYCONTIN 10MG TABLETS 100S |
01/01/2020 |
20.12 |
422.58 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011041020 |
OXYCONTIN 10MG TABLETS HUD 20S |
01/01/2020 |
4.13 |
86.77 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011041510 |
OXYCONTIN 15MG TABLETS 100S |
01/01/2020 |
29.62 |
622.11 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011041520 |
OXYCONTIN 15MG TABLETS HUD 20S |
01/01/2020 |
6.08 |
127.64 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011042010 |
OXYCONTIN 20MG TABLETS 100S |
01/01/2020 |
37.53 |
788.10 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011042020 |
OXYCONTIN 20MG TABLETS HUD 20S |
01/01/2020 |
7.70 |
161.66 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011043010 |
OXYCONTIN 30MG TABLETS 100S |
01/01/2020 |
52.19 |
1096.05 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011043020 |
OXYCONTIN 30MG TABLETS HUD 20S |
01/01/2020 |
10.71 |
224.88 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011044010 |
OXYCONTIN 40MG TABLETS 100S |
01/01/2020 |
64.27 |
1349.70 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011044020 |
OXYCONTIN 40MG TABLETS HUD 20S |
01/01/2020 |
13.18 |
276.75 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011046010 |
OXYCONTIN 60MG TABLETS 100S |
01/01/2020 |
91.00 |
1910.96 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011046020 |
OXYCONTIN 60MG TABLETS HUD 20S |
01/01/2020 |
18.67 |
392.05 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011048010 |
OXYCONTIN 80MG TABLETS 100S |
01/01/2020 |
112.15 |
2355.18 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011048020 |
OXYCONTIN 80MG TABLETS HUD 20S |
01/01/2020 |
23.01 |
483.13 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000166 |
Redhill Biopharma, Inc. |
03/31/2020 |
71068000110 |
AEMCOLO (rifamycin sodium), 194 mg delayed released Oral Tablet, 12 Oral Tablets per 1 Box, package size is 1 box |
01/01/2020 |
14.24 |
171.24 |
05/03/2025 |
Single Source Drug |
21 |
None |
Started discount process with Pharmacy Distributors, Payers, and For Government Programs |
None |
No Change Improvements |
None |
10/18/2019 |
Cosmo Technologies |
None |
None |
RedHill did not purchase the product from Cosmo, but instead Cosmo purchased 1,714,286 ADS at an agreed value of $12 million as an upfront payment, plus the ADS as part of the 36.3 million investment into RedHill.
Please see Supporting Docs for full Press Release details. |
157.00 |
None |
2018 |
144.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=345 |
None |
| Rx0000166 |
Redhill Biopharma, Inc. |
03/31/2020 |
71068000111 |
AEMCOLO (rifamycin sodium), 194 mg delayed released tablet, 36 Oral Tablets per 1 Box, package size is 1 box |
01/01/2020 |
42.72 |
513.72 |
05/03/2025 |
Single Source Drug |
1 |
None |
Started discount process with Pharmacy Distributors, Payers, and For Government Programs |
None |
No Change Improvements |
None |
10/18/2019 |
Cosmo Technologies |
None |
None |
RedHill did not purchase the product from Cosmo, but instead Cosmo purchased 1,714,286 ADS at an agreed value of $12 million as an upfront payment, plus the ADS as part of the 36.3 million investment into RedHill.
Please see Supporting Docs for full Press Release details. |
471.00 |
None |
2018 |
432.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=346 |
For US Volume, there have been no sales within the US for this product, however the for will not allow a 0, so we are submitting this with a 1. |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
03/31/2020 |
71332000101 |
Tavalisse 100mg tablet, 1 bottle of 60 tablets |
02/15/2020 |
484.00 |
11246.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(Columns 14 - 22) TAVALISSE was developed by Rigel Pharmaceuticals; the drug was not acquired from a third party.
The information reported is limited to that which is in the public domain or otherwise publicly available. To help clarify blank responses, we have marked the non-public indicator fields, where relevant. |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
09/30/2020 |
71332000101 |
Tavalisse 100mg tablet, 1 bottle of 60 tablets |
07/07/2020 |
564.00 |
11810.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(Columns 14 - 22) TAVALISSE was developed by Rigel Pharmaceuticals; the drug was not acquired from a third party.
The information reported is limited to that which is in the public domain or otherwise publicly available. To help clarify blank responses, we have marked the non-public indicator fields, where relevant. |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
03/31/2020 |
71332000201 |
Tavalisse 150mg tablet, 1 bottle of 60 tablets |
02/15/2020 |
484.00 |
11246.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(Columns 14 - 22) TAVALISSE was developed by Rigel Pharmaceuticals; the drug was not acquired from a third party.
The information reported is limited to that which is in the public domain or otherwise publicly available. To help clarify blank responses, we have marked the non-public indicator fields, where relevant. |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
09/30/2020 |
71332000201 |
Tavalisse 150mg tablet, 1 bottle of 60 tablets |
07/07/2020 |
564.00 |
11810.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(Columns 14 - 22) TAVALISSE was developed by Rigel Pharmaceuticals; the drug was not acquired from a third party.
The information reported is limited to that which is in the public domain or otherwise publicly available. To help clarify blank responses, we have marked the non-public indicator fields, where relevant. |
| Rx0000158 |
RISING PHARMA HOLDINGS, INC. |
03/31/2020 |
64980013301 |
Dipyridamole Oral Tablet 25 MG 100 |
01/23/2020 |
78.71 |
118.41 |
None |
Non-innovator Multiple Source Drug |
21648 |
None |
Change in market conditions |
None |
Change in Market Dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000158 |
RISING PHARMA HOLDINGS, INC. |
03/31/2020 |
64980013401 |
Dipyridamole Oral Tablet 50 MG 100 |
01/23/2020 |
126.76 |
190.70 |
None |
Non-innovator Multiple Source Drug |
34464 |
None |
Change in market conditions |
None |
Change in Market Dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000158 |
RISING PHARMA HOLDINGS, INC. |
03/31/2020 |
64980013501 |
Dipyridamole Oral Tablet 75 MG 100 |
01/23/2020 |
169.62 |
255.18 |
None |
Non-innovator Multiple Source Drug |
29280 |
None |
Change in market conditions |
None |
Change in Market Dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000158 |
RISING PHARMA HOLDINGS, INC. |
03/31/2020 |
57237000114 |
Lansoprazole Delayed-Release Capsules USP, 30 mg Amoxicillin Capsules USP, 500 mg Clarithromycin Tablets USP, 500 mg 112 |
01/23/2020 |
437.49 |
887.49 |
None |
Non-innovator Multiple Source Drug |
25000 |
None |
Change in Market Dynamics |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Change in Market Dynamics. No 5 Yr History. Rising Pharmaceuticals the ANDA drug. |
| Rx0000321 |
R-Pharm US, LLC |
12/31/2020 |
70020191001 |
1 KIT in 1 PACKAGE, COMBINATION * 15 mg in 1 VIAL, SINGLE-USE * 8 mL in 1 VIAL, SINGLE-USE |
10/05/2020 |
143.00 |
1625.00 |
03/01/2022 |
Single Source Drug |
5338 |
None |
Increases in raw materials and manufacturing cost (since this is manufactured by third party. Additionally, we had increase cost from our 3PL for providing services. |
None |
None |
1 |
01/01/2016 |
BMS |
None |
1 |
None |
1080.62 |
1080.62 |
2007 |
900.00 |
None |
Sales have decreased by ~40% from acquisition to present. |
| Rx0000321 |
R-Pharm US, LLC |
12/31/2020 |
70020191101 |
1 KIT in 1 PACKAGE, COMBINATION * 45mg in 3 VIAL, SINGLE-USE * 8 mL in 1 VIAL, SINGLE-USE |
10/05/2020 |
429.00 |
4875.00 |
03/01/2022 |
Single Source Drug |
2762 |
None |
Increases in raw materials and manufacturing cost (since this is manufactured by third party. Additionally, we had increase cost from our 3PL for providing services. |
None |
None |
1 |
01/01/2016 |
BMS |
None |
1 |
None |
3241.86 |
3241.86 |
2007 |
2700.00 |
None |
Sales have decreased by ~40% from acquisition to present. |
| Rx0000322 |
SA3, LLC |
12/31/2020 |
69420307701 |
Lidocaine/Tetracaine 7%/7% Cream (30g) |
10/23/2020 |
636.67 |
1075.00 |
01/14/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=465 |
Authorized Generic |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649040130 |
ANUSOl-HC? (Hydrocortisone Cream, USP) 2.5%, 30gm |
01/09/2020 |
8.00 |
141.31 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649041112 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 12 |
01/09/2020 |
35.61 |
629.18 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649041124 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 24 |
01/09/2020 |
71.23 |
1258.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649024141 |
AZASAN? (Azathioprine Tablets, USP) 100mg, 100ct |
01/09/2020 |
44.85 |
792.43 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649023141 |
AZASAN? (Azathioprine Tablets, USP) 75mg, 100ct |
01/09/2020 |
100.61 |
1777.46 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649020175 |
MOVIPREP? (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate & Ascorbic Acid for Oral Solution), 1 Kit |
01/09/2020 |
6.34 |
112.03 |
09/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649070141 |
OSMOPREP? (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) 1500mg Tablets, 100ct |
01/09/2020 |
41.22 |
728.15 |
06/22/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649065103 |
UCERIS? (budesonide) Rectal Aerosol, Foam, two 54 ml Canisters, 2 mg/actuation |
01/09/2020 |
37.65 |
665.18 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649030103 |
XIFAXAN? (rifaximin) 200mg Tablets, 30ct |
01/09/2020 |
49.08 |
670.36 |
07/24/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649030303 |
XIFAXAN? (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card |
01/09/2020 |
187.11 |
2555.59 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649030302 |
XIFAXAN? (rifaximin) 550mg Tablets, 60ct |
01/09/2020 |
187.11 |
2555.59 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000011 |
Sanofi |
03/31/2020 |
49281025051 |
IMOVAX single carton containing 1 single-dose Vial With 1 Single-dose Prefilled Syringe of diluent with the potency of one dose (1.0 mL) of Imovax Rabies vaccine is equal to or greater than 2.5 international units of rabies antigen. |
01/01/2020 |
17.82 |
374.17 |
None |
Innovator Multiple Source Drug |
None |
1 |
In 2017, Sanofi announced our progressive and industry-leading pricing principles to help stakeholders understand our pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. These principles include a pledge to keep annual list price increases at or below the projected U.S. National Health Expenditure (NHE) growth rate, an estimate of medical spending calculated by the Centers for Medicare and Medicaid Services (CMS) and often used as a measure of healthcare inflation. These principles apply to all of our prescription medicines if a pricing decision results in more than a $15 annual increase in the price of the medication. In addition, we committed to making both our average aggregate list and net price changes across our portfolio transparent to help illustrate how revenue accrues to Sanofi versus other parts of the pharmaceutical supply chain.
In determining our list price increases, we balance the rising demands by payors/intermediaries, and the increased costs of manufacturing and distribution of our products with the need to fund our pipeline while also working to limit the out of pocket burden on patients. Across our entire portfolio of medicines, the average aggregate list price increase was 2.9 percent while the average aggregate net price – that is, the actual price paid to Sanofi – declined by 11.1 percent.
Sanofi fully understands the affordability of our products is critical to patients. We are committed to helping patients get the treatment that they are prescribed by their healthcare professional.
We do not attribute a specific portion of the total list price increase to any one factor. Sanofi is committed to helping ensure patients can afford the treatments they are prescribed by their healthcare professional. |
None |
See response for cost increase factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank because the drug was not acquired within the previous 5 years |
| Rx0000092 |
Santarus, Inc. |
03/31/2020 |
68012025820 |
CYCLOSET (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct |
01/09/2020 |
50.32 |
889.06 |
04/30/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2020 |
70504012602 |
VARIZIG, single dose vial, 125IU, 1.2mL vial |
03/01/2020 |
162.52 |
1804.14 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc |
65000000 |
None |
65,000,000 upfront cost. 74,500,000 total value. Multiple products/ NDCs were part of the total acquisition. Varizig was one of the products acquired. |
1306.34 |
1256.10 |
2012 |
682.50 |
None |
Varizig was introduced to the market in 2012 as a lyophilized powder. The current formulation is liquid.
Products were acquired in September 2017. Scaling the manufacturing process to meet product demand was a costly process that contributed to the price increase. Other costly factors that contributed to the increase were: scaling supply chain capabilities to meet additional product overhead: shipping, stocking and distribution. Financial costs and debt incurred with acquiring the products and contract rights were also contributing factors.
Patent Exp. Date: N/A (Biologic drug status) |
| Rx0000086 |
Seattle Genetics, Inc. |
03/31/2020 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
01/01/2020 |
310.00 |
8270.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1) Seattle Genetics does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seattle Genetics limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seattle Genetics to insert only a year for this data field. As a result, Seattle Genetics has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seattle Genetics' patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seattle Genetics did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-U blank because they are not applicable to this product. |
| Rx0000086 |
Seattle Genetics, Inc. |
09/30/2020 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
07/01/2020 |
322.00 |
8592.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-S blank because they are not applicable to this product. |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2020 |
71779011502 |
Copiktra 15 mg oral capsule, 56 capsules per package |
12/04/2020 |
1226.61 |
13616.61 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2020 |
71779012502 |
Copiktra 25 mg oral capsule, 56 capsules per package |
12/04/2020 |
1226.61 |
13616.61 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2020 |
00078065006 |
Farydak 10 mg capsule 6x blister pack |
03/23/2020 |
927.20 |
10687.18 |
09/30/2026 |
Single Source Drug |
None |
1 |
Secura Bio is required to spend millions of dollars on FDA and other agency required clinical trials and studies which results in the company losing money at the current price and sales volumes of Farydak. |
None |
No changes have been made to the product. |
None |
03/01/2019 |
Novartis |
None |
1 |
Disclosure of the acquisition price of Farydak from Novartis is restricted by non-disclosure provisions in the related legal agreements. |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
While Secura Bio, Inc. has been issued the labeler code 73116, Farydak product with this labeler code has not yet been introduced in the U.S. market. Current product being distributed in the U.S. market was produced by Novartis and accordingly is identified with Novartis' 00078 labeler code.
The Farydak product being supplied to the U.S. market currently is and will be produced by Novartis for the next couple of years under a supply agreement. We expect existing inventories with the Novartis labeler code to be sold for most of 2020. |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2020 |
00078065106 |
Farydak 15 mg capsule 6x blister pack |
03/23/2020 |
927.20 |
10687.18 |
09/30/2026 |
Single Source Drug |
None |
1 |
Secura Bio is required to spend millions of dollars on FDA and other agency required clinical trials and studies which results in the company losing money at the current price and sales volumes of Farydak. |
None |
No changes have been made to the product. |
None |
03/01/2019 |
Novartis |
None |
1 |
Disclosure of the acquisition price of Farydak from Novartis is restricted by non-disclosure provisions in the related legal agreements. |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
While Secura Bio, Inc. has been issued the labeler code 73116, Farydak product with this labeler code has not yet been introduced in the U.S. market. Current product being distributed in the U.S. market was produced by Novartis and accordingly is identified with Novartis' 00078 labeler code.
The Farydak product being supplied to the U.S. market currently is and will be produced by Novartis for the next couple of years under a supply agreement. We expect existing inventories with the Novartis labeler code to be sold for most of 2020. |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2020 |
00078065206 |
Farydak 20 mg capsule 6x blister pack |
03/23/2020 |
927.20 |
10687.18 |
09/30/2026 |
Single Source Drug |
None |
1 |
Secura Bio is required to spend millions of dollars on FDA and other agency required clinical trials and studies which results in the company losing money at the current price and sales volumes of Farydak. |
None |
No changes have been made to the product. |
None |
03/01/2019 |
Novartis |
None |
1 |
Disclosure of the acquisition price of Farydak from Novartis is restricted by non-disclosure provisions in the related legal agreements. |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
While Secura Bio, Inc. has been issued the labeler code 73116, Farydak product with this labeler code has not yet been introduced in the U.S. market. Current product being distributed in the U.S. market was produced by Novartis and accordingly is identified with Novartis' 00078 labeler code.
The Farydak product being supplied to the U.S. market currently is and will be produced by Novartis for the next couple of years under a supply agreement. We expect existing inventories with the Novartis labeler code to be sold for most of 2020. |
| Rx0000028 |
Servier Pharmaceuticals LLC |
03/31/2020 |
72694095401 |
Oncaspar 750 IU/mL injection, 5 mL single use vial |
01/02/2020 |
1590.52 |
18601.38 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/31/2018 |
Shire |
None |
1 |
None |
14544.54 |
14544.54 |
1994 |
1.00 |
None |
Note, the value of "$1.00" is a placeholder, because the system would not allow an empty field. The placeholder was necessary because the WAC at introduction is unknown to Servier.
Servier acquired Shire's oncology business on August 31, 2018 and the BLA for Oncaspar (NDC 00944381001) was transferred to Servier in August 2019.
At the time of Servier's 60-day notice of price increase, Servier was selling product labeled with the 00944381001 NDC (the NDC/label used by Shire). The vials with this NDC are now sold out and the Shire NDC should be made obsolete. Since the 60-day notice of price increase, Servier obtained its own NDC (72694095401) for Oncaspar and began selling Servier labeled Oncaspar on 4/1/2020. |
| Rx0000028 |
Servier Pharmaceuticals LLC |
03/31/2020 |
00944381001 |
Oncaspar 750 IU/mL injection, 5 mL single-use vial |
01/02/2020 |
1590.52 |
18601.38 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/31/2018 |
Shire |
None |
1 |
None |
14544.54 |
14544.54 |
1994 |
1.00 |
None |
Note, the value of "$1.00" is a placeholder, because the system would not allow an empty field. The placeholder was necessary because the WAC at introduction is unknown to Servier.
Servier acquired Shire's oncology business on August 31, 2018 and the BLA for Oncaspar (NDC 00944381001) was transferred to Servier in August 2019. |
| Rx0000004 |
Shionogi Inc. |
03/31/2020 |
59630058090 |
Osphena (ospemifene) 60MG Tablets |
01/01/2020 |
32.40 |
680.40 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Osphena was developed by Shionogi. The pricing at launch was $474.00 |
| Rx0000175 |
Sobi Inc |
03/31/2020 |
66658011203 |
Kepivance-lyophilized powder containing 6.25 mg of Palifermin. - 3-pack |
01/01/2020 |
414.66 |
8093.62 |
04/11/2023 |
Single Source Drug |
176 |
None |
acquiring/producing/shipping goods. |
None |
acquiring/producing/shipping goods. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
we did not acquire this drug within the last five years |
| Rx0000175 |
Sobi Inc |
03/31/2020 |
66658011206 |
Kepivance-lyophilized powder containing 6.25 mg of Palifermin. - 6-pack |
01/01/2020 |
829.33 |
16187.26 |
04/11/2023 |
Single Source Drug |
441 |
None |
acquiring/producing/shipping goods. |
None |
acquiring/producing/shipping goods. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
we did not acquire this drug within the last five years |
| Rx0000175 |
Sobi Inc |
03/31/2020 |
66658023407 |
Kineret- Single-use 100 mg prefilled syringe -7-pack |
01/01/2020 |
55.59 |
1085.06 |
07/29/2020 |
Single Source Drug |
6461 |
None |
acquiring/producing/shipping goods. |
None |
acquiring/producing/shipping goods. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
we did not acquire this drug within the last five years |
| Rx0000244 |
Sprout Pharmaceuticals, Inc. |
03/31/2020 |
58604021430 |
Addyi 100 mg tablets 30-count bottle |
01/01/2020 |
37.50 |
437.50 |
05/09/2023 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000221 |
Strides Pharma, Inc. |
09/30/2020 |
64380072006 |
Tacrolimus Capsules 0.5mg, 100 |
09/14/2020 |
18.68 |
55.56 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement have been made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
#6:No patent expiration date listed; #8 and #10 are left blank because these are confidential, trade secret information of Strides Pharma Inc. ("Strides") that would cause competitive harm to Strides if publicly disclosed because: (1) Strides uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Strides' ability to negotiate terms of such contracts; (2) Strides competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Strides production cost, other product costs, and profit margin, it will prejudice Strides' ability to competitively price its products. For these reasons, Strides requests protection of the information of this submission from public disclosure; #14-22: This product was developed by Strides and therefore the acquisition sections are left blank |
| Rx0000221 |
Strides Pharma, Inc. |
09/30/2020 |
64380072206 |
Tacrolimus Capsules 5mg, 100 |
09/14/2020 |
201.40 |
555.55 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement have been made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
#6:No patent expiration date listed; #8 and #10 are left blank because these are confidential, trade secret information of Strides Pharma Inc. ("Strides") that would cause competitive harm to Strides if publicly disclosed because: (1) Strides uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Strides' ability to negotiate terms of such contracts; (2) Strides competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Strides production cost, other product costs, and profit margin, it will prejudice Strides' ability to competitively price its products. For these reasons, Strides requests protection of the information of this submission from public disclosure; #14-22: This product was developed by Strides and therefore the acquisition sections are left blank |
| Rx0000149 |
Strongbridge Biopharma plc |
03/31/2020 |
71090000101 |
Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100 |
01/06/2020 |
1706.57 |
20668.38 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/12/2016 |
Taro Pharmaceuticals Industries |
8500000 |
None |
None |
13650.00 |
13650.00 |
2015 |
13650.00 |
None |
None |
| Rx0000001 |
SUN PHARMACEUTICALS |
03/31/2020 |
47335030383 |
Odomzo Oral Capsule 200 MG/ Pkg 30 |
03/01/2020 |
565.17 |
11868.59 |
09/15/2029 |
Single Source Drug |
None |
1 |
The increase to the WAC is intended to offset the cost of higher discounts and rebates offered to higher volume customers |
None |
No change or improvement have been made |
None |
01/27/2017 |
Novartis Pharmaceutical |
None |
1 |
Confidential: Odomzo was purchased from Novartis for $175M. |
10060.00 |
10060.00 |
2017 |
10060.00 |
None |
This report includes confidential, trade secret information of Sun Pharmaceutical Industries, Inc. (Sun) that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable. |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772012101 |
Oxtellar XR, 150mg Capsule, 100CT |
01/01/2020 |
52.98 |
715.19 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772012201 |
Oxtellar XR, 300mg Capsule, 100CT |
01/01/2020 |
73.60 |
993.59 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772012301 |
Oxtellar XR, 600mg Capsule, 100CT |
01/01/2020 |
134.75 |
1819.17 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010301 |
Trokendi XR, 100mg Capsule, 100CT |
01/01/2020 |
197.37 |
2664.55 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010330 |
Trokendi XR, 100mg Capsule, 30 CT |
01/01/2020 |
59.21 |
799.36 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010315 |
Trokendi XR, 100mg Capsule, 30 CT Blister Pack |
01/01/2020 |
59.21 |
799.36 |
04/04/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010401 |
Trokendi XR, 200mg Capsule, 100CT |
01/01/2020 |
269.99 |
3644.91 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010430 |
Trokendi XR, 200mg Capsule, 30 CT |
01/01/2020 |
81.00 |
1093.48 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010415 |
Trokendi XR, 200mg Capsule, 30 CT Blister Pack |
01/01/2020 |
81.00 |
1093.48 |
04/04/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010101 |
Trokendi XR, 25mg Capsule, 100 CT |
01/01/2020 |
76.48 |
1032.43 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010130 |
Trokendi XR, 25mg Capsule, 30 CT |
01/01/2020 |
22.94 |
309.73 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010115 |
Trokendi XR, 25mg Capsule, 30 CT Blister Pack |
01/01/2020 |
22.94 |
309.73 |
04/04/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010201 |
Trokendi XR, 50mg Capsule, 100CT |
01/01/2020 |
99.62 |
1344.85 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010230 |
Trokendi XR, 50mg Capsule, 30 CT |
01/01/2020 |
29.88 |
403.44 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010215 |
Trokendi XR, 50mg Capsule, 30 CT Blister Pack |
01/01/2020 |
29.88 |
403.44 |
04/04/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
12/31/2020 |
27505011130 |
Xadago, 100 mg, 30 CT |
10/01/2020 |
65.45 |
904.56 |
12/10/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
None |
839.11 |
780.57 |
2017 |
730.19 |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
12/31/2020 |
27505011030 |
Xadago, 50mg, 30 CT |
10/01/2020 |
65.45 |
904.56 |
12/10/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
None |
839.11 |
780.57 |
2017 |
730.19 |
None |
None |
| Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2020 |
64764030020 |
Entyvio 300mg 20mL Vial |
01/03/2020 |
258.75 |
6727.65 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
12/31/2020 |
64764030020 |
Entyvio 300mg 20mL Vial |
10/19/2020 |
269.11 |
6996.76 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2020 |
64764073030 |
Trintellix 10mg 30ct Tablet |
01/03/2020 |
19.18 |
402.85 |
03/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2020 |
64764075030 |
Trintellix 20mg 30ct Tablet |
01/03/2020 |
19.18 |
402.85 |
03/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2020 |
64764072030 |
Trintellix 5mg 30ct Tablet |
01/03/2020 |
19.18 |
402.85 |
03/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000232 |
TerSera Therapeutics LLC |
06/30/2020 |
70720072010 |
Prialt Intrathecal Solution 100 MCG/ML, 1ML Vial, Qty 1 |
06/29/2020 |
53.95 |
883.95 |
10/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
None |
744.98 |
716.05 |
2004 |
608.33 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. Note: per MediSpan there may be only one price increase listed for this Prialt product - note that our Five-Year History includes price increase information prior to TerSera's acquisition of Prialt, at which time TerSera acquired new NDC numbers for the Prialt line of products. |
| Rx0000232 |
TerSera Therapeutics LLC |
06/30/2020 |
70720072210 |
Prialt Intrathecal Solution 100 MCG/ML, 5ML Vial, Qty 1 |
06/29/2020 |
207.50 |
4357.50 |
10/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
None |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. Note: per MediSpan there may be only one price increase listed for this Prialt product - note that our Five-Year History includes price increase information prior to TerSera's acquisition of Prialt, at which time TerSera acquired new NDC numbers for the Prialt line of products. |
| Rx0000232 |
TerSera Therapeutics LLC |
06/30/2020 |
70720072310 |
Prialt Intrathecal Solution 25 MCG/ML, 20ML Vial, Qty 1 |
06/29/2020 |
207.50 |
4357.50 |
10/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
None |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 10/09/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. Note: per MediSpan there may be only one price increase listed for this Prialt product - note that our Five-Year History includes price increase information prior to TerSera's acquisition of Prialt, at which time TerSera acquired new NDC numbers for the Prialt line of products. |
| Rx0000232 |
TerSera Therapeutics LLC |
12/31/2020 |
70183012584 |
XERMELO (telostristat ethyl), Oral Tablet, 250mg, 1 Case/84 Tablets |
11/09/2020 |
649.34 |
7208.34 |
02/27/2031 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
No Change |
None |
09/08/2020 |
Lexicon Pharmaceuticals, Inc. |
160000000 |
None |
Lexicon received approximately $160M in upfront payments and up to $65 million in future milestone payments plus mid-teens royalties on net sales of XERMELO for the treatment of biliary tract cancer. |
6559.00 |
5961.00 |
2017 |
5164.00 |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2020 |
68546017260 |
AUSTEDO TABLETS 12MG 60 |
01/01/2020 |
323.30 |
5802.20 |
03/27/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Launched NDC’s subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.” |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2020 |
68546017060 |
AUSTEDO TABLETS 6MG 60 |
01/01/2020 |
215.50 |
3868.10 |
03/27/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Launched NDC’s subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.” |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2020 |
68546017160 |
AUSTEDO TABLETS 9MG 60 |
01/01/2020 |
242.40 |
4351.60 |
03/27/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Launched NDC’s subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.” |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2020 |
68546014256 |
AZILECT TABLETS 0.5MG 30 |
01/01/2020 |
50.10 |
832.60 |
08/27/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2020 |
68546022956 |
AZILECT TABLETS 1MG 30 |
01/01/2020 |
50.10 |
832.60 |
08/27/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459051230 |
ACTIQ BKU 1200MCG 1CTNX30 US |
01/01/2020 |
314.40 |
5227.40 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459051630 |
ACTIQ BKU 1600MCG 1CTNX30 US |
01/01/2020 |
387.90 |
6448.70 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459050230 |
ACTIQ BKU 200MCG 1CTNX30 US |
01/01/2020 |
131.80 |
2190.40 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459050430 |
ACTIQ BKU 400MCG 1CTNX30 US |
01/01/2020 |
166.80 |
2772.30 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459050630 |
ACTIQ BKU 600MCG 1CTNX30 US |
01/01/2020 |
204.40 |
3397.60 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459050830 |
ACTIQ BKU 800MCG 1CTNX30 US |
01/01/2020 |
241.90 |
4021.60 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
57844011001 |
ADDERALL(R) TABLETS 10MG 100 |
01/01/2020 |
45.00 |
748.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
57844011201 |
ADDERALL(R) TABLETS 12.5MG 100 |
01/01/2020 |
45.00 |
748.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
57844011501 |
ADDERALL(R) TABLETS 15MG 100 |
01/01/2020 |
45.00 |
748.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
57844012001 |
ADDERALL(R) TABLETS 20MG 100 |
01/01/2020 |
45.00 |
748.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
57844013001 |
ADDERALL(R) TABLETS 30MG 100 |
01/01/2020 |
45.00 |
748.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
57844010501 |
ADDERALL(R) TABLETS 5MG 100 |
01/01/2020 |
45.00 |
748.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
57844011701 |
ADDERALL(R) TABLETS 7.5MG 100 |
01/01/2020 |
45.00 |
748.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459070060 |
AMRIX CAP 15 MG 1BT X60 |
01/01/2020 |
152.50 |
2535.50 |
02/26/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459070160 |
AMRIX CAP 30 MG 1BTLX60 |
01/01/2020 |
152.50 |
2535.50 |
02/26/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459054128 |
FENTORA TB 100MCG 1CTNX28 US |
01/01/2020 |
96.40 |
1603.30 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459054228 |
FENTORA TB 200MCG 1CTNX28 US |
01/01/2020 |
121.80 |
2025.70 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459054428 |
FENTORA TB 400MCG 1CTNX28 US |
01/01/2020 |
176.80 |
2939.20 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459054628 |
FENTORA TB 600MCG 1CTNX28 US |
01/01/2020 |
229.50 |
3815.90 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459054828 |
FENTORA TB 800MCG 1CTNX28 US |
01/01/2020 |
282.80 |
4701.10 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
52544008001 |
FIORICET 50/300/40MG CAPSULES 100 |
01/01/2020 |
32.80 |
544.80 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/02/2016 |
Watson/Actavis |
None |
1 |
"Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price." |
449.93 |
None |
2013 |
227.00 |
None |
"No patent expiration date listed - no patents ever listed" |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
52544008201 |
FIORICET/CODEINE 50/300/40/30MG CAPS 100 |
01/01/2020 |
68.60 |
1140.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/02/2016 |
Watson/Actavis |
None |
1 |
"Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price." |
942.09 |
None |
2013 |
475.00 |
None |
"No patent expiration date listed - no patents ever listed" |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459041230 |
GABITRIL TAB 12MG 1BTLX30 |
01/01/2020 |
23.20 |
385.90 |
06/10/2017 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459041630 |
GABITRIL TAB 16MG 1BTLX30 |
01/01/2020 |
30.40 |
505.30 |
06/10/2017 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459040230 |
GABITRIL TAB 2MG 1BTLX30 |
01/01/2020 |
18.00 |
298.50 |
06/10/2017 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459040430 |
GABITRIL TAB 4MG 1BTLX30 |
01/01/2020 |
18.00 |
298.50 |
06/10/2017 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
57844021552 |
GALZIN CAPSULES 25MG 250 |
01/01/2020 |
26.10 |
433.40 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
57844020852 |
GALZIN CAPSULES 50MG 250 |
01/01/2020 |
43.40 |
722.20 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459021530 |
NUVIGIL TAB 150MG 1BTLX30 |
01/01/2020 |
50.90 |
846.80 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459022030 |
NUVIGIL TAB 200MG 1BTLX30 |
01/01/2020 |
50.90 |
846.80 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459022530 |
NUVIGIL TAB 250MG 1BTLX30 |
01/01/2020 |
50.90 |
846.80 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459020530 |
NUVIGIL TAB 50MG 1BTLX30 |
01/01/2020 |
16.90 |
281.40 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
00575620030 |
PROGLYCEM ORAL SUSPENSION 50MG/ML 30ML |
01/01/2020 |
20.70 |
344.40 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed; CMS Market Date is defaulted to 1990." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459010130 |
PROVIGIL TAB 100MG 1BTLX30 |
01/01/2020 |
71.30 |
1185.00 |
05/29/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459020130 |
PROVIGIL TAB 200MG 1BTLX30 |
01/01/2020 |
107.70 |
1790.50 |
05/29/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2020 |
63459017714 |
SYNRIBO INJECTION 3.5 MG VIAL |
01/01/2020 |
66.90 |
1112.00 |
10/26/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2020 |
59310057922 |
PROAIR INH AERO 90MCG 1INH 200/ACT |
01/01/2020 |
1.95 |
66.88 |
05/18/2031 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.” |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2020 |
59310058020 |
PROAIR RESPICLICK 200 DOSE-117UG |
01/01/2020 |
1.82 |
62.52 |
08/28/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.” |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2020 |
59310021012 |
QNASL AERO 80MCG 8.7GM 120/SPRAY |
01/01/2020 |
14.63 |
243.18 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2020 |
59310040606 |
QNASL PLV INHALER 40MCG 60/ACT TRADE |
01/01/2020 |
14.63 |
243.18 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2020 |
59310041012 |
QNASL PLV INHALER 80MCG 120/ACT TRADE |
01/01/2020 |
14.63 |
243.18 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2020 |
59310030240 |
QVAR BA INHALER 40MCG 120/ACT TRADE |
01/01/2020 |
10.77 |
190.21 |
01/01/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years. This drug was initially published in the Pricing Compendia, with a WAC of $156.74, in December 2017 (before its launch). The drug was then launched, on February 12, 2018, with a WAC of $169.28, and the price was adjusted to $179.44– the first WAC increase taken following the product’s launch – on 1/1/2019." |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2020 |
59310030480 |
QVAR BA INHALER 80MCG 120/ACT TRADE |
01/01/2020 |
14.42 |
254.68 |
01/01/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years. This drug was initially published in the Pricing Compendia, with a WAC of $209.87, in December 2017 (before its launch). The drug was then launched, on February 12, 2018, with a WAC of $226.66, and the price was adjusted to $240.26 – the first WAC increase taken following the product’s launch – on 1/1/2019." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285052302 |
ANTABUSE TABLETS 250MG 100 |
01/01/2020 |
52.80 |
877.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285052402 |
ANTABUSE TABLETS 500MG 100 |
01/01/2020 |
84.40 |
1403.30 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285042410 |
AYGESTIN(R) TABLETS 5MG 50 |
01/01/2020 |
15.20 |
253.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285013197 |
LOESTRIN (R) 21 TABLETS 1.0MG/20MCG 105 |
01/01/2020 |
42.30 |
703.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285012797 |
LOESTRIN (R) 21 TABLETS 1.5MG/30MCG 105 |
01/01/2020 |
42.30 |
703.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285012570 |
LOESTRIN (R) FE 28 TAB 1MG/20MCG 140 |
01/01/2020 |
42.30 |
703.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285012870 |
LOESTRIN (R) FE 28 TABLETS 1.5MG/30MCG 140 |
01/01/2020 |
42.30 |
703.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285009287 |
LOSEASONIQUE™ TAB 182 |
01/01/2020 |
49.20 |
818.20 |
12/05/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285012058 |
MIRCETTE 28 TABLETS .15MG/.02MG .01MG |
01/01/2020 |
53.00 |
881.50 |
10/20/2008 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285006390 |
PREFEST(R) TABLETS 180 |
01/01/2020 |
54.00 |
898.00 |
03/20/2020 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285043187 |
QUARTETTE (TM) TAB 182 |
01/01/2020 |
58.90 |
979.80 |
03/11/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285008787 |
SEASONIQUE(TM) TAB 182 |
01/01/2020 |
49.20 |
818.20 |
12/05/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285036801 |
TREXALL(R) (METHOTREXATE TAB, USP 10MG) |
01/01/2020 |
58.10 |
966.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285036901 |
TREXALL(R) (METHOTREXATE TAB, USP 15MG) |
01/01/2020 |
87.20 |
1449.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285036601 |
TREXALL(R) (METHOTREXATE TAB, USP 5MG) |
01/01/2020 |
29.10 |
483.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285036701 |
TREXALL(R) (METHOTREXATE TAB, USP 7.5MG) |
01/01/2020 |
43.60 |
724.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285004001 |
ZIAC(R) TABLETS 10MG/6.25MG 30 |
01/01/2020 |
12.40 |
206.40 |
03/24/2000 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285004702 |
ZIAC(R) TABLETS 2.5MG/6.25MG 100 |
01/01/2020 |
41.40 |
687.80 |
03/24/2000 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2020 |
51285005002 |
ZIAC(R) TABLETS 5MG/6.25MG 100 |
01/01/2020 |
41.40 |
687.80 |
03/24/2000 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2020 |
24478032204 |
Quillivant XR (methylphenidate hydrochloride) 300 mg/120 mL |
01/06/2020 |
27.97 |
310.47 |
02/15/2031 |
Single Source Drug |
64913 |
None |
Increased operational costs associated with product acquisition in 2018. |
None |
N/A |
None |
09/21/2018 |
Pfizer |
None |
1 |
Acquisition price also included another product not required for this report - Quillichew ER. |
282.50 |
272.70 |
2015 |
192.94 |
None |
None |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2020 |
24478020020 |
Quillivant XR (methylphenidate hydrochloride) 300 mg/120 mL - PFE |
01/06/2020 |
27.97 |
310.47 |
02/15/2031 |
Single Source Drug |
841 |
None |
Increased operational costs associated with product acquisition in 2018. |
None |
N/A |
None |
09/21/2018 |
Pfizer |
None |
1 |
Acquisition price also included another product not required for this report - Quillichew ER. |
282.50 |
272.70 |
2015 |
192.94 |
None |
Pfizer NDC numbers, 24478019010, 24478020020, 24478020525 and 24478021030 discontinued after acquisition in 2018. 2019 unit volume represents remainder in distribution. |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2020 |
24478032102 |
Quillivant XR (methylphenidate hydrochloride) 300 mg/60 mL |
01/06/2020 |
27.97 |
310.47 |
02/15/2031 |
Single Source Drug |
25285 |
None |
Increased operational costs associated with product acquisition in 2018. |
None |
N/A |
None |
09/21/2018 |
Pfizer |
None |
1 |
Acquisition price also included another product not required for this report - Quillichew ER. |
282.50 |
272.70 |
2015 |
192.94 |
None |
None |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2020 |
24478019010 |
Quillivant XR (methylphenidate hydrochloride) 300 mg/60 mL - PFE |
01/06/2020 |
27.97 |
310.47 |
02/15/2031 |
Single Source Drug |
218 |
None |
Increased operational costs associated with product acquisition in 2018. |
None |
N/A |
None |
09/21/2018 |
Pfizer |
None |
1 |
Acquisition price also included another product not required for this report - Quillichew ER. |
282.50 |
272.70 |
2015 |
192.94 |
None |
Pfizer NDC numbers, 24478019010, 24478020020, 24478020525 and 24478021030 discontinued after acquisition in 2018. 2019 unit volume represents remainder in distribution. |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2020 |
24478032305 |
Quillivant XR (methylphenidate hydrochloride) 750 mg/150 mL |
01/06/2020 |
27.97 |
310.47 |
02/15/2031 |
Single Source Drug |
36556 |
None |
Increased operational costs associated with product acquisition in 2018. |
None |
N/A |
None |
09/21/2018 |
Pfizer |
None |
1 |
Acquisition price also included another product not required for this report - Quillichew ER. |
282.50 |
272.70 |
2015 |
192.94 |
None |
None |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2020 |
24478020525 |
Quillivant XR (methylphenidate hydrochloride) 750 mg/150 mL - PFE |
01/06/2020 |
27.97 |
310.47 |
02/15/2031 |
Single Source Drug |
866 |
None |
Increased operational costs associated with product acquisition in 2018. |
None |
N/A |
None |
09/21/2018 |
Pfizer |
None |
1 |
Acquisition price also included another product not required for this report - Quillichew ER. |
282.50 |
272.70 |
2015 |
192.94 |
None |
Pfizer NDC numbers, 24478019010, 24478020020, 24478020525 and 24478021030 discontinued after acquisition in 2018. 2019 unit volume represents remainder in distribution. |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2020 |
24478032406 |
Quillivant XR (methylphenidate hydrochloride) 900 mg/180 mL |
01/06/2020 |
27.97 |
310.47 |
02/15/2031 |
Single Source Drug |
50008 |
None |
Increased operational costs associated with product acquisition in 2018. |
None |
N/A |
None |
09/21/2018 |
Pfizer |
None |
1 |
Acquisition price also included another product not required for this report - Quillichew ER. |
282.50 |
272.70 |
2015 |
192.94 |
None |
None |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2020 |
24478021030 |
Quillivant XR (methylphenidate hydrochloride) 900 mg/180 mL - PFE |
01/06/2020 |
27.97 |
310.47 |
02/15/2031 |
Single Source Drug |
1128 |
None |
Increased operational costs associated with product acquisition in 2018. |
None |
N/A |
None |
09/21/2018 |
Pfizer |
None |
1 |
Acquisition price also included another product not required for this report - Quillichew ER. |
282.50 |
272.70 |
2015 |
192.94 |
None |
Pfizer NDC numbers, 24478019010, 24478020020, 24478020525 and 24478021030 discontinued after acquisition in 2018. 2019 unit volume represents remainder in distribution. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474087015 |
BRIVIACT CV 10 MG/ML, 300ML ORAL SOLUTION |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474077009 |
BRIVIACT CV 100 MG, 100 UNIT DOSE TABLETS |
01/01/2020 |
57.25 |
1965.59 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474077066 |
BRIVIACT CV 100 MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474037066 |
BRIVIACT CV 10MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474047009 |
BRIVIACT CV 25MG, 100 UNIT DOSE TABLETS |
01/01/2020 |
57.25 |
1965.59 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474047066 |
BRIVIACT CV 25MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474057066 |
BRIVIACT CV 50MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474057009 |
BRIVIACT CV 5OMG, 100 UNIT DOSE TABLETS |
01/01/2020 |
57.25 |
1965.59 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474067066 |
BRIVIACT CV 75MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474097075 |
BRIVIACT INJECTION FOR INTRAVENOUS USE, CV 50 MG/5ML, 10 VIALS |
01/01/2020 |
14.71 |
505.43 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474070062 |
CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS |
01/01/2020 |
302.92 |
4630.35 |
02/13/2024 |
Single Source Drug |
1217472000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474071079 |
CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES |
01/01/2020 |
302.92 |
4630.35 |
02/13/2024 |
Single Source Drug |
1217472000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474071081 |
CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES |
01/01/2020 |
908.75 |
13891.04 |
02/13/2024 |
Single Source Drug |
1217472000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080103 |
NEUPRO 1 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080203 |
NEUPRO 2 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080303 |
NEUPRO 3 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080403 |
NEUPRO 4 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080503 |
NEUPRO 6 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080603 |
NEUPRO 8 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247835 |
VIMPAT CV 100MG, 60 TABLETS |
01/01/2020 |
25.92 |
890.25 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247860 |
VIMPAT CV 100MG, 60 UNIT DOSE TABLETS |
01/01/2020 |
28.52 |
979.35 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131541071 |
VIMPAT CV 10MG/ML ORAL SOLUTION, 200 ML |
01/01/2020 |
10.72 |
368.30 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131541070 |
VIMPAT CV 10MG/ML ORAL SOLUTION, 465 ML |
01/01/2020 |
21.45 |
736.59 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247935 |
VIMPAT CV 150MG, 60 TABLETS |
01/01/2020 |
27.46 |
942.85 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247960 |
VIMPAT CV 150MG, 60 UNIT DOSE TABLETS |
01/01/2020 |
30.22 |
1037.19 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131248035 |
VIMPAT CV 200MG, 60 TABLETS |
01/01/2020 |
27.46 |
943.11 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131248060 |
VIMPAT CV 200MG, 60 UNIT DOSE TABLETS |
01/01/2020 |
30.22 |
1037.52 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247735 |
VIMPAT CV 50MG, 60 TABLETS |
01/01/2020 |
16.58 |
569.43 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247760 |
VIMPAT CV 50MG, 60 UNIT DOSE TABLETS |
01/01/2020 |
18.23 |
626.43 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2020 |
00131181067 |
VIMPAT INJECTION FOR INTRAVENOUS USE, CV 200MG/20ML, 10 VIALS |
01/01/2020 |
22.68 |
778.94 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000036 |
United Therapeutics |
09/30/2020 |
66302020603 |
"Tyvaso 1.74 mg Inhalation 2.9 mL/ampule *4" |
07/01/2020 |
111.42 |
2587.32 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency
This information is confidential and proprietary, and not publicly available or within the public domain. |
| Rx0000036 |
United Therapeutics |
09/30/2020 |
66302020604 |
"Tyvaso 1.74 mg Inhalation 2.9 mL/ampule*4" |
07/01/2020 |
201.54 |
4680.17 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency
This information is confidential and proprietary, and not publicly available or within the public domain. |
| Rx0000036 |
United Therapeutics |
09/30/2020 |
66302020602 |
"Tyvaso Refill kit 1.74 mg Inhalation 2.9 mL/ampule * 28" |
07/01/2020 |
779.91 |
18111.22 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency
This information is confidential and proprietary, and not publicly available or within the public domain. |
| Rx0000036 |
United Therapeutics |
09/30/2020 |
66302020601 |
"Tyvaso Starter kit 1.74 mg Inhalation 2.9 mL/ampule * 28" |
07/01/2020 |
870.03 |
20204.08 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency
This information is confidential and proprietary, and not publicly available or within the public domain. |
| Rx0000036 |
United Therapeutics |
09/30/2020 |
66302001401 |
"Unituxin 17.5mg/5 ML Injection/vial 5ml Vial" |
08/15/2020 |
401.77 |
11880.77 |
03/01/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain. |
| Rx0000036 |
United Therapeutics |
03/31/2020 |
66302001401 |
Unituxin Dinutuximab; 17.5mg/5mL; Injection/vial; 5mL vial |
01/01/2020 |
639.50 |
11479.00 |
03/01/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit sales data- This information is confidential and proprietary, and not publicly available or within the public domain.
Cost increase factors- This information was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain.
Change/Improvement description- This information was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain.
Acquisition fields have not been completed because the product was not acquired from another manufacturer within the last 5 years |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107430 |
Qudexy XR 100mg Cpsl Btl 30 |
01/31/2020 |
37.06 |
654.75 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107530 |
Qudexy XR 150mg Cpsl Btl 30 |
01/31/2020 |
45.59 |
805.38 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107330 |
Qudexy XR 200mg Cpsl Btl 30 |
01/31/2020 |
50.70 |
895.67 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107130 |
Qudexy XR 25mg Cpsl Btl 30 |
01/31/2020 |
14.36 |
253.70 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107230 |
Qudexy XR 50mg Cpsl Btl 30 |
01/31/2020 |
18.71 |
330.47 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107430 |
Topiramate ER 100mg Cpsl Btl 30 |
01/31/2020 |
30.22 |
533.91 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107530 |
Topiramate ER 150mg Cpsl Btl 30 |
01/31/2020 |
37.17 |
656.72 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107330 |
Topiramate ER 200mg Cpsl Btl 30 |
01/31/2020 |
41.34 |
730.38 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107130 |
Topiramate ER 25mg Cpsl Btl 30 |
01/31/2020 |
11.71 |
206.89 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |
| Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107230 |
Topiramate ER 50mg Cpsl Btl 30 |
01/31/2020 |
15.25 |
269.48 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187006410 |
ATIVAN® Tablets 1mg 1,000s |
02/06/2020 |
2554.56 |
34890.72 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187006301 |
ATIVAN® Tablets .5mg 100s |
02/06/2020 |
195.26 |
2666.86 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187006401 |
ATIVAN® Tablets 1mg 100s |
02/06/2020 |
260.83 |
3562.53 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187006501 |
ATIVAN® Tablets 2mg 100s |
02/06/2020 |
415.69 |
5677.56 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187301220 |
MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle |
01/09/2020 |
74.41 |
1314.63 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187301030 |
MESTINON 60mg TABLETS 100s (pyridostigmine bromide) |
01/09/2020 |
91.61 |
1618.51 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187301330 |
MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT |
01/09/2020 |
52.13 |
920.95 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
66490069110 |
MYSOLINE 250 mg TABLETS, 100s (primidone) |
02/06/2020 |
374.17 |
5110.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
66490069010 |
MYSOLINE 50 mg TABLETS, 100s (primidone) |
02/06/2020 |
108.73 |
1485.06 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187305050 |
ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 50g Pump |
01/09/2020 |
33.55 |
592.71 |
08/05/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187442010 |
PEPCID® (Famotidine) Tablets, 20mg, 100 |
01/09/2020 |
64.29 |
1135.80 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/10/2015 |
Marathon Pharmaceuticals, LLC |
286000000 |
None |
Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. |
309.13 |
309.13 |
2012 |
222.22 |
None |
The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187442030 |
PEPCID® (Famotidine) Tablets, 20mg, 30 |
01/09/2020 |
19.29 |
340.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/10/2015 |
Marathon Pharmaceuticals, LLC |
286000000 |
None |
Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. |
92.74 |
92.74 |
2012 |
66.67 |
None |
The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187444010 |
PEPCID® (Famotidine) Tablets, 40mg, 100 |
01/09/2020 |
124.26 |
2195.32 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/10/2015 |
Marathon Pharmaceuticals, LLC |
286000000 |
None |
Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. |
597.50 |
597.50 |
2014 |
597.50 |
None |
The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187444030 |
PEPCID® (Famotidine) Tablets, 40mg, 30 |
01/09/2020 |
37.28 |
658.56 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/10/2015 |
Marathon Pharmaceuticals, LLC |
286000000 |
None |
Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. |
179.24 |
179.24 |
2014 |
179.24 |
None |
The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187149825 |
TIMOPTIC? in OCUDOSE? (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL Vial |
01/09/2020 |
25.10 |
443.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 11/6/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
| Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187149605 |
TIMOPTIC? in OCUDOSE? (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL Vial |
01/09/2020 |
28.62 |
505.59 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 8/9/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010102 |
Fanapt 1 mg tablets; bottles of 60 |
01/01/2020 |
94.17 |
1271.27 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010102 |
Fanapt 1 mg tablets; bottles of 60 |
09/14/2020 |
114.41 |
1385.68 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068011002 |
Fanapt 10 mg tablets; bottles of 60 |
01/01/2020 |
185.56 |
2505.01 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068011002 |
Fanapt 10 mg tablets; bottles of 60 |
09/14/2020 |
225.45 |
2730.46 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068011202 |
Fanapt 12 mg tablets; bottles of 60 |
01/01/2020 |
185.56 |
2505.01 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068011202 |
Fanapt 12 mg tablets; bottles of 60 |
09/14/2020 |
225.45 |
2730.46 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010202 |
Fanapt 2 mg tablets; bottles of 60 |
01/01/2020 |
94.17 |
1271.27 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010202 |
Fanapt 2 mg tablets; bottles of 60 |
09/14/2020 |
114.41 |
1385.68 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010402 |
Fanapt 4 mg tablets; bottles of 60 |
01/01/2020 |
94.17 |
1271.27 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010402 |
Fanapt 4 mg tablets; bottles of 60 |
09/14/2020 |
114.41 |
1385.68 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010602 |
Fanapt 6 mg tablets; bottles of 60 |
01/01/2020 |
115.87 |
1564.21 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010602 |
Fanapt 6 mg tablets; bottles of 60 |
09/14/2020 |
140.78 |
1704.99 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010802 |
Fanapt 8 mg tablets; bottles of 60 |
01/01/2020 |
115.87 |
1564.21 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010802 |
Fanapt 8 mg tablets; bottles of 60 |
09/14/2020 |
140.78 |
1704.99 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068011304 |
Fanapt 8 tablet titration pack (1mg, 2mg, 4mg, 6mg) |
01/01/2020 |
12.57 |
169.52 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068011304 |
Fanapt 8 tablet titration pack (1mg, 2mg, 4mg, 6mg) |
09/14/2020 |
15.26 |
184.78 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068022001 |
Hetlioz; 20 mg capsules; bottles of 30 |
01/01/2020 |
942.08 |
16643.43 |
07/27/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
12/31/2020 |
43068022001 |
Hetlioz; 20 mg capsules; bottles of 30 |
10/01/2020 |
1997.21 |
18640.64 |
08/29/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025007130 |
CONZIP (tramadol hydrochloride), CAPSULE EXTENDED RELEASE, 100 mg, 30 ct |
01/01/2020 |
25.32 |
341.82 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025007230 |
CONZIP (tramadol hydrochloride), CAPSULE EXTENDED RELEASE, 200 mg, 30 ct |
01/01/2020 |
33.18 |
447.96 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025007330 |
CONZIP (tramadol hydrochloride), CAPSULE EXTENDED RELEASE, 300 mg, 30 ct |
01/01/2020 |
45.90 |
619.62 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025005230 |
CORVITE 150, TABLET, MULTI, 30 ct |
01/01/2020 |
9.58 |
129.32 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025006030 |
CORVITE FE, TABLET, MULTI, 30 ct |
01/01/2020 |
12.60 |
170.11 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025006530 |
DIVIGEL (estradiol gel) GEL, 0.25 mg, 30 ct |
01/01/2020 |
9.97 |
142.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025006630 |
DIVIGEL (estradiol gel) GEL, 0.50 mg, 30 ct |
01/01/2020 |
9.97 |
142.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025008330 |
DIVIGEL (estradiol gel) GEL, 0.75 mg, 30 ct |
01/01/2020 |
9.97 |
142.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025006730 |
DIVIGEL (estradiol gel) GEL, 1.0 mg, 30 ct |
01/01/2020 |
9.97 |
142.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004610 |
LORZONE (chlorzoxazone USP) TABLET, 375 mg, 30 ct |
01/01/2020 |
81.87 |
908.86 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004710 |
LORZONE (chlorzoxazone USP) TABLET, 750 mg, 30 ct |
01/01/2020 |
91.55 |
1016.26 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004960 |
OB COMPLETE DHA, SOFTGEL CAPSULE, MULTI, 60 ct |
01/01/2020 |
13.07 |
176.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004430 |
OB COMPLETE ONE, CAPSULE, MULTI, 30 ct |
01/01/2020 |
13.31 |
179.67 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025005930 |
OB COMPLETE PETITE, SOFTGEL CAPSULE, MULTI, 30 ct |
01/01/2020 |
12.90 |
174.18 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004330 |
OB COMPLETE PREMIER, TABLET, MULTI, 30 ct |
01/01/2020 |
9.33 |
125.92 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025001010 |
OB COMPLETE PRENATAL, CAPLET, MULTI, 100ct |
01/01/2020 |
16.63 |
224.51 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000066 |
ViiV Healthcare |
03/31/2020 |
49702022613 |
TIVICAY TAB 10MG - 30 tablets per bottle |
01/01/2020 |
17.20 |
365.30 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000066 |
ViiV Healthcare |
03/31/2020 |
49702022713 |
TIVICAY TAB 25MG - 30 tablets per bottle |
01/01/2020 |
42.99 |
913.24 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000066 |
ViiV Healthcare |
03/31/2020 |
49702022813 |
TIVICAY TAB 50MG - 30 tablets per bottle |
01/01/2020 |
85.98 |
1826.47 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
42211020329 |
Diclofenac 18 MG Capsule 90 EA |
01/01/2020 |
64.35 |
714.35 |
04/23/2030 |
Innovator Multiple Source Drug |
11374 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
383.05 |
350.14 |
2013 |
225.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
42211020429 |
Diclofenac 35 MG Capsule 90 EA |
01/01/2020 |
64.35 |
714.35 |
04/23/2030 |
Innovator Multiple Source Drug |
82603 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
383.05 |
350.14 |
2013 |
225.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
42211010111 |
Indomethacin Oral Suspension 25 mg per 5mL (237mL/Bottle) |
01/01/2020 |
176.61 |
1960.57 |
None |
Non-innovator Multiple Source Drug |
4070 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
891.98 |
891.98 |
1985 |
232.17 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
42211010243 |
Indomethacin Suppository 50mg per suppository (30 Suppository/Box) |
01/01/2020 |
504.90 |
5604.90 |
None |
Non-innovator Multiple Source Drug |
12256 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
2550.00 |
2550.00 |
1984 |
309.62 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
42211020623 |
Meloxicam 10 MG Capsule 30 EA |
01/01/2020 |
77.70 |
862.57 |
03/31/2035 |
Innovator Multiple Source Drug |
26446 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
784.87 |
717.43 |
2015 |
594.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 11/30/2015) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
42211020523 |
Meloxicam 5 MG Capsule 30 EA |
01/01/2020 |
77.70 |
862.57 |
03/31/2035 |
Innovator Multiple Source Drug |
5490 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
784.87 |
717.43 |
2015 |
594.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 11/30/2015) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344010101 |
Oral Suspension Indocin 25 mg per 5mL (237mL/Bottle) |
01/01/2020 |
176.61 |
1960.57 |
None |
Non-innovator Multiple Source Drug |
4070 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
891.98 |
891.98 |
1985 |
232.17 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively.
Lastly, Zyla notes that this NDC represents the same product as 42211010111. Zyla changed the NDC of this product in the second half of 2019 from beginning with 42211 (Iroko labeler name) to 69344 (Zyla labeler name). Zyla only took one price increase on this product while under its new NDC; however, in an effort to be fully transparent, Zyla provided the same information for this NDC on the 5 year history as it provided for the 42211010111 NDC. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344011311 |
Oxaydo 5 mg/1 Tablet (100 per Bottle) |
01/01/2020 |
72.70 |
807.04 |
03/16/2025 |
Innovator Multiple Source Drug |
10966 |
None |
None |
1 |
None |
1 |
01/07/2015 |
Acura Pharmaceuticals, Inc. |
7500000 |
None |
In addition to the upfront cash payment of $7.5M, Egalet US Inc. is also required to pay royalty of single-digit to double-digit percent based on sales thresholds. Upfront acquisition payment also does not include the following additional expenses associated with the purchase and ongoing maintenance of the product:
- Significant sales milestone payments
- Significant post-marketing requirement and development costs
- Debt burden, maintenance and servicing costs to finance the original purchase
- Second debt burden, maintenance and servicing costs, along with additional royalty payments on sales, associated with financing ongoing operations
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Manufacturing costs |
425.00 |
None |
2011 |
425.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 9/11/2015) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344021311 |
Oxaydo 7.5mg/1 Tablet (100 per Bottle) |
01/01/2020 |
108.93 |
1209.24 |
03/16/2025 |
Innovator Multiple Source Drug |
4892 |
None |
None |
1 |
None |
1 |
01/07/2015 |
Acura Pharmaceuticals, Inc. |
7500000 |
None |
In addition to the upfront cash payment of $7.5M, Egalet US Inc. is also required to pay royalty of single-digit to double-digit percent based on sales thresholds. Upfront acquisition payment also does not include the following additional expenses associated with the purchase and ongoing maintenance of the product:
- Significant sales milestone payments
- Significant post-marketing requirement and development costs
- Debt burden, maintenance and servicing costs to finance the purchase
- Second debt burden, maintenance and servicing costs, along with additional royalty payments on sales, associated with financing ongoing operations
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Manufacturing costs |
638.00 |
None |
2011 |
638.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 9/11/2015) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344014463 |
Sprix 15.75mg/1 Spray, Metered (1 Bottle) |
01/01/2020 |
35.38 |
392.70 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/08/2015 |
Luitpold Pharmaceuticals, Inc. |
7000000 |
None |
In addition to the upfront cash payment of $7M, Egalet US Inc. is also required to pay a fixed, single-digit royalty on net sales. Upfront acquisition payment also does not include the following additional expenses associated with the purchase and ongoing maintenance of the product:
- Transition services
- Debt burden, maintenance and servicing costs to finance the purchase
- Second debt burden, maintenance and servicing costs, along with additional royalty payments on sales, associated with financing ongoing operations
commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Component and manufacturing costs |
282.60 |
None |
2010 |
282.60 |
None |
Comment on #8: This NDC, which is the single vial configuration of Sprix, was approved in the NDA as a marketable item; however, this has never been commercialized either by Zyla or by Luitpold, previously. There were zero sales of this NDC in 2019. The system would not allow Zyla to input "0" as a value.
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 9/15/2015) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344014443 |
Sprix 15.75mg/1 Spray, Metered (5 Bottles per Carton) |
01/01/2020 |
176.88 |
1963.52 |
None |
Innovator Multiple Source Drug |
70680 |
None |
None |
1 |
None |
1 |
01/08/2015 |
Luitpold Pharmaceuticals, Inc. |
7000000 |
None |
In addition to the upfront cash payment of $7M, Egalet US Inc. is also required to pay a fixed, single-digit royalty on net sales. Upfront acquisition payment also does not include the following additional expenses associated with the purchase and ongoing maintenance of the product:
- Transition services
- Debt burden, maintenance and servicing costs to finance the purchase
- Second debt burden, maintenance and servicing costs, along with additional royalty payments on sales, associated with financing ongoing operations
commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Component and manufacturing costs |
1413.00 |
None |
2010 |
1413.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 9/15/2015) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344010233 |
Suppository Indocin 50mg per suppository (30 Suppository/Box) |
01/01/2020 |
504.90 |
5604.90 |
None |
Non-innovator Multiple Source Drug |
12256 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
2550.00 |
2550.00 |
1984 |
309.62 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively.
Lastly, Zyla notes that this NDC represents the same product as 42211010243. Zyla changed the NDC of this product in the second half of 2019 from beginning with 42211 (Iroko labeler name) to 69344 (Zyla labeler name). Zyla only took one price increase on this product while under its new NDC; however, in an effort to be fully transparent, Zyla provided the same information for this NDC on the 5 year history as it provided for the 42211010243 NDC. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344020623 |
Vivlodex 10 MG Capsule 30 EA |
01/01/2020 |
77.70 |
862.57 |
03/31/2035 |
Innovator Multiple Source Drug |
26446 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
784.87 |
717.43 |
2015 |
594.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 11/30/2015) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively.
Lastly, Zyla notes that this NDC represents the same product as 42211020623. Zyla changed the NDC of this product in the second half of 2019 from beginning with 42211 (Iroko labeler name) to 69344 (Zyla labeler name). Zyla only took one price increase on this product while under its new NDC; however, in an effort to be fully transparent, Zyla provided the same information for this NDC on the 5 year history as it provided for the 42211020623 NDC. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344020523 |
Vivlodex 5 MG Capsule 30 EA |
01/01/2020 |
77.70 |
862.57 |
03/31/2035 |
Innovator Multiple Source Drug |
5490 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
784.87 |
717.43 |
2015 |
594.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 11/30/2015) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively.
Lastly, Zyla notes that this NDC represents the same product as 42211020523. Zyla changed the NDC of this product in the second half of 2019 from beginning with 42211 (Iroko labeler name) to 69344 (Zyla labeler name). Zyla only took one price increase on this product while under its new NDC; however, in an effort to be fully transparent, Zyla provided the same information for this NDC on the 5 year history as it provided for the 42211020523 NDC. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344020329 |
Zorvolex 18 MG Capsule 90 EA |
01/01/2020 |
64.35 |
714.35 |
04/23/2030 |
Innovator Multiple Source Drug |
11374 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
383.05 |
350.14 |
2013 |
225.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively.
Lastly, Zyla notes that this NDC represents the same product as 42211020329. Zyla changed the NDC of this product in the second half of 2019 from beginning with 42211 (Iroko labeler name) to 69344 (Zyla labeler name). Zyla only took one price increase on this product while under its new NDC; however, in an effort to be fully transparent, Zyla provided the same information for this NDC on the 5 year history as it provided for the 42211020329 NDC. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2020 |
69344020429 |
Zorvolex 35 MG Capsule 90 EA |
01/01/2020 |
64.35 |
714.35 |
04/23/2030 |
Innovator Multiple Source Drug |
82603 |
None |
None |
1 |
None |
1 |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
383.05 |
350.14 |
2013 |
225.00 |
None |
Comment on #21 and #22:
Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore:
- Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21
- Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013) for #22
General Comment on report: Zyla Life Sciences US Inc. is not a profitable company; it has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2019, December 31, 2018 and 2017, Zyla reported a net loss of approximately $46.6 million, $95.5 million and $69.4 million, respectively.
Lastly, Zyla notes that this NDC represents the same product as 42211020429. Zyla changed the NDC of this product in the second half of 2019 from beginning with 42211 (Iroko labeler name) to 69344 (Zyla labeler name). Zyla only took one price increase on this product while under its new NDC; however, in an effort to be fully transparent, Zyla provided the same information for this NDC on the 5 year history as it provided for the 42211020429 NDC. |